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ABSTRACT
Hereditary hemochromatosis (HH) is a prevalent genetic disorder that results in the daily
excess absorption of dietary iron.  If untreated this disease leads to systemic organ failure
and death.  HH is caused by mutations to the gene coding for a protein called HFE, a type
I transmembrane glycoprotein with a demonstrated role in regulating cellular iron
homeostasis.  HFE binds to the cell-surface receptor transferrin receptor (TfR), a dimeric
type II transmembrane glycoprotein responsible for iron uptake into most mammalian
cell types.  TfR binds iron-loaded transferrin (Fe-Tf) from the blood and transports it to
acidic recycling endosomes where iron is released from Fe-Tf in a TfR-facilitated
process.  Iron-free transferrin (apo-Tf) remains bound to TfR and is recycled to the cell
surface, where apo-Tf rapidly dissociates from TfR upon exposure to the basic pH of
blood.  HFE and Fe-Tf can bind simultaneously to TfR to form a ternary complex, but
HFE binding to TfR lowers the apparent affinity of the Fe-Tf/TfR interaction.  This
reduction could result from direct competition between HFE and Fe-Tf for receptor
binding sites, from negative cooperativity, or both.  We sought to understand the
mechanism of HFE, Fe-Tf, and apo-Tf binding by TfR to help define HFE's role in iron
homeostasis.  We determined the binding constants for HFE, Fe-Tf, and apo-Tf to an
extensive set of site-directed TfR mutants and discovered that HFE and Tf bind to an
overlapping site on TfR, indicating the two proteins compete with each other for receptor
binding.  The mutagenesis results also identified differences in the contact points between
TfR and the two forms of Tf, Fe-Tf and apo-Tf.  By combining the mutations that are
required for apo-Tf, but not Fe-Tf, binding we find that a highly conserved hydrophobic
patch on the TfR surface is required for the receptor-mediated stimulation of iron release
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from Fe-Tf.  From these data we propose a structure-based model for the mechanism of
TfR-assisted iron release.
To explore the mechanism of the HFE-induced affinity reduction for Fe-Tf binding by
TfR, we engineered a heterodimeric TfR (hdTfR) that contains mutations such that one
TfR chain binds only HFE and the other binds only Fe-Tf.  Competition binding
experiments using hdTfR demonstrate that TfR does not exhibit cooperativity in
heterotropic ligand binding, suggesting that some or all of HFE's effects on iron
homeostasis result from competition with Fe-Tf for TfR binding.  Using transfected cell
lines we show that HFE is dependent on its interactions with TfR for transport to
endosomal compartments and that competition with extracellular Fe-Tf can alter HFE
trafficking patterns.  These data suggest that HFE's role in iron homeostasis is as a sensor
of body iron status.
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INTRODUCTION
Iron is Required to Sustain Life
During the pre-biotic age of our planet there was very little oxygen in the atmosphere, and
free iron was abundant.  The concentration of the ferrous ion (Fe2+) in the oceans was 50
µM (Holland, 1984) compared with only ~20 nM today (Silver, 1993).  About 3 billion
years ago photosynthetic cyanobacteria began producing di-oxygen as a metabolic waste
product, thereby increasing the level of atmospheric oxygen close to its present level
(~23%) (Allegre & Schneider, 1994).  This resulted in massive amounts of iron
precipitation as magnetite (Fe3O4) and hematite (Fe2O3), which are the modern commercial
iron ores (Holland, 1984).
Since the days of cyanobacteria, life has continued to depend on the versatile chemistry of
iron to sustain biological reactions, such that iron is required to sustain almost all life on
Earth (Stamatoyannopoulos, 1994).  The only identified exceptions are the soil bacteria
Lactobacillus plantarum (Archibald, 1983) and the Lyme disease-causing bacteria Borrelia
burgdorferi (Posey & Gherardini, 2000).  Biological systems have numerous uses for iron.
Many enzymes coordinate it directly using sidechains to create a reactive center for
chemical reactions (e.g., ribonucleotide reductase (Jordan & Reichard, 1998) or 5-
lipoxygenase (Lange & Que, 1998)), as part of a cofactor such as the iron-sulfur cluster
found in many metabolic proteins, electron transfer as in the respiratory complexes, bound
to heme either for oxygen binding and transport, as in myoglobin and hemoglobin, or in
enzymes such as the cytochromes (reviewed in Groves, 2003). However, in every case the
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iron is sequestered to prevent the biologically dangerous products of the Fenton reaction,
which can be described as
Fe3+ + O2
-  Fe2+ + O2
Fe2+ + H2O2  Fe
3+ + OH- + OH.
In the absence of free superoxide in cells, other molecules such as ascorbate can substitute
for the reducing agent in the above reaction (Halliwell & Gutteridge, 1990).  In vivo the
resultant hydroxy radical will abstract a hydrogen atom from almost any organic molecule
to generate an organic radical that can react to form various end products such as lipid
peroxides, modified DNA bases, broken DNA strands, or radial cascade reactions
(Halliwell & Gutteridge, 1990).
Iron sequestration serves another purpose in addition to preventing free radical cascades.
Since iron is required to sustain most organisms, successful colonization of a host by a
pathogen requires that iron be taken from the host. In humans the level of free iron is ~10-18
M (Bullen, 1981), which is well below the concentration required for bacterial growth
(~10-6 to 10-7 M) (Weinberg, 1978).  As part of the primary immune response to bacterial
infection, host cells produce excess lactoferrin, a potent iron-binding protein, to limit
available iron in an attempt to slow bacterial growth (Jurado, 1997).  Bacteria have evolved
numerous ways of abstracting host iron, including secretion of siderophores (small
molecule iron sequestering agents) and expression of receptors capable of binding and
taking up iron-containing host proteins (Jurado, 1997).
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Iron Balance in the Human Body
In order to exploit the advantages of utilizing iron, mammals have overcome the issues
involved in working with this inherently toxic element.  Iron must be absorbed from dietary
sources and then sequestered to prevent oxidative damage or uptake by adventitious
organisms.   However, this sequestration must be reversible so the element can be used,
recycled, and be transported throughout the body to adequately supply every tissue and cell
type with the appropriate amount.  Additionally, sufficient iron must be stored in case of
nutritional deficiency.  The average adult human has 3-4 grams of this potentially
hazardous substance iron in his/her body and possesses no regulated mechanism for iron
excretion, creating the possibility of iron overload if there is a defect in the checkpoints
regulating dietary absorption (Andrews, 1999).  Thus, the processes of iron uptake,
transport, storage, and recycling are performed by a variety of proteins.  Some of these
proteins, such as hemoglobin, have been studied for over a century, whereas others, such as
hemojuvelin reported in January of this year (Papanikolaou et al., 2004), were discovered
only recently.  Because of the large number of molecules involved in mammalian iron
homeostasis, and the even larger number of interactions between them, various
environmental and genetic disturbances to the balance maintained by these proteins leads to
a myriad of diseases characterized by iron deficiency, overload, and sometimes both
(Andrews, 1999).
Imbalance of Iron Handling Leads to Anemia
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In 1713 Lemery and Geoffroy demonstrated that iron is transported in the blood.  Today we
know that approximately 66% of iron in an adult human is bound to hemoglobin in red
blood cells for the purpose of oxygen transport through the bloodstream (Beutler, 2002).
Because iron is often the limiting factor in hemoglobin production, and because of the
fundamental role of hemoglobin in sustaining cellular respiration, many conditions that
perturb iron homeostasis result in anemia, a condition in which red blood cells are not
properly oxygenating tissue (Schrieber, 1989).  Anemia is most commonly the result of
internal bleeding, but an iron-poor diet, and other environmental factors can play a role
(Schrieber, 1989).  Dietary iron deficiency used to be relatively common in the United
States until the fortification of foods with various vitamins and minerals, such as iron in
1938, ameliorated many cases of nutrition-related anemia (Junod, 2001).  However many
environmental factors other than diet can lead to deficient iron delivery to red blood cell
precursors.  In the simplest case, continuous internal bleeding will deplete iron stores
eventually leading to iron deficiency and anemia (Schreier et al., 1994). Another example
of deficiency is the anemia of chronic disease, also called anemia of inflammation.  This is
an acquired condition brought on by a variety of persistent inflammatory disorders
resulting in an attenuated response to red blood cell-stimulating factors, such as
erythropoietin, decreasing red blood cell production.  Additionally, iron availability for
erythropoeisis is lowered, possibly because of a defect in the iron recycling pathway of
macrophages, which provide the bulk of the iron for red blood cell production (reviewed in
Weinstein et al., 2002).  Anemia can also be a secondary result of other nutritional
disorders.  For example, pernicious anemia, a form of megaloblastomic anemia, results
from a lack of vitamin B-12, which is necessary in part for healthy red blood cell
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production (Cohen, 2004).  The B-12 deficiency can arise from poor diet, as in the case of
strict vegans who do not supplement with B-12, or a loss of intrinsic factor, which is
required for B-12 absorption.  Loss of intrinsic factor can result from surgical removal of
the stomach, and most commonly from atrophic gastric mucosa, autoimmunity against
gastric parietal cells, autoimmunity against intrinsic factor, triggered by other autoimmune
endocrine disorders, or very rarely by a genetic deficiency for factor expression (Cohen,
2004).  These examples show that iron homeostasis is complicated by the influence of other
nutrients in the body.
There are also numerous genetic causes of anemia.  Sickle cell anemia results from a
genetic mutation in hemoglobin that causes it to aggregate and distort the shape of the red
blood cell impairing its function (Schreier et al., 1994).  Other examples of genetic anemia
are the thalassemias, which result from deletions and mutations in the genes coding for
hemoglobin causing the production of cells with insufficient oxygen transport activity
(Olivieri, 1999).  Although thalassemias are characterized by anemia and the inability to
effectively transport oxygen throughout the body, they also result in the second
consequence of perturbing the iron-homeostatic balance: iron overload.  The lack of
efficient erythropoesis is interpreted by the body as an iron deficiency and it responds by
increasing dietary iron absorption and expanding the erythroid marrow by nearly 30-fold
(Olivieri, 1999).  This results in the uptake of an additional iron burden of 2 to 5 grams of
iron per year (Olivieri, 1999).  The anemia accompanied with iron overload puts the
thalessemias in a disease class called secondary iron overload disorders.  Secondary iron
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overload disorders are often side effects of other problems such as liver disease,
environmental iron overload, or difficulty with erythropoesis.  When iron overload has
progressed to the point where iron is deposited into tissues, the patient is said to have
hemochromatosis (Schreier et al., 1994).
Imbalance of Iron Handling Leads to Toxic Iron Overload:  Hemochromatosis
The thalassemias, in addition to the sideroblastic and congenital dyserthropoetic anemias,
are diseases that disturb red blood cell production, resulting in excessive iron uptake and
iron deposition in erythropoetic tissue in an attempt to ameliorate the lack of functional red
blood cell production by providing more iron (Olivieri, 1999).  While these diseases are
generally genetic in nature, iron overload can be caused by environmental factors.  It is
difficult, though possible, to induce an overloaded state through the ingestion of excess
iron, but more common in modern day is the case of transfusional iron overload
(Bottomley, 1998).  One milliliter of packed red blood cells contains approximately 1
milligram of iron.  Therefore, each transfused unit incorporates approximately 200 mg of
unexcreteable iron into a patient (Bottomley, 1998).  An individual receiving regular
transfusions, for example, to treat any refractory anemia, requires chelation therapy to
prevent progressive iron overload and subsequent damage to parenchymal tissues.  Another
environmentally induced iron overload results from excessive alcohol consumption
(Bottomley, 1998).  It is thought that damage to the liver induced by chronic drinking leads
to the excessive absorption of iron by the liver while other organs are spared (Bottomley,
1998).  A rare secondary iron overload disorder called atransferrinemia, or
hypotransferrinemia (Hayashi et al., 1993), is characterized by splicing defects that result
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in little to no expression of transferrin, a serum protein responsible for shuttling iron atoms
through the circulatory system.  In the absence of transferrin, erythroid tissues do not
receive the iron they need to produce red blood cells.  In this case, patients present with
extreme siderosis of parenchymal tissues.  The anemia is corrected upon administration of
plasma or transferrin injections (Bottomley, 1998).  Hereditary ceruloplasmin deficiency is
characterized by iron deposition in various tissues leading to neurological symptoms,
cerebellar ataxia, diabetes mellitus, retinal pigment degeneration, and involuntary
movements (reviewed in Sheth & Brittenham, 2000).  Ceruloplasmin is a copper-
containing serum protein with ferroxidase and is involved in the release of iron from tissue
stores (Osaki & Johnson, 1969).  Clinical symptoms do not occur until late in life,
possibility because hephaestin, a copper-containing membrane bound protein with high
sequence similarity to ceruloplasmin, can also function in the export of iron from cells
(Sheth & Brittenham, 2000).
Types of Hereditary Hemochromatosis
In recent years several new forms of hereditary hemochromatosis, also called primary iron
overload, and their causes have been identified.  The first gene to be linked to hereditary
hemochromatosis was HFE (Feder et al., 1996), a class I MHC homolog that binds to
transferrin receptor 1 (TfR) (Parkkila et al., 1997; Feder et al., 1998).  Mutations in HFE
result in type I hemochromatosis (Feder et al., 1996).  HFE and TfR are the focus of this
thesis and their interactions and role in iron overload are discussed later.  Type II
hemochromatosis is clinically and genetically different than type I hemochromatosis
(Cazzola et al., 1998) and is characterized by the onset of iron loading resulting in diabetes,
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and hypogonadism during the teens and early 20s.  If untreated, type II hemochromatosis
leads to early death from cardiac dysfunction (Cazzola et al., 1983).  The defect was
initially mapped to the centromeric region of chromosome 1q, which is incomplete in the
human genome assembly (Roetto et al., 1999), but subsequent studies identified the gene
whose product is called hemojuvelin (Papanikolaou et al., 2004).  While mutations to the
protein are linked to disease (Lanzara et al., 2004; Lee et al., 2004), the function of
hemojuvelin is currently unknown (Brissot et al., 2004).  Type III hemochromatosis, which
is characterized by severe iron loading and clinical complications that are phenotypically
indistinguishable from type I hemochromatosis (Camaschella et al., 2000), results from
mutations to a protein called transferrin receptor 2 (TfR2) (Kawabata et al., 1999; Fleming
et al., 2002). TfR2 is expressed mainly by hepatocytes and has high sequence and
functional similarity to TfR1 (Kawabata et al., 1999).  The role of TfR2 in acting as a
regulator of iron homeostasis is not clear at this time.  The cause of type IV
hemochromatosis has been mapped to mutations to a recently identified protein called
ferroportin (Fpn) (Abboud & Haile, 2000; Donovan et al., 2000; McKie et al., 2000;
Fleming & Sly, 2001; Montosi et al., 2001; Roetto et al., 2002; Jouanolle et al., 2003;
Rivard et al., 2003).  Fpn is a membrane protein capable of transferring ferrous iron from
the interior to exterior of the cell.  Iron release from cellular warehouses is an important
first step in mobilization and defects in ferroportin result in iron loading (Brissot et al.,
2004).
The Identification of HFE as a Regulator of Iron Homeostasis
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The most common form of hemochromatosis is primary, or type I hemochromatosis, also
known as idiopathic hemochromatosis, primary iron overload, or hereditary
hemochromatosis (HH) (Feder et al., 1996).  The result of HH is the excess deposition of
iron in liver, pancreas, and heart leading to cirrhosis, cancer, myocardial failure,
arrhythmias, type II diabetes, arthritis, hypogonadism, and an iron-induced melanin over-
expression that can lead to bronzing of the skin, which earned it the name “the bronze
killer” (reviewed in Hanson et al., 2001).  Individuals afflicted with HH absorb 1 to 3 mg
of iron per day in excess of their body’s needs.  Small amounts of excess iron are well
tolerated and can be stored.  However, this daily excess iron absorption occurs throughout a
lifetime and eventually exceeds the body’s iron storage capacities, resulting in the
circulation of iron not tightly bound to protein cofactors (Schrieber, 1989).  The liver is
responsible for clearing this form of iron and so it is often the first target of iron-mediated
tissue damage, soon followed by other organs (Craven et al., 1987).  At the onset of
systemic disease, an affected individual may have an iron load of 20-40 grams, many times
that found in a healthy adult (3-5 grams) (reviewed in Schrieber, 1989).  While the disease
was recognized and carefully documented in the 19th century, the exact cause was not
identified until nearly a hundred years later (reviewed in Beutler, 2002).  In the late 1970s
the gene responsible for HH was shown to be linked the major histocompatibility complex
(MHC) and eventually mapped to the short arm of chromosome 6.  In the mid 1990s, John
Feder and colleagues at Mercator Genetics utilized positional cloning during a proof-of-
principle pilot experiment that sought to identify genes linked to disease (Feder et al.,
1996).  Their work identified a gene, now called HFE, that codes for a type I
transmembrane glycoprotein homologous to the heavy chain of class I MHC molecules.  In
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their original study of patients identified with hemochromatosis, 83% were homozygous
for a mutation converting guanosine 845 to adenosine and resulting in a tyrosine
substitution for a cysteine at position 260 (C260Y) in the HFE protein (Feder et al., 1996).1
A second mutation (H41D) was found in some HH patients.  Subsequent population studies
indicate that H41D hetero- and homozygotes are more common than C260Y hetero- and
homozygotes, though the degree of iron loading associated with H41D is not as great
compared with C260Y (Waalen et al., 2002).  The role of H41D in primary
hemochromatosis is less clear, but a recent study utilizing transgenic mice demonstrates
that H41D homozygotes have an increased iron load compare to wild-type littermates
(Tomatsu et al., 2003).  H41D/C260Y compound heterozygous mice are significantly less
iron loaded that C260Y homozygotes, but have a much greater hepatic iron load than wild-
type mice, H41D/C260Y mice, or H41D homozygotes (Tomatsu et al., 2003).  These data
indicate that the H41D substitution leads to a partial loss of HFE function.
HFE Binds the Transferrin Receptor, a Protein Central to Iron Regulation
The discovery that HFE binds to the transferrin receptor (TfR) linked it to one of the most
central proteins in iron metabolism (Parkkila et al., 1997; Feder et al., 1998).  TfR is a
dimeric type II transmembrane glycoprotein expressed on virtually all mammalian cell
types and serves as the primary entry point for iron into cells (Enns, 2002).  The central
role of TfR in maintaining iron balance is illustrated by a study of TfR knockout mice
(Levy et al., 1999).  Homozygous TfR negative animals do not develop beyond embryonic
                                                 
1 There is a discrepancy in the HFE field in terms of numbering systems.  Here I use the numbering
convention for MHC molecules and other cell surface proteins that begins with the first residue of the
mature protein after the hydrophobic signal sequence has been removed.  Many reports on HFE begin
numbering from the start of the signal sequence and differ by 22 residues.
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day E12.5 and exhibit extreme anemia and defects in neural tube formation (Levy et al.,
1999).  That the embryos develop this far indicates that there must be another route for iron
delivery at the early stages of development, and there is evidence this role is played by a
siderophore-binding lipocalin (Yang et al., 2002).  Therefore, unlike most of the proteins
already discussed, there are no known alleles of TfR associated with any kind of iron
overload or deficiency, as an inactive form of TfR would likely be lethal before the end of
the gestation period.
Transferrin Receptor Binds Transferrin, an Iron Transport Protein
As its name implies, TfR is a receptor for transferrin (Tf) (Leibman & Aisen, 1977).
Serum Tf takes advantage of the circulatory system to fulfill the requirement of iron
transport and delivery to tissues throughout an organism (Schade, 1946).  Tf is an ~80 kDa
soluble glycoprotein and is the third most abundant protein in blood after albumin and
immunoglobulin (Schrieber, 1989). Tf was the first identified protein to evolve from
ancestral gene duplication and fusion: each Tf molecule is composed of two lobes related
by high structural and sequence similarity (Park et al., 1985) (Fig 1A).  Each lobe
comprises two smaller domains, N-I and N-II in the N-lobe and C-I and C-II in the C-lobe
(Anderson et al., 1987).  The transferrin superfamily comprises numerous homologs and
orthologs such as the ovotransferrins, melanotransferrins, and lactoferrins (Nakamasu et al.,
1999).  Members of the transferrin family are found throughout eukarya with more recently
identified molecules in the hemolymph of the tobacco hornworm (Manduca sexta)
(Bartfeld & Law, 1990), the cockroach (Blaberus discoidalis) (Jamroz et al., 1993), and
even in the unicellular green algae Dunaliella salina (Fisher et al., 1997).  Each lobe of
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transferrin binds a single ferric (Fe3+) ion and coordinates it with two tyrosine resides, one
histidine, one aspartate, and the synergistic anion bicarbonate (Anderson et al., 1987) (Fig
1A).  The mechanisms of iron binding and release are complicated and involve multiple
protonation steps, the presence of helper ions, chelators, interactions between Tf lobes, and
local and large-scale structural changes (reviewed in He, 2002).  The most striking
structural feature of transferrin is the large conformation change induced by the loss of
iron.   Upon loss of iron, there is a 54-63º rotation between the domains that comprise each
lobe and a repacking of the interface between each lobe, burying previously exposed
residues and exposing previously buried residues (Gerstein et al., 1993; Kurokawa et al.,
1999) (Fig 1B).  Mechanisms of iron release are discussed in more detail in Chapter 4.
While only about 0.1% of the total iron in a healthy adult human is loaded on transferrin,
there is significant flux of iron through this member of the iron-transport compartment.
The reticuloendothelial system alone requires about 24 mg of iron for the daily production
of about 200 billion new erythrocytes (Knutson & Wessling-Resnick, 2003).  Transferrin
mitigates the inherent danger in transporting potentially reactive iron through an
oxygenated aqueous solution, such as blood, by binding the ferric ion with extremely high
affinity (KA~10
22 M) (Aisen et al., 1978).  The spontaneous release of iron from transferrin
at basic pH is extremely slow with a half-life of days to weeks.  Acidic pH destabilizes iron
binding, however even at pH 5.5 the half-life of bound iron is greater than three hours
(reviewed in He and Mason, 2002).  There are four iron-binding states for the transferrin
molecule.  Since each lobe can bind an iron atom, and binding of iron in one lobe is not
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requisite for binding in the other lobe, then Tf may exist in the diferric state (here referred
to as Fe-Tf), monoferric with the C-lobe loaded (FeC-Tf), monoferric with the N-lobe
loaded (FeN-Tf), or iron free (apo-Tf).  All of these forms of Tf can be found in the blood
with ~70% of the total protein in the apo-Tf form (Aisen et al., 1978; Leibman & Aisen,
1979).
Transferrin and Transferrin Receptor Work Together to Deliver Iron to Cells
When circulating Fe-Tf encounters TfR the two proteins bind with high affinity (~1 nM)
(Dautry-Varsat et al., 1983). TfR is a dimeric protein and can accommodate two Tf
molecules (Enns & Sussman, 1981).  The cytoplasmic domain of TfR contains a YTRF
sequence that directs it to clathrin-coated pits for endocytosis into the tubulo-vesicular
endosomal system.  TfR is transported through an acidic compartment and then sorted back
to the cell surface (reviewed in Schmid, 1992).  When Fe-Tf is bound to TfR during its
journey, the exposure to the low pH compartment stimulates the removal of iron from Tf
such that release is complete within 2-3 minutes (Aisen & Leibman, 1973).  The released
iron is then shuttled, presumably through the divalent metal transporter DMT1, to the
cytosol where it is picked up for use by the cellular machinery, or incorporated into the
iron-storage protein ferritin (Richardson & Ponka, 1997).  At acidic pH, apo-Tf and TfR
still have a high affinity for each other (~5 nM) and the two proteins stay together through
sorting back to the cell surface.  Upon exposure to the slightly basic pH of blood (pH~7.4),
apo-Tf rapidly dissociates due to its barely detectable affinity for TfR at this pH and renters
the circulation (reviewed in Enns, 2002).  The amount of TfR-mediated iron uptake is
regulated at the translational level such that when iron is low, the translation rate of TfR
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mRNA is increased, and when iron is high, TfR translation is decreased (reviewed in Theil,
1994).
HFE Modulates Iron Homeostasis
The interaction between HFE and TfR has been characterized by biochemical and cellular
methods (Feder et al., 1998; Gross et al., 1998; Riedel et al., 1999; Roy et al., 1999; Salter-
Cid et al., 1999; Roy et al., 2000; Davies et al., 2003).  HFE binds to TfR with an
equilibrium dissociation constant of ~50 nM at the basic pH of the cell surface (pH~7.4)
(Lebrón et al., 1998; Lebrón & Bjorkman, 1999; Lebrón et al., 1999; West et al., 2000;
West et al., 2001; Giannetti et al., 2003; Giannetti & Bjorkman, 2004).  This is
significantly weaker than the binding of Fe-Tf at the same pH (~1 nM) (Lebrón et al.,
1998).   However, HFE binding does not occur at acidic pH (<6.3) (Lebrón et al., 1998).
This pH dependence is opposite that of apo-Tf, which binds to TfR at acidic but not basic
pH (Paterson et al., 1984; Lebrón et al., 1998).  Early cellular studies on HFE-transfected
HeLa cells indicated that expression of HFE lowered the observed affinity of the cells for
Tf suggesting an activity for HFE in modulating the binding properties of TfR (Feder et al.,
1998; Riedel et al., 1999; Roy et al., 1999; Salter-Cid et al., 1999).  Subsequent in vitro
studies using soluble versions of HFE and TfR reported the same result (Lebrón et al.,
1999; Roy et al., 2000).  This lead to an initial hypothesis that HFE lowers the amount of
endocytosed iron by reducing TfR’s ability to bind and transport iron-loaded transferrin.
Indeed, some of the early cellular studies noted a marked decrease in cellular iron content
of HFE-transfected cells (Gross et al., 1998).  These experiments have been repeated using
various cell lines.  Not all studies are in agreement and virtually every possible result has
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been reported, including increased iron uptake, decreased transferrin cycling, altered
receptor trafficking rates, identical transferrin uptake but lower iron donation by transferrin,
and reduced iron export (Gross et al., 1998; Corsi et al., 1999; Riedel et al., 1999; Roy et
al., 1999; Salter-Cid et al., 1999; Roy et al., 2000; Feeney & Worwood, 2001; Drakesmith
et al., 2002; Waheed et al., 2002; Wang et al., 2003).  Emerging from the aggregate of
these results is the awareness that HFE may have differential effects on iron levels
depending on cell type.  Since almost all cells express TfR, this would suggest that HFE
has an alternate binding partner, though TfR binding may be a prerequisite for recognition
by this as yet unidentified protein.  Hypotheses regarding the identity of this mystery
receptor are discussed at the end of this chapter and in chapter 3.
The Molecular Structures of HFE and TfR
HFE and TfR have been structurally characterized alone and in complex (Lebrón et al.,
1998; Bennett et al., 2000).  As predicted from sequence homology, HFE is structurally
similar to the class I major histocompatibility complex (MHC) molecules (Lebrón et al.,
1998), which present antigenic peptides to T lymphocytes (Garcia et al., 1999) (Fig 2).  In
addition to the characteristic long α−helices, the β−sheet platform, and the α3 domain that
are found in class I MHC proteins, HFE also binds the class I MHC light chain β2-
microglobulin (Feder et al., 1997).  The significance of the similarity between HFE and
class I MHC molecules is unclear since HFE has no known function in the immune
response.  In fact, the HFE counterpart of the class I MHC peptide-presenting groove is
closed in HFE as the result of sidechain substitutions and a 4 Å translation of the α1
domain helix towards the α2 domain helix (Lebrón et al., 1998).  Cysteine 260, which is
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mutated to tyrosine in individuals with hereditary hemochromatosis, is part of a disulphide
bridge in the α3 domain. This bridge is highly conserved in MHC molecules and
disruption, as in the common HH mutation C260Y, prevents proper folding, β2-
microglobulin binding, and cell surface expression, effectively abrogating HFE function
(Feder et al., 1997; Waheed et al., 1997).
Transferrin receptor is also a transmembrane glycoprotein.  As previously discussed, the N-
terminal tail, which is exposed to the cytosol, contains an endocytic motif (Enns, 2002) in
addition to a cysteine-linked palmitate (Adam et al., 1984) and a serine residue that can be
phosphorylated by protein kindase C (Rothenberger et al., 1987).  The extracellular domain
of TfR begins with an ~33 residue stalk domain that contains two cysteines that form
disulphide bonds to their counterparts on the second chain of the obligate TfR dimer (Enns,
2002).  The stalk also contains the only site of O-linked glycosylation and serves a
protective role by preventing proteolytic cleavage of TfR near the plasma membrane
(Rutledge, Green et al., 1994; Rutledge, Root et al., 1994; Rutledge & Enns, 1996).
Despite the covalent linkage of the two TfR chains by cysteines in the stalk region, the
dimeric nature of TfR is maintained by the remaining ~640 residues that make up the
remainder of the ectodomain (Turkewitz et al., 1988; Lebrón et al., 1998).  The crystal
structure of TfR ectodomain dimer shows that each monomer is formed from three
domains (Lawrence et al., 1999) (Fig 3A).  The first domain is called the protease-like
domain because of its high sequence and structural similarity to carboxypeptidases.  The
capacity for peptide hydrolysis has been eliminated by substitution of three of the residues
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that would coordinate the active site zincs (Lawrence et al., 1999).  Inserted between the
first and second strands of the central β-sheet of the protease-like domain is the apical
domain.  The physiological function of the apical domain is unknown; however, it is
recognized by parvoviruses making TfR the point of cellular entry for those pathogens
(Palermo et al., 2003).  The third domain of TfR is a large four-helix bundle that comprises
a significant fraction of the dimerization surface and contacts all three domains on the
partnered monomer (Lawrence et al., 1999).
The crystal structure of HFE bound to TfR has also been reported (Bennett et al., 2000)
(Fig 3B).  The complex is formed from associations between the helical domain of TfR and
the α1 helix of HFE to form a 3-helix bundle and burying ~2,000 Å2 of total surface area.
There are additional contacts from the α2 helix of HFE with TfR’s helical domain that are
not part of the 3-helix bundle.  Before the structure of this complex was solved, it was not
clear if HFE molecules would preferentially interact with TfR molecules on the same
membrane, or perhaps bind TfR on an adjacent cell.  To form the structure observed in the
crystal, HFE molecules would only be able to interact with TfR molecules on a common
membrane, and in fact would have to “lie down” relative to the orientation commonly
associated with class I MHC molecules (Bennett et al., 2000) (Fig. 3).
The Mechanism by Which HFE Regulates Iron Metabolism Is Not Known
The observation that HFE binds to TfR circumstantially involves HFE in an important
system for iron transport and uptake.  However, TfR binding does not explain HFE’s role
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as a modulator of iron homeostasis.  Over the last eight years, hundreds of biochemical,
cellular, and physiological studies have been reported in an attempt to understand the role
of HFE in maintaining iron balance, and to develop an understanding of the molecular
pathology of hereditary hemochromatosis.  Theories and models continue to be proposed,
but each is confounded either by conflicting reports or the continuous discovery of new
proteins involved in maintaining iron balance.  Therefore, my approach to studying this
system was to focus on the structural and chemical aspects of the HFE/TfR/Tf system and
attempt to relate those findings to the cellular case.  The dimeric nature of TfR coupled
with its ability to bind two ligands, each with different dependency on pH for binding, and
one of which (transferrin) has multiple structural and chemical configurations, results in a
complex chemical equilibrium, aspects of which may have significant consequences for the
mechanism of HFE action (Fig 4).
Thus, I undertook a careful examination of the structural and biochemical interactions
between HFE and TfR, Fe-Tf and TfR, and apo-Tf and TfR.  The early cellular and
biochemical studies involving HFE indicated that HFE lowered the observed affinity of
TfR for Tf (Feder et al., 1998; Gross et al., 1998), and competition binding experiments
suggested that HFE and Tf shared the same or similar binding footprint on the receptor
surface (Lebrón et al., 1999).  While the HFE binding footprint on TfR had been
characterized by crystallography (Bennett et al., 2000), there were only two studies
mapping the Tf binding site.  Using human/chicken TfR chimeras the binding site for Tf
had been mapped to the C-terminal 192 amino acids of TfR (Buchegger et al., 1996), while
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a small qualitative mutagenesis study indicated that residues in a conserved Arg-Gly-Asp
(RGD) motif (Dubljevic et al., 1999), also in the TfR helical domain, were important.
Together all of these data suggested that HFE and Tf have an overlapping binding site on
TfR, but more functional information would be required to understand the significance of
this overlap to TfR ligand binding.
A Mutagenesis Study Reveals the Binding Footprints of HFE, Fe-Tf, and apo-Tf on the
Surface of TfR
While a co-crystal structure of two proteins identifies the interaction surface, it does not
reveal which interactions are most functionally relevant.  Only by systematically
mutagenizing residues in an interface can a map of the functional epitope (those residues
contributing at least 2 kcal/mol of free energy of binding) be defined (Cunningham &
Wells, 1993).  Utilizing the crystal structure of HFE/TfR and the results of a mutagenesis
study of HFE that identified some functionally important residues, I began working with
Dr. Anthony West in our laboratory to mutate residues in TfR to identify what residues
were important for binding HFE.  Our hypothesis was that if the binding sites for HFE and
Tf overlap, then mapping the HFE interface would reveal some residues responsible for Tf
binding.  It was initially noted that one of the TfR mutations, L619A, eliminates detectable
HFE binding and affects a concomitant drop in Fe-Tf affinity providing the first functional
evidence of overlapping binding sites.  Another mutation, Y643A, had a similar effect
(West et al., 2001).  The results of this early mutagenesis work are described in Appendix I.
However transferrin is a large molecule about the same size as a TfR monomer  (~90Å x
50Å x 40 Å; measured using the structure of iron-bound ovotransferrin (Kurokawa et al.,
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1995), suggesting that Tf could contact multiple domains of TfR.  For example, an early
modeling study indicated that Tf possesses sufficient surface area to contact all three TfR
domains at once (Lawrence et al., 1999).  Therefore, I expanded the mutagenesis screen to
include residues from disparate parts of the receptor within a radius defined by the long
axis of Tf.  The search for functional residues mostly involved identifying exposed
hydrophobic sidechains, although substitution of some charged residues also significantly
affected binding.  The results of the mutagenesis study are described in Chapter 2
(Giannetti et al., 2003), along with a description of technical improvements in screening
and methodology.  One development was the use of binding models that better describe the
TfR system.  A second was the redesign of the assay methodology to develop a new
protocol that has higher throughput, requires 1/1000th of the amount of starting material,
and eliminates the need to purify the TfR before the binding analysis.
Mutagenesis Reveals a Mechanism for TfR-Assisted Iron Release from Tf
The mutagenesis screen revealed several features of HFE, Fe-Tf, and apo-Tf binding,
including the observation that Fe-Tf and apo-Tf have differential binding footprints on the
TfR surface (Giannetti et al., 2003).  While most of the residues that affect binding of one
form of Tf also affect binding of the other form, there are key functional differences. From
the comprehensive mutagenesis study of TfR we identified residues that are specific for
binding apo-Tf (Giannetti et al., 2003).  Chapter 4 describes experiments that reveal that
these conserved residues, which form a hydrophobic patch on the TfR surface, are required
for TfR to stimulate the release of iron from Fe-Tf at acidic pH.  We hypothesize that this
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patch facilitates the opening of the Tf molecule to expose the iron atom, thereby enhancing
the efficiency of iron removal by cellular chelators.
Biochemical and Biophysical Studies Using an Engineered Transferrin Receptor
We also sought to understand the molecular mechanism for the observed decrease in Tf
binding affinity by cells expressing HFE (Feder et al., 1998; Riedel et al., 1999; Roy et al.,
1999) by investigating the possibility of cooperativity in ligand binding to TfR.  This
requires measurement of the formation of the HFE/TfR/Tf ternary complex, which is
impossible given the complex equilibrium between HFE, Fe-Tf, and TfR when all three
proteins are mixed.  In Chapter 3, I describe how this problem was solved by creating a
heterodimeric transferrin receptor (hdTfR) in which one chain of the dimer is able to bind
HFE but not Tf, and the other chain can bind Tf but not HFE.  Characterization of the
ligand-binding stoichiometries of hdTfR using sedimentation velocity analytical
ultracentrifugation revealed that the hdTfR forms 1:1 complexes with HFE and Fe-Tf
according to its design.  I also designed and developed a competition assay that allowed the
potential for cooperativity to be assessed.  Binding studies performed with this assay
demonstrate that TfR does not exhibit cooperativity in heterotropic ligand binding,
suggesting that some or all of HFE’s effects on iron homeostasis result from competition
with Fe-Tf for TfR binding.  Additionally, we showed that soluble HFE is incapable of
competing with Fe-Tf for binding to TfR at any physiologically relevant concentration of
Fe-Tf.  If HFE competes with Fe-Tf for TfR binding in vivo, then the tethering of HFE and
TfR to a common membrane, which increases their effective local concentration, may be
an important feature of HFE’s role in iron homeostasis.
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Biochemical Competition Alters HFE’s Cellular Trafficking
Given that the concentration of iron-loaded transferrin in blood fluctuates with body iron
status (Schrieber, 1989), and that these fluctuations should affect HFE binding to TfR since
Fe-Tf and HFE compete for binding to TfR, we sought to test this prediction by
investigating the biological relevance of this competition.  In Chapter 3, I describe how I
used cell lines that either lack TfR expression, or express human TfR (McGraw et al.,
1987), to demonstrate that HFE is dependent on TfR binding to traffic from the cell surface
to TfR positive endosomes (schematically diagrammed in Fig 5).  I then showed that at
physiologically-relevant concentrations of Fe-Tf, HFE is able to compete for TfR binding
sites and is transported to endosomes.  However, at concentrations exceeding those of a
healthy individual and approaching those of someone with a high body iron load (Henry,
1991), HFE cannot compete against the high concentrations of Fe-Tf and becomes
localized to the cell membrane.
Theories about HFE’s Action in Iron Homeostasis
Since the description of HFE as the protein mutated in patients with hereditary
hemochromatosis (Feder et al., 1996), much has been learned about HFE and other proteins
involved in iron homeostasis that will not be discussed at length here (e.g., hepcidin
(Nicolas et al., 2001), hemojuvelin (Papanikolaou et al., 2004), TfR2 (Kawabata et al.,
1999), hephaestin (Vulpe et al., 1999), ceruloplasmin (Gitlin, 1998), SFT-1 (Yu &
Wessling-Resnick, 1998), frataxin (Radisky et al., 1999), ABC7 (Savary et al., 1997;
Allikmets et al., 1999), ALAS2 (Cotter et al., 1994), DcytB (McKie et al., 2001),
pantothenate kinase (Zhou et al., 2001), CD163 (Knutson & Wessling-Resnick, 2003),
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ferritin (Beaumont et al., 1995), DMT1 (Gunshin et al., 1997), ferroportin (Abboud &
Haile, 2000; Donovan et al., 2000; McKie et al., 2000), and the entire network of iron
response proteins that regulate the translational rates of some proteins such as TfR and
ferritin (reviewed in Theil, 1994)).  The complexity of iron handling by the body is
illustrated by considering that in the above list of nearly 20 proteins, none actually use the
iron directly for chemical reactions or oxygen binding, but act to manage the problem of
iron absorption, transport, and regulation so that other proteins, such as hemoglobin,
lipoxygenase, and ribonucleotide reductase have the metal they need to carry out their
functions.  Considering that most of the proteins listed here and elsewhere in this work
were only discovered in the last 10 years, and considering that there are probably more to
be discovered, one realizes that developing a model explaining HFE’s function in iron
homeostasis is challenging.
Currently there are several hypotheses for the function of HFE (Drakesmith et al., 2002;
Frazer & Anderson, 2003).  One proposal is that at the cell surface, free HFE can act as a
regulator of iron export, possibly through interactions with the iron export protein
ferroportin (Drakesmith et al., 2002). Two studies have noted that HFE expression
decreases iron export rates from cells, though there is as yet no evidence that this results
from direct interactions with ferroportin (Drakesmith et al., 2002; Davies & Enns, 2004).
In another hypothesis (Frazer & Anderson, 2003), the amount of free HFE at the cell
surface may act as a regulator for the expression of hepcidin, a peptide hormone that
regulates body iron load (Nicolas et al., 2001; Weinstein et al., 2002).  Expression of
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hepcidin results in lower body iron, whereas elimination of hepcidin function, for example,
by mutation or transgenic knockout, leads to iron overload (Fleming et al., 2001).  In this
model, free HFE stimulates the production of hepcidin, thereby down-regulating iron
levels.  Loss of HFE function, as in hereditary hemochromatosis, would result in down-
regulated hepcidin expression and subsequent iron overload.  The commonality of both
models is that competition between HFE and Fe-Tf for TfR modulates the amounts of free
HFE and HFE that is bound to TfR.  Therefore, we believe that competition is central both
to HFE’s role in maintaining iron homeostasis, and key to understanding the molecular
basis for the iron overload disorder hereditary hemochromatosis.
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Figure 1.  Ribbon diagrams of transferrin.  A)  Structure of di-ferric ovotransferrin
(Kurokawa et al., 1995) colored by domain as shown.  Residues coordinating the iron
atoms (red spheres) are shown as sticks and colored at atom type (yellow, carbon; blue,
nitrogen; red, oxygen). (B)  Structure of apo-ovotransferrin (Kurokawa et al., 1999) as in
(A) illustrating the large conformational change associated with iron release.
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Figure 2:  Comparison of the structures of a class I MHC molecule and HFE.  HLA-A2
complexed with the tax peptide (Khan et al., 2000) (PDB code: 1DUY) is shown with the
various domains and light chain labeled.  The peptide is shown as ball-and-sticks.  The
HFE molecule (Lebron et al., 1998) (PDB code: 1A6Z) is shown for comparison.
Residues that are mutated in hemochromatosis patients are indicated.
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Figure 3.  Schematic of the TfR alone (Lawrence et al., 1999) or bound to HFE (Bennett
et al., 2000).  The soluble domains are shown above a representation of the membrane
(yellow).  TfR is colored yellow (protease-like domain), orange (apical domain), and
magenta (helical domain).  The HFE molecules in (B) are colored blue (heavy chain) and
green (light chain).
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Figure 4:  Equilibrium diagram of all possible stoichiometries formed by TfR with apo-
Tf, Fe-Tf, and HFE with measured KD values reported from (Giannetti et al., 2003).  HFE
and apo-Tf exhibit pH dependence of binding and are colored separately.  Fe-Tf binds
well at both acidic and basic pH.  The ternary complex can only form at basic pH.  The
KD values for formation of the ternary complex cannot be determined and are labeled as
N.D.
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Figure 5:  Model of TfR mediated uptake of Fe-Tf and HFE to acidic recycling
endosomes.  HFE and Fe-Tf can bind to TfR at the basic pH of the cell surface.  Receptor
mediated endocytosis translocates TfR and its cargo to acidic recycling endosomes where
iron is released from Tf, shuttled through DMT1 to the cytosol where it is stored in
ferritin.  The endosome is recycled to the cell surface where apo-Tf dissociates.  The fate
of HFE is less clear.  HFE is dependent on TfR binding for transport to endosomes
(Giannetti and Bjorkman, 2004), but does not bind TfR in biochemical experiments at
acidic pH and has been indicated to dissociate within the endosome, though some data
suggests the two proteins may remain associated (Davies et al., 2003).
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Chapter 2:
The Mechanism for Multiple Ligand
Recognition by the Transferrin Receptor
In this paper we report the mapping of the structural and functional binding epitopes for
HFE, Fe-Tf and apo-Tf on the surface of TfR, as well as determine the orientation of Tf
on the receptor.  Peter Snow is director of Caltech’s Protein Expression Facility and he
generated baculovirus stocks and expressed the wild-type and mutant transferrin
recepetors used in this study.  Olga Zak produced the recombinant transferrin C-lobe we
used to map the site of C-lobe specific contacts to TfR.
47
Mechanism for Multiple Ligand Recognition
by the Human Transferrin Receptor
Anthony M. Giannetti
1
, Peter M. Snow
2
, Olga Zak
3
, Pamela J. Bjo¨rkman
4*
1 Graduate Option in Biochemistry and Molecular Biophysics, California Institute of Technology, Pasadena, California, United States of America, 2 Caltech Protein Expression
Center, Division of Biology, California Institute of Technology, Pasadena, California, United States of America, 3 Department of Physiology and Biophysics, Albert Einstein
College of Medicine, Bronx, New York, United States of America, 4 Division of Biology and Howard Hughes Medical Institute, California Institute of Technology, Pasadena,
California, United States of America
Transferrin receptor 1 (TfR) plays a critical role in cellular iron import for most higher organisms. Cell surface TfR binds
to circulating iron-loaded transferrin (Fe-Tf) and transports it to acidic endosomes, where low pH promotes iron to
dissociate from transferrin (Tf) in a TfR-assisted process. The iron-free form of Tf (apo-Tf) remains bound to TfR and is
recycled to the cell surface, where the complex dissociates upon exposure to the slightly basic pH of the blood. Fe-Tf
competes for binding to TfR with HFE, the protein mutated in the iron-overload disease hereditary hemochromatosis.
We used a quantitative surface plasmon resonance assay to determine the binding affinities of an extensive set of site-
directed TfR mutants to HFE and Fe-Tf at pH 7.4 and to apo-Tf at pH 6.3. These results confirm the previous finding that
Fe-Tf and HFE compete for the receptor by binding to an overlapping site on the TfR helical domain. Spatially distant
mutations in the TfR protease-like domain affect binding of Fe-Tf, but not iron-loaded Tf C-lobe, apo-Tf, or HFE, and
mutations at the edge of the TfR helical domain affect binding of apo-Tf, but not Fe-Tf or HFE. The binding data
presented here reveal the binding footprints on TfR for Fe-Tf and apo-Tf. These data support a model in which the Tf C-
lobe contacts the TfR helical domain and the Tf N-lobe contacts the base of the TfR protease-like domain. The
differential effects of some TfR mutations on binding to Fe-Tf and apo-Tf suggest differences in the contact points
between TfR and the two forms of Tf that could be caused by pH-dependent conformational changes in Tf, TfR, or both.
From these data, we propose a structure-based model for the mechanism of TfR-assisted iron release from Fe-Tf.
Introduction
Transferrin receptor 1 (TfR) is a homodimeric type II
membrane protein that plays a critical role in the primary
iron acquisition mechanism for all iron-requiring cell types
in vertebrates (Enns 2002). TfR binds the serum iron-carrier
protein transferrin (Fe-Tf) and imports it to acidic endo-
somes, where iron is released and transported to the cytosol.
The complex between TfR and iron-free transferrin (apo-Tf)
is then recycled to the cell surface where apo-Tf dissociates
and returns to circulation (reviewed in Enns et al. 1996). TfR
also binds the hereditary hemochromatosis protein HFE
(Parkkila et al. 1997; Feder et al. 1998). HFE is a class I major
histocompatibility complex (MHC)-related protein that is
mutated in patients with hereditary hemochromatosis (Feder
et al. 1996), an iron-storage disease characterized by excessive
iron absorption leading to an accumulation of iron princi-
pally in the liver, heart, pancreas, parathyroid, and pituitary
gland, leading to tissue damage (Cullen et al. 1999).
The X-ray crystal structures of the human TfR ectodomain,
both alone (Lawrence et al. 1999) and in complex with HFE
(Bennett et al. 2000), have been reported. The homodimeric
TfR ectodomain contains three domains on each polypeptide
chain: a protease-like domain resembling amino- and
carboxypeptidases (residues 121–188 and 384–606), an apical
domain (residues 189–383), and a helical domain involved in
TfR homodimerization (residues 607–760). Intact TfR also
includes a glycosylated stalk region (residues 90–120), a
transmembrane domain (residues 62–89), and an N-terminal
cytoplasmic domain (residues 1–61) that includes a tyrosine-
based endosomal sorting sequence (YTRF) (Enns 2002). The
structure of a 2:1 HFE/TfR complex (two HFEs bound to a
homodimeric TfR) shows that each HFE interacts with helices
1 and 3 of the TfR helical domain (Bennett et al. 2000) (Figure
1A and 1B). The central portion of the interface includes a
hydrophobic core consisting of TfR residues Leu619, Val622,
and Tyr643 packed against hydrophobic residues from the a1
domain helix of HFE.
The structures of various transferrins (Tfs) and related
proteins such as lactoferrin have been studied extensively by
X-ray crystallography (Bailey et al. 1988; Anderson et al. 1989;
Gerstein et al. 1993; Zuccola 1993; Kurokawa et al. 1995, 1999;
Baker et al. 1998; Karthikeyan et al. 1999). Tf and its relatives
are single-chain molecules consisting of two similarly folded
lobes (the N- and C-lobes), each of which contains two
domains (NI and NII in the N-lobe; CI and CII in the C-lobe).
Diferric Tf (Fe-Tf) contains two iron atoms, each held in a
cleft between the domains of each lobe. Transition between
the ferric and iron-free states of Tf involves significant
conformational changes (Grossmann et al. 1992, 1993).
Specifically, loss of iron results in a 548–638 rotation between
the two domains that comprise each lobe (Gerstein et al.
Received July 15, 2003; Accepted September 10, 2003; Published December 22,
2003
DOI: 10.1371/journal.pbio.0000051
Copyright:  2003 Giannetti et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Abbreviations: apo-Tf, iron-free transferrin; Fe-C-lobe, iron-loaded transferrin C-
lobe; Fe-Tf, diferric transferrin; HFE, hereditary hemochromatosis protein; KD,
equilibrium dissociation constant; MHC, major histocompatibility complex; PIPES,
piperazine-1,4-bis(2-ethanesulphonic) acid; RU, resonance unit; Tf, transferrin; TfR,
transferrin receptor
Academic Editor: Janet Thornton, European Bioinformatics Institute
*To whom correspondence should be addressed. E-mail: bjorkman@caltech.edu
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 341
PLoS BIOLOGY48
1993). Additionally, the interface between the lobes repacks,
exposing previously buried residues and burying previously
exposed residues (Kurokawa et al. 1999). In vivo, these
conformational changes presumably take place while Tf is
bound to TfR, as the two proteins remain complexed
throughout endocytosis and recycling (Dautry-Varsat et al.
1983).
Free Fe-Tf releases iron at acidic pH, but binding to TfR
affects the iron release at both basic and acidic pH (Bali and
Aisen 1991, 1992; Bali et al. 1991). At pH 7.4, iron release
from Fe-Tf bound to TfR is slower than from free Fe-Tf. At
low pH, the opposite effect is observed, such that binding to
TfR significantly increases the iron-release rate (Bali and
Aisen 1991, 1992; Bali et al. 1991; Sipe and Murphy 1991).
Attempts to determine the mechanism by which TfR mediates
these effects on the iron release rate have been hampered by
a lack of detailed knowledge of the binding footprints of Fe-
Tf and apo-Tf on TfR and by the unavailability of crystal
structures of Fe-Tf or apo-Tf bound to TfR.
Although the structural details of the interaction between
Tf and TfR remain unknown, early studies established that
two Tf molecules bind to each TfR homodimer (Enns and
Sussman 1981) by primarily interacting with what is now
structurally defined as the TfR helical domain (Buchegger et
al. 1996). A subsequent mutagenesis study further localized
the binding site to include a conserved RGD sequence
(residues 646–648) within the TfR helical domain (Dubljevic
et al. 1999). The HFE/TfR co-crystal structure revealed that
HFE directly contacts TfR residues 646 and 648 (Bennett et al.
2000), which is consistent with biochemical inhibition studies
that suggested that HFE and Tf bind to the same or an
overlapping site on TfR (Lebro´n et al. 1999). As Fe-Tf is a
large protein (approximately 90A˚ 3 50A˚ 3 40 A˚, measured
using the structure of iron-bound ovo-Tf [Kurokawa et al.
1995]), the remainder of the Tf contact site on TfR could
include other TfR domains, the TfR interdomain cleft, or
both (Figure 1B), as previously suggested (Lawrence et al.
1999). A subsequent mutagenesis study sought to identify
other Tf-contacting residues on TfR (West et al. 2001). In that
study, residues identified from the HFE/TfR co-crystal
structure as involved in contacting HFE were mutated, and
their effects on binding to HFE and Fe-Tf were quantitatively
evaluated. These experiments identified several residues
within the TfR helical domain that are involved in binding
to each protein (defined as a substitution producing a greater
than or equal to 5-fold reduction in binding affinity) and
confirmed that the Fe-Tf- and HFE-binding sites on TfR
overlap. However, the larger size of Tf relative to the HFE
ectodomain (679 amino acids in Tf compared with 374 for the
HFE/b2-microglobulin ectodomain) suggested that Fe-Tf
could contact residues outside of the TfR helical domain.
Also, the effects of the TfR substitutions on binding to apo-Tf
were not evaluated; thus, the question of whether Fe-Tf and
apo-Tf bind differently to TfR was not addressed.
We therefore sought to expand the library of TfR mutants
to more extensively map the Fe-Tf interface and to compare
the effects of TfR mutants for binding to Fe-Tf versus apo-Tf.
Here we report the affinities of 30 mutants of human TfR for
binding to HFE and Fe-Tf at pH 7.5 and to apo-Tf at pH 6.3.
As expected, the most important residues for Tf binding are
located in the center of the TfR helical domain in the vicinity
of critical residues for HFE binding. However, we also
identified residues within the TfR protease-like domain that
make significant contributions to binding of Fe-Tf, but not
apo-Tf, to TfR. Conversely, substitution of residues at the
edge of the TfR helical domain affects binding of apo-Tf, but
not Fe-Tf. This information, together with the identification
of common Fe-Tf- and apo-Tf-contacting residues within the
helical domain, constrains the possible positions of Fe-Tf and
apo-Tf on TfR, allowing for construction of structural models
for the placement of the two forms of Tf on TfR. Our data
also suggest a structural mechanism to explain TfR’s role in
the pH-dependent modulation of iron release rates from Fe-
Tf.
Figure 1. TfR Structure
(A) Ribbon diagram of TfR homodimer
derived from the 3.2 A˚ structure of TfR
(Lawrence et al. 1999). The HFE-binding
site (deduced from an analysis using the
HFE/TfR co-crystal structure [Bennett et
al. 2000]) on the TfR helical domain
closest to the viewer is highlighted in
cyan.
(B) Space-filling representation of one
chain from the TfR homodimer, with the
HFE structural epitope residues high-
lighted as in (A). The location of the
interdomain cleft is indicated by an
orange asterisk.
(C–E) Summary of effects of TfR sub-
stitutions for binding HFE (C), Fe-Tf (D),
and apo-Tf (E). Color-coding of the TfR
sidechains designates the effects of the
substitutions on binding affinities as
indicated.
Figures were made with Molscript (Krau-
lis 1991) or GRASP (Nicholls et al. 1993)
and rendered with Raster3D (Merritt and
Bacon 1997).
DOI: 10.1371/journal.pbio.0000051.g001
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Results
Design of TfR Mutants
Our choice of TfR residues to substitute was guided by the
crystal structures of TfR alone and bound to HFE (Lawrence
et al. 1999; Bennett et al. 2000) and by a previous binding
study involving ten TfR point mutants (West et al. 2001) (§
symbol in Table 1). Four substitutions at the HFE-binding site
on the TfR helical domain (L619A, R629A, Y643A, and
F650A) were found to significantly reduce (greater than or
equal to 5-fold) the binding affinity for both HFE and Fe-Tf at
pH 7.5, giving a first-order map of the Fe-Tf-binding site on
TfR (West et al. 2001). In order to identify additional TfR
residues critical for Fe-Tf binding and to evaluate their
effects on apo-Tf binding, we extended our TfR mutant
library to include an additional 20 mutants. The new set of
mutations were chosen using three different strategies: (1) an
alanine scan involving solvent-exposed residues on helix 3 of
the helical domain (R651A, S654A, T658A, N662A, E664A)
(classified as H3 in Table 1); (2) substitution of residues in the
TfR interdomain cleft (see Figure 1B), suggested to be part of
the Fe-Tf-binding site (Lawrence et al. 1999), for the residues
of chicken TfR, which does not bind human Tf (Buchegger et
al. 1996) (P710R, K717Q) (classified as IDC in Table 1); (3)
mutation of large solvent-exposed hydrophobic residues,
which often provide much of the free energy of binding in
protein–protein interactions (Jones and Thornton 1996; Tsai
et al. 1997; Lo Conte et al. 1999), throughout the remaining
TfR surface area (Y123S, F187A, F396A, F521A, Y523S,
W528A, W702A, F760A) (classified as Hu in Table 1). A
second generation of mutants was subsequently made to
further define newly identified binding sites (W124A, D125K,
E606K, D610A) and to test the effect of combining sub-
stitutions (Y123S/G647A). Mutants involving TfR residues
known from the HFE/TfR crystal structure (Bennett et al.
2000) to contact HFE are denoted as part of the HFE
structural epitope in Table 1.
TfR mutants were expressed as N-terminally 6x-His-tagged
soluble ectodomains in baculovirus-infected cells, as pre-
viously described (Lebro´n et al. 1998; West et al. 2001). In a
previous TfR mutagenesis study, it was shown that mutants
that had a strong effect on binding were properly folded as
determined by comparison of their far-UV circular dichroism
spectra and gel filtration profiles to that of wild-type TfR
(West et al. 2001). In this study, we note that all of the newly
made mutants retain wild-type or near wild-type binding
affinities for at least one of the three TfR ligands tested (HFE,
Fe-Tf, or apo-Tf) (Table 1), confirming their structural
integrity.
Affinity Measurements and Analyses
Each of the TfR mutants designed in the current screen,
plus the mutants from the previous study (West et al. 2001),
were tested in a surface plasmon resonance-based assay for
binding to either a soluble form of HFE at pH 7.5, Fe-Tf at pH
7.5, or apo-Tf at pH 6.3 (Table 1; Figure 2). For these
experiments, filtered insect cell supernatants containing
secreted recombinant TfR mutants were injected over a
biosensor chip to which an anti-pentaHis antibody had been
immobilized. The antibody captures TfR by binding to its two
6x-His tags, thereby allowing oriented coupling of the
receptors to the biosensor chip. HFE, Fe-Tf, or apo-Tf was
then injected over the antibody/TfR-coupled sensor chip, and
binding data were fit to a bivalent ligand model in which
equilibrium dissociation constants (KD1 and KD2) were
derived for binding to the first and the second binding sites
on homodimeric TfR (see Table 1) (West et al. 2001).
Our previous mutagenesis study established that both the
HFE- and Fe-Tf-binding sites on TfR include residues within
helices 1 and 3 of the TfR helical domain (West et al. 2001)
(see Figure 1A and 1B). In the present study, we tested the
previously prepared TfR mutants for binding apo-Tf at pH
6.3 and re-evaluated their binding to HFE and Fe-Tf at pH
7.5. In agreement with the previous results, we found that two
Figure 2. Biosensor Analyses of Tf Binding
to Immobilized Wild-Type and Selected
Mutant TfR Molecules
Sensorgrams (black lines) of injected Fe-
Tf or apo-Tf binding to wild-type TfR
(top left) or the indicated TfR mutants
are shown with best-fit binding curves
(red lines) derived from a bivalent ligand
model (see Materials and Methods)
superimposed. The sensorgrams demon-
strate that the binding responses are
concentration dependent, and the super-
imposed binding curves demonstrate the
close fit of the binding model to the
experimental data. Concentrations of
injected proteins for each sensorgram
are given below as two numbers: the first
is the highest injected concentration
(nM), and the second is the dilution
factor, either 2-fold (23) or 3-fold (33),
that relates successive injections. For
each TfR sample, there are two sets of
numbers, the first being for Fe-Tf and
the second for apo-Tf. Wild-type (31, 23;
200, 23), Y123S (250, 23; 330, 33), W124A
(2,000, 33; 2,000, 23), D125K (2,000, 33;
1,000, 23), W641A (110, 33; 1,000, 33),
G647A (6,000, 33; 780, 33), R651A (5,000,
33; 1,000, 33), F760A (110, 33; 270, 33).
DOI: 10.1371/journal.pbio.0000051.g002
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mutants, L619A and Y643A, showed no detectable HFE
binding and a significant (greater than or equal to 5-fold)
decrease in Fe-Tf binding. These substitutions also signifi-
cantly reduced apo-Tf binding at acidic pH. Two other
mutants, R629A and Q640A, were again found to significantly
reduce HFE binding and to have a relatively minor effect on
Fe-Tf binding (R629A) or no significant effect (Q640A). The
effects of these substitutions on apo-Tf binding correlated
with their effects on Fe-Tf binding. Likewise, the F650A
mutant, which shows a moderate reduction in binding affinity
for both HFE and Fe-Tf, also shows a reduced affinity for
binding apo-Tf. Only one of the previously analyzed mutants,
G647A, exhibited a major (greater than 100-fold) reduction in
Fe-Tf binding affinity, and the present analysis reveals that it
has a similar effect on apo-Tf binding. Interestingly, one of
the previously analyzed mutants, W641A, which does not
significantly affect HFE or Fe-Tf binding at pH 7.5, exerted a
significant reduction in the binding affinity for apo-Tf at pH
6.3 (see Table 1; Figure 1E; Figure 2), suggesting that it might
be possible to find additional substitutions with differential
effects on binding of the two forms of Tf.
Our first strategy for finding additional residues critical for
Tf binding involved substitution of solvent-exposed residues
C-terminal to the Tf-binding epitope residues Gly647 and
Phe650 on helix 3 of the TfR helical domain. Of the five new
TfR mutants constructed (R651A, S654A, T658A, N662A,
E664A), only one (R651A) affected Tf binding, resulting in a
greater than 2,800-fold reduction in binding of Fe-Tf and
apo-Tf. Having identified a ‘‘hot spot’’ for Tf binding
involving TfR helical domain residues Gly647 and Arg651,
we then searched for residues affecting Tf binding that were
distant from this site, which would allow approximate
positioning of the bi-lobed Tf structure on TfR. Two residues
within the cleft formed by portions of the three TfR domains
were changed to their chicken TfR counterparts to test the
prediction that Tf binds to the TfR interdomain cleft
(Lawrence et al. 1999). There were no significant differences
in Tf binding affinity for either the P710R or the K717Q
mutants, suggesting that at least this region of the interdo-
main cleft is not critical for binding to either form of Tf.
Consistent with this interpretation, we found a second
binding site at the base of the TfR protease-like domain that
is distant from the interdomain cleft (approximately 46 A˚).
The Y123S mutant, which was constructed as part of a screen
to test the effects of changing large solvent-exposed hydro-
phobic residues, shows a significantly reduced affinity for Fe-
Tf, but not to apo-Tf or HFE. To confirm that Tyr123 forms
part of the Fe-Tf-binding site, three additional mutants were
constructed: the double mutant Y123S/G647A and the two
single mutants W124A and D125K. The double mutant
showed an increased effect on Fe-Tf binding compared to
the G647A alone, consistent with the involvement of Tyr123
in Fe-Tf binding. In addition, the W124A and D125K single
mutants, which change residues adjacent to Tyr123, also
reduced TfR’s affinity for Fe-Tf, but not apo-Tf. Thus, the
base of the protease-like domain in the vicinity of Tyr123 is
involved in differential binding to the iron-loaded form of Tf,
but not apo-Tf. None of the other substitutions constructed
in the screen of solvent-exposed hydrophobic residues
significantly affected binding to either form of Tf or to HFE.
As Tf is a bi-lobed structure, it should be possible to
evaluate the binding of isolated lobes to wild-type and mutant
TfRs to gain information regarding the positions of the two
Tf lobes on TfR. Isolated iron-loaded Tf C-lobe (Fe-C-lobe)
binds to TfR with an affinity of approximately 650 nM (Zak et
al. 1994; Zak and Aisen 2002). Assuming independent binding
of the two Tf lobes without effects of cooperativity, the
affinity increase to a KD of approximately 1 nM for intact Fe-
Tf binding to TfR suggests the KD for binding isolated N-lobe
would be approximately 1.5 mM. This affinity is too weak to
be detected by most binding assays. Consistent with this
assumption, isolated Tf N-lobe neither binds detectably to
TfR nor donates iron to TfR-expressing cells (Zak et al. 1994;
Mason et al. 1997). We therefore tested purified Fe-C-lobe
(Zak and Aisen 2002) for binding to wild-type TfR and
selected TfR mutants.
Fe-C-lobe was injected over wild-type TfR and TfR mutants
(Y123S, D125K, R651A, F760A) in a biosensor binding assay as
described for Fe-Tf above. Binding data were analyzed using
an equilibrium-based approach because the rapid kinetics of
the Fe-C-lobe interaction with wild-type TfR do not allow
accurate derivation of kinetic rate constants (Figure 3). No
significant changes in affinity were observed for Fe-C-lobe
binding to two mutants in the TfR protease-like domain
(Y123S, D125K), but a mutation in the central portion of the
Fe-Tf functional epitope on TfR, R651A, eliminated detect-
able binding (Figure 3). In addition, binding of Fe-C-lobe was
not significantly affected by the F760A mutation in the TfR
helical domain, which reduces the affinity of apo-Tf, but not
Fe-Tf (see Figure 2; Table 1). These results suggest that Tf C-
lobe contacts the TfR helical domain, but not the protease-
like domain.
Figure 3. Biosensor Analyses of Fe-C-Lobe Binding to Immobilized Wild-
Type and Selected Mutant TfR Molecules
Plots of the equilibrium binding response, normalized to the Rmax
value (the ligand immobilization value) derived from fitting, versus
concentration of injected Fe-C-lobe, are shown for the indicated TfR
mutants along with the wild-type TfR control that was present in an
adjacent flow cell on the same biosensor chip. Best-fit binding curves
derived from a bivalent ligand model are shown as solid lines
connecting the datapoints (squares for wild-type TfR and triangles
for TfR mutants). The R651A mutant exhibited no binding and was
not fit. A summary of derived binding constants is shown in the lower
right panel. The KDs for wild-type TfR are averages derived from
three independent measurements, and the number after the plus/
minus sign represents the standard deviation.
DOI: 10.1371/journal.pbio.0000051.g003
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Discussion
Despite many years of investigation of the Tf/TfR pathway
for iron uptake, molecular details about the interaction
between TfR and Tf have been limited largely due to a lack of
structural information for a Tf/TfR complex. In the absence
of a three-dimensional structure, site-directed mutagenesis
can be used to map out a protein–protein interaction. To
narrow down a subset of residues for mutageneis from the
639 residues in a soluble TfR monomer, we used the crystal
structures of TfR alone (Lawrence et al. 1999) and TfR bound
to HFE (Bennett et al. 2000) to locate solvent-exposed
residues in the vicinity of the HFE-binding site, which was
suggested from competition studies to overlap with the Tf-
binding site on TfR (Lebro´n et al. 1999). We identified
residues within the TfR helical domain whose substitution
affected binding of both HFE and Fe-Tf at pH 7.5 in a
previous mutagenesis study involving ten human TfR mutants
(West et al. 2001). These results established that HFE and Fe-
Tf bind to the same or an overlapping site on TfR. In the
present study, we have expanded the library of TfR mutants
to more precisely map the Tf-binding site on TfR and
compared binding of Fe-Tf and apo-Tf to TfR. From a survey
of 29 point mutants of human TfR, we identified 11 residues,
which, when substituted, reduce the affinity of TfR for either
human Fe-Tf, apo-Tf, or both (see Table 1). Six of the 11
residues are completely conserved in different species of TfR
and in a more recently identified Tf-binding receptor, TfR2,
which shares 45% sequence identity with TfR (Kawabata et al.
1999). Most notably, four of the residues exerting the largest
effects on Fe-Tf binding, apo-Tf binding, or both (Leu619,
Trp641, Gly647, and Arg651) are completely conserved across
all currently known TfR and TfR2 sequences (see Table 1).
Others, such as the tyrosines at positions 123 and 643, are
either conserved or conservatively substituted for phenyl-
alanine in some TfR species. By contrast, of the 18 positions
at which substitutions did not significantly affect Tf binding,
16 are not conserved, and two (Phe187 and Glu664) are
conservatively substituted (see Table 1). These results suggest
that our conclusions about the mode of binding between
human Tf and human TfR can be generalized to include Tf/
TfR complexes from other species and the interaction
between TfR2 and Tf.
From a quantitative analysis of the affinities of the
different TfR mutants for Fe-Tf and apo-Tf, we can classify
the residues we mutated using the criteria of Wells and
colleagues (Cunningham and Wells 1993), which categorize
the structural and functional epitope residues in a protein–
protein interaction. The functional epitope is defined as
residues exerting a major effect on the binding affinity (a
G value, 2 kcal/mol after substitution of a single residue,
corresponding to an affinity reduction of at least 30-fold at
room temperature). The structural epitope on a protein is all
residues at the contact interface with the binding partner,
which can be deduced from a co-crystal structure (Cunning-
ham and Wells 1993). Substitution of some, but not all, of the
residues at the structural epitope of a protein–protein
interface will result in affinity changes (Cunningham and
Wells 1993). This is illustrated in our study by comparing the
crystallographically-defined structural epitope on TfR for
binding HFE (Bennett et al. 2000) (see Figure 1A and 1B;
Table 1; Figure S1) with the results of mutagenic mapping of
residues affecting HFE binding (see Figure 1C). In the absence
of a Tf/TfR co-crystal structure, we can use our mutagenesis
results to predict the functional and structural epitope
residues (affinity reductions of greater than or equal to 30-
fold or between 5- and 30-fold, respectively) on TfR for
binding to Fe-Tf and apo-Tf. From the comparison of wild-
type and mutant TfR binding affinities, Arg651 was identified
as a functional epitope residue for binding both Fe-Tf at pH
7.5 and binding apo-Tf at pH 6.3, as substitution of this single
residue to alanine greatly reduces binding to either form of
Tf (see Table 1). In combination with the previously studied
G647A mutant (Dubljevic et al. 1999; West et al. 2001), which
reduces affinity for both Fe-Tf and apo-Tf by over 100-fold,
these residues define a functional epitope for Fe-Tf and apo-
Tf binding located in the bottom central portion of the TfR
helical domain (see Figure 1D and 1E). Two other nearby
residues, Leu619 and Trp641, can be considered part of the
functional epitope for binding apo-Tf. The HFE/TfR crystal
structure shows that these residues are at the contact
interface with HFE (see Figure 1A and 1B) (Bennett et al.
2000), but with the exception of Leu619, their substitutions
do not significantly affect HFE binding (see Table 1). Instead,
the functional epitope for HFE binding is shifted slightly
upwards on the TfR helical domain from the Fe-Tf functional
epitope to include residues Leu619 and Tyr643 (see Figure
1C). Thus, although most of the functional epitope residues
for binding of HFE and Tf are physically separated, they are
close enough that binding of either HFE or Fe-Tf to TfR
would sterically preclude binding of the other species (see
Figure 1C and 1D). In addition, some substitutions in TfR
significantly lower the affinity for both HFE and Tf (L619A,
R629A, Y643A, and F650A) (see Table 1).
Since Tf is a larger molecule than HFE, we reasoned that Tf
could also interact with residues not contained in the HFE
binding footprint on TfR. We therefore tested substitutions
of residues outside of the TfR helical domain for their effects
on binding to Tf. To narrow down the search, we chose to
substitute solvent-exposed hydrophobic residues, which are
often found in protein–protein interfaces (Jones and Thorn-
ton 1996; Lo Conte et al. 1999). We also restricted the search
to residues within approximately 90 A˚ (the longest dimension
of Fe-Tf) of the Fe-Tf functional-binding epitope for
substitution. Using this strategy, we identified a region at
the base of the protease-like domain involving residues
Tyr123, Trp124, and Asp125, where substitutions showed
significant effects on binding to Fe-Tf at pH 7.5, but not to
HFE at pH 7.5 or to apo-Tf at pH 6.3 (see Figure 1D and 1E;
Table 1). Having defined two predicted Fe-Tf contact areas
on TfR that are separated by approximately 33 A˚ (measured
between TfR residues Arg651 and Tyr123) constrains the ways
in which Tf can interact with TfR. In particular, computer
modeling suggests that a single Tf lobe cannot make
productive contacts with both regions of TfR (A. M.
Giannetti, unpublished data); thus both lobes of Fe-Tf are
likely to be involved in the interface with TfR. Previous
studies of the binding of isolated Fe-N- and Fe-C-lobes of Tf
suggested that the majority of the binding energy in the Tf/
TfR interaction comes from the C-lobe (Zak et al. 1994; Zak
and Aisen 2002). It has also been observed that mixing
purified N- and C-lobes results in a significant enhancement
of TfR binding over that of C-lobe alone (Mason et al. 1997;
Zak and Aisen 2002). These observations are consistent with a
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Tf orientation on TfR in which the C-lobe contacts the Tf
functional epitope on the TfR helical domain and the N-lobe
contacts the Tyr123 area at the base of the TfR protease-like
domain (Figure 4). In this model, allosteric effects need not be
invoked to explain the increased affinity of the N-lobe/C-lobe
mixture over C-lobe alone (Zak and Aisen 2002). Instead, the
observed increase in affinity is predicted to arise from direct
contacts between the N-lobe and TfR. To test the predicted
orientation of Tf on TfR (Figure 4), we compared the
affinities of isolated Fe-C-lobe (Zak and Aisen 2002) to wild-
type TfR and to TfR mutants with substitutions in the helical
domain (R651A, F760A) and the protease-like domain (Y123S,
D125K) (see Figure 3). As predicted, substitutions in the
protease-like domain do not affect binding of Fe-C-lobe,
whereas a functional epitope substitution (R651A) in the TfR
helical domain eliminates detectable binding of Fe-C-lobe to
TfR.
Our binding data also allow us to assess potential differ-
ences in the binding of Fe-Tf versus apo-Tf to TfR. Two prior
observations are consistent with differences in the binding
footprints of Fe-Tf and apo-Tf on TfR. First, Fe-Tf undergoes
a large conformational change upon acidification and release
of iron, as deduced by comparison of crystal structures of
ferric and iron-free forms of Tf and Tf-related molecules
such as the lactoferrins (Bailey et al. 1988; Anderson et al.
1989; Gerstein et al. 1993; Zuccola 1993; Kurokawa et al. 1995,
1999; Baker et al. 1998; Karthikeyan et al. 1999) (see Figure 4).
Second, TfR has been suggested to undergo a pH-dependent
conformational change resulting in aggregation at pH ,6 in
the absence of Tf (Turkewitz et al. 1988). Our finding of
differential effects of TfR substitutions for binding Fe-Tf at
pH 7.5 versus apo-Tf at pH 6.3 is consistent with conforma-
tional changes in Tf,TfR, or both at acidic pH. We find one
TfR region that affects binding of Fe-Tf, but not apo-Tf (the
region near Tyr123 involving TfR residues 123–125 at the
base of the protease-like domain), and another region that
affects binding of apo-Tf, but not Fe-Tf or Fe-C-lobe (the
region defined by Trp641 and Phe760, two spatially proximal
residues [10.2 A˚ apart] at the edge of the TfR helical domain)
(see Figure 1E and 1F). The apo-Tf-specific binding site may
be important for TfR’s ability to significantly accelerate iron
release from receptor-bound Fe-Tf (Bali and Aisen 1991).
Taking all of our data into account, we propose the following
structure-based mechanism to explain TfR-assisted iron
release from Fe-Tf (see Figure 4; Video S1).
First, Fe-Tf binds to TfR at pH 7.5, with the C-lobe making
critical contacts to the TfR region defined by Arg651 in the
helical domain and the N-lobe making additional favorable
contacts with the second Tf-binding site defined by Tyr123,
Trp124, and Asp125. The interaction of the complementary
surfaces on each protein presumably limits Fe-Tf’s freedom
to sample more open states, thereby favoring the closed iron-
bound state and lowering the iron release rate from both Tf
lobes. This is consistent with the experimental evidence
(Navati et al. 2003) suggesting that iron release is reduced by
an order of magnitude under conditions favoring a closed Tf
conformation relative to conditions favoring an open
conformation.
Second, as the pH is lowered, protonation of key residues
in Fe-Tf allows it to sample open conformations that
facilitate iron release (Navati et al. 2003). A conformational
change in Tf, TfR, or both allows additional Tf interactions
between Tf and the hydrophobic binding surface defined by
TfR residues Trp641 and Phe760. These new interactions
stabilize Tf in an open conformation exposing the iron-
binding site and thereby enhancing the rate of iron release.
The extensive mutagenic mapping of ligand binding to TfR
reported here has revealed residues responsible for func-
tional binding to HFE, Fe-Tf, and apo-Tf. These data confirm
that HFE and Tf bind to a physically and functionally
overlapping site on the TfR helical domain, although the
most important receptor residues for binding are different
for the two proteins. Thus, HFE and Fe-Tf must compete with
each other for binding to cell surface TfR, which may have
functional significance in HFE’s role in maintaining iron
homeostasis (Townsend and Drakesmith 2002). Additionally,
we have found that Fe-Tf makes specific contacts not only to
the TfR helical domain through its C-lobe, but also to the TfR
protease-like domain, which implies that there are specific N-
lobe/TfR contacts contributing to Tf binding. Finally, our
demonstration that Fe-Tf and apo-Tf have different binding
footprints on the surface of TfR provides insight into the
mechanism by which TfR binding differentially affects iron
release rates from Fe-Tf at acidic and basic pH.
Figure 4. Model for the Binding of Fe-Tf and
Apo-Tf to TfR
The figures representing each molecule are
drawn to scale as an outline around the
known structures of TfR (Lawrence et al.
1999), Fe-ovo-Tf (Kurokawa et al. 1995), and
apo-ovo-Tf (Kurokawa et al. 1999). Mem-
brane-bound TfR includes a stalk region that
places the TfR ectodomain about 30 A˚ above
the cell surface (Fuchs et al. 1998), which
would allow the Tf molecule to extend below
the plane of the TfR ectodomain. At basic
pH, Fe-Tf (orange, with the iron atom
positions shown as black dots) and TfR
(blue) associate to make a complex contain-
ing one TfR homodimer and two Fe-Tf
molecules, one bound to each polypeptide
chain of the TfR homodimer. Fe-Tf makes energetically favorable contacts at basic pH to residues identified by mutagenesis in the TfR helical
domain (red) and the protease-like domain (green). Acidification results in iron release and large conformational changes in the Tf structure as
it becomes apo-Tf (gray). Apo-Tf does not make energetically favorable contacts with the protease-like domain, but retains binding to the helical
domain-binding site (red) and makes new contacts to the helical domain (yellow), thereby stabilizing the complex. Upon return to basic pH, the
apo-Tf molecules dissociate from TfR. This is also illustrated in Video S1.
DOI: 10.1371/journal.pbio.0000051.g004
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Materials and Methods
Preparation of TfR ligands. A soluble form of human HFE
(residues 1–275 of the mature protein noncovalently associated with
the light chain b2-microglobulin) was expressed and purified as
previously described (Lebro´n et al. 1998). Human Fe-Tf was prepared
from apo-Tf (Sigma, St. Louis, Missouri, United States) by incubation
with bicarbonate and excess ferric ammonium sulfate. Free iron was
removed by dialysis, and the protein was further purified by gel-
filtration chromatography. Iron saturation was 100% as determined
spectrophotometrically (A465/A280, ;0.05) (He and Mason 2002).
Purified recombinant Fe-C-lobe was cleaved from a full-length Fe-
Tf in which the loop that connects the N- and C-lobes was replaced
with a Factor Xa site (Zak and Aisen 2002). Concanavalin A
chromatography was used to separate the glycosylated C-lobe from
unglycosylated N-lobe (Zak and Aisen 2002). Protein concentrations
were determined from the A280- value using extinction coefficients of
52,200 M1 cm1 (Fe-C-lobe) (O. Zak, personal communication),
83,360 M1 cm1 (Tf), and 96,570 M1 cm1 (HFE/b2-microglobulin)
(Lebro´n et al. 1998).
Production of wild-type TfR and TfR mutants. Soluble human TfR
and TfR mutants were expressed in a lytic baculovirus/insect cell
expression system as previously described (Lebro´n et al. 1998).
Mutations were introduced through PCR mutagenesis (Quickchange,
Strategene, La Jolla, California, United States) into a baculovirus
expression vector (pACGP67A; Pharmingen, San Diego, California,
United States) containing a hydrophobic leader sequence, 6x-His tag,
Factor Xa site, and residues 121–760 of human TfR. All mutations
were confirmed by DNA sequencing of the protein-coding region of
the vector. The Y123S mutation was further confirmed by N-terminal
sequencing of the purified mutant protein, yielding the sequence
ADPHHHHHHSSGIEGRGEFRLSWDD (the serine substitution for
tyrosine is underlined), corresponding to residual leader sequence
residues (A), vector-encoded sequence (DP), the 6x-His tag, spacer
residues (SSG), a Factor Xa site (IEGR), a spacer segment (GEF), and
residues 121–126 of the mutant TfR (RLSWDD). The double mutant
Y123S/G647A was constructed by introducing the Y123S substitution
into the G647A–TfR expression construct, after which the protein-
coding region of the expression plasmid was again sequenced.
Recombinant viruses were generated by cotransfection of a transfer
vector with linearized viral DNA (Baculogold, Pharmingen). Super-
natants of baculovirus-infected High 5 cells were used as the source of
wild-type TfR and TfR mutants for surface plasmon resonance-based
affinity measurements.
Affinity measurements. We used a BIACORE 2000 biosensor
system (Pharmacia, LKB Biotechnology, Uppsalla, Sweden) to assay
the interaction between TfR and HFE, Fe-Tf, and apo-Tf as described
(West et al. 2001). Binding of injected proteins (the analytes were
HFE, Fe-Tf, or apo-Tf) to a protein immobilized on the sensor chip
(the ligand was TfR) results in changes in surface plasmon resonance
that are read out in real time as resonance units (RUs) (Fa¨gerstam et
al. 1992; Malmqvist 1993).
For each experiment, the four flow cells of a CM5 biosensor chip
(Pharmacia) were prepared by covalently attaching an anti-His-tag
antibody (anti-PentaHis; Qiagen, Valencia, California, United States)
to a coupling density of 2,000–4,000 RUs through standard amine
coupling chemistry (BIACORE manual). Insect cell supernatants (50–
300 ll) containing secreted 6x-His-tagged wild-type or mutant TfR
were passed through a 0.2 lm filter and injected over one of the four
flow cells of a biosensor chip at a flow rate of 30 ll/min, resulting in
stable binding of TfR to density of 200–400 RUs. In a typical
experiment, a small amount of TfR immediately dissociates from the
anti-His antibody, but most TfR protein (.85%) remains bound
during the course of the injection of the TfR ligands, resulting in a
negligible baseline drift. On each biosensor chip, one flow cell
containing only the immobilized antibody was used as the reference
cell, one cell containing wild-type TfR served as an internal control
for binding of the three TfR binding partners, and TfR mutants were
coupled to the other two flow cells. HFE or Fe-Tf was injected over
the flow cells at 50 ll/min or 70 ll /min, respectively, at 258 C in 50
mM PIPES (pH 7.5), 150 mM NaCl, and 0.005% surfactant P20 (v/v).
All analyte injections were made as serial 2- or 3-fold dilutions. The
HFE concentration series ranged from 30 nM to 10 lM, and the Fe-Tf
and apo-Tf injections typically spanned from 1 nM to 200 nM, except
for experiments involving low-affinity mutants requiring higher
concentrations to properly derive affinities (see legend to Figure 2).
In test experiments, the sensorgrams from duplicate injections could
be overlaid to within the experimental noise; thus, single injections
were done for each concentration of injected protein in a binding
experiment. Between successive injections of analytes, the chips were
regenerated to preinjection response levels by either flowing with
running buffer until baseline was achieved (in the case of HFE) or by
a 12-second injection of the injection buffer containing 0.5 M MgCl2
(in the case of Fe-Tf). This treatment did not cause dissociation of
TfR from the anti-His-tag antibody. Apo-Tf was injected in 50 mM
PIPES (pH 6.3), 150 mM NaCl, 0.005% surfactant P20 (v/v), including
50 lM desferrioxamine as an iron chelator, and chip regeneration
was achieved with an injection of the same buffer at pH 7.5.
Raw sensorgram data were preprocessed using the Scrubber
software package (BioLogic Software, Campbell, Australia; www.bio-
logic.com.au). The response from the reference flow cell was
subtracted from the experimental flow cells to eliminate bulk
refractive index changes. The response from the average of at least
three buffer-only injections was then subtracted to correct for
potential systematic instrument artifacts. Kinetic constants were
obtained by simultaneous fitting of the association and dissociation
phases of all curves in the working set using the program Clamp99
(Morton and Myszka 1998). The data were fit to a bivalent ligand
model, which describes the two sequential binding events for either
Tf or HFE binding to homodimeric TfR. A simple 1:1 binding model
did not account for the observed data as judged from large residuals
in the fits (data not shown). Equilibrium dissociation constants (KDs)
were calculated from the ratio of the dissociation and association rate
constants, koff (s
1) and kon (M
1s1), respectively, yielding KDs for the
first and second binding events (KD1 and KD2) in the following
reaction mechanism:
Aþ TfR $ A:TfR ðrate constants: kon;1 and koff;1Þ
KD1 ¼ koff;1=kon;1
Aþ A: TfR $ A2 :TfR ðrate constants: kon;2 and koff;2Þ
KD2 ¼ koff;2=kon;2
where A is either HFE, Fe-Tf, or apo-Tf. For independent binding
sites, the apparent stepwise equilibrium dissociation constants (KD1
and KD2) are related to the intrinsic binding constants for the first
and second binding events to TfR (KD,intrinsic and KD,intrinsic), as
follows:
KD1;intrinsic ¼ KD1=2
KD2;intrinsic ¼ 2KD2
Hence, if the binding of a TfR ligand is independent of whether a
ligand is bound on the other face of the TfR homodimer, KD2¼ 4KD1.
For each mutant, the relative effect on HFE, Fe-Tf, or apo-Tf
binding was calculated as a ratio between the mutant KD and the
average of 22 independent determinations of the wild-type KD (see
Table 1) and as a ratio between the mutant KD and the wild-type KD
derived from wild-type protein coupled to a flow cell on the same
sensor chip as the mutant (data not shown). No significant differences
were found for the two methods of calculating the ratios. All mutants
were evaluated for HFE and Fe-Tf binding in at least two
independent experiments. For apo-Tf binding, those mutants that
showed a significant difference in binding compared to wild-type TfR
were reevaluated in a separate, independent experiment. No
significant differences in KDs were observed in independent
determinations of mutant affinities. When accurate affinities could
not be derived in a duplicate experiment due to problems with
baseline drift, visual inspection of the sensorgrams demonstrated that
each mutant exerted the same relative effects compared with wild-
type TfR in independent binding experiments. Table 1 presents
affinities derived from one binding experiment per mutant/ligand
pair. The reproducibility of the binding experiments can be assessed
by the standard deviation of the wild-type TfR affinity for each of the
ligands (derived from 22 independent binding experiments) and from
the fact that the affinities of many of the mutants are not significantly
changed compared to wild-type TfR.
For binding interactions involving the Fe-C-lobe, which reach
equilibrium quickly, we derived KDs using an equilibrium-based
approach. In these experiments, KDs were derived by non-linear
regression analysis of plots of Req (the equilibrium binding response)
versus the log of the analyte concentration. The data were fit to a
binding model assuming a bivalent ligand in BIAevaluation 3.0
(BIACORE). We were unable to detect significant amounts of binding
between apo-C-lobe and wild-type TfR at pH 6.3, presumably due to
an intrinsically weak binding affinity.
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Supporting Information
Figure S1. G for Mutant TfR Binding to HFE, Fe-Tf, and Apo-Tf
Histogram of G values for the change relative to wild-type TfR in
TfR mutant affinities for HFE (blue), Fe-Tf (pink), and apo-Tf (gray).
G values (the difference in binding energy for a mutant TfR
compared to wild-type TfR) were calculated using the KD1 values
from Table 1 as G¼RTln(KD1,mut/KD1,wild-type), where R is the gas
constant (1.99 3 103 kcal mol1 K1), and T is the temperature in
degrees Kelvin (298 K). The dashed green line represents the cutoff
for TfR mutants with a greater than or equal to 5-fold affinity
reduction in ligand binding, and the dashed red line indicates a
greater than or equal to 30-fold affinity reduction. An orange star
indicates non-binding mutants and mutants with a greater than 160-
fold affinity reduction whose G values exceed the y-axis limit of
the histogram (L619A and Y643A, 4 kcal/mol; G647A¼ 3.2 kcal/mol;
and R651A, 4.6 kcal/mol).
View online at DOI: 10.1371/journal.pbio.0000051.sg001 (1.86 MB
TIFF).
Video S1. Model of TfR-Assisted Iron Release from Fe-Tf
View online at DOI: 10.1371/journal.pbio.0000051.sv001 (12 MB
MOV).
Accession Numbers
The SwissProt accessions numbers for the proteins discussed in
this paper are b2-microglobulin (P01884), Fe-Tf (P02787), HFE
(Q30201), TfR canine (Q9GLD3), TfR chicken (Q90997), TfR feline
(Q9MYZ3), TfR hamster (Q07891), TfR human (P02786), TfR mouse
(Q62351), TfR rat (Q99376), TfR2 human (Q9UP52), and TfR2 mouse
(Q62351).
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Chapter 3:
The Mechanism for Multiple Ligand
Recognition by the Transferrin Receptor
This chapter has been published and Giannetti, A.M. and Björkman, P.J. (2004) HFE and
Transferrin Directly Compete for Transferrin Receptor in Solution and at the Surface of
Cells, Journal of Biological Chemistry, Vol. 279, No. 24, pp. 25866–25875, 2004
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The cover shows a structural view of the interactions of transferrin receptor (TfR) (blue
surface) with the hemochromatosis protein HFE (green and yellow ribbon) and the serum
iron carrier protein transferrin (Tf) (cyan and magenta ribbon). TfR can bind one or two
HFEs, one or two Tfs, or one of each to form the ternary complex (all represented). HFE
has been hypothesized to block the function of ferroportin, a transmembrane iron export
protein. Two molecules of a ferroportin model are shown in pink surface representation.
One is freely exporting iron (red spheres) whereas the other has been blocked by HFE.
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Transferrin receptor (TfR) is a dimeric cell surface
protein that binds both the serum iron transport protein
transferrin (Fe-Tf) and HFE, the protein mutated in pa-
tients with the iron overload disorder hereditary hemo-
chromatosis. HFE and Fe-Tf can bind simultaneously to
TfR to form a ternary complex, but HFE binding to TfR
lowers the apparent affinity of the Fe-Tf/TfR interac-
tion. This apparent affinity reduction could result from
direct competition between HFE and Fe-Tf for their
overlapping binding sites on each TfR polypeptide
chain, from negative cooperativity, or from a combina-
tion of both. To explore the mechanism of the affinity
reduction, we constructed a heterodimeric TfR that con-
tains mutations such that one TfR chain binds only HFE
and the other binds only Fe-Tf. Binding studies using a
heterodimeric form of soluble TfR demonstrate that TfR
does not exhibit cooperativity in heterotropic ligand
binding, suggesting that some or all of the effects of HFE
on iron homeostasis result from competition with Fe-Tf
for TfR binding. Experiments using transfected cell
lines demonstrate a physiological role for this competi-
tion in altering HFE trafficking patterns.
Hereditary hemochromatosis is a prevalent genetic disorder
characterized by a defect in a checkpoint of iron homeostasis
resulting in the absorption of dietary iron beyond the body’s
needs. If left untreated, hereditary hemochromatosis results in
the deposit of iron primarily in the liver, heart, pancreas, and
parathyroid and pituitary glands, leading to pathologies such
as arthritis, liver cancer, diabetes, cardiomyopathy, and bronz-
ing of skin (1, 2). Positional cloning revealed that most hered-
itary hemochromatosis patients carry mutations in the gene
coding for a protein called HFE (3). HFE is a membrane protein
homologous to class I major histocompatibility complex pro-
teins (3), which present antigenic peptides to T lymphocytes
(4). Like class I major histocompatibility complex molecules
and most other class I homologs, HFE is a heterodimer in
which a membrane-bound heavy chain associates nonco-
valently with the light chain 2-microglobulin (3). Most hered-
itary hemochromatosis patients are homozygous for a mutation
that converts residue 260 of the mature HFE protein from
cysteine to tyrosine (3), preventing proper folding, 2-micro-
globulin association, and cell surface expression and eliminat-
ing its effects on cellular iron levels (5–7).
A potential link between HFE and the regulation of iron
homeostasis was established by the observation that HFE
binds to transferrin receptor 1 (TfR)1 (8, 9), a homodimeric cell
surface glycoprotein that serves as the receptor for iron-loaded
transferrin (Fe-Tf) (10). Each chain of the TfR homodimer
contains an 640-residue ectodomain, a glycosylated stalk re-
gion, a membrane-spanning segment, and an N-terminal cyto-
plasmic domain containing a YTRF endosomal sorting signal.
This motif serves as a signal for endocytosis and transport back
to the cell surface through recycling endosomes (11–13). The
extracellular domain of TfR forms a high affinity complex with
circulating Fe-Tf and transports it to acidic endosomes. At the
low pH of endosomes (pH 6.5), TfR assists in the release of
iron from Fe-Tf (14, 15). The iron-free form of Tf (apo-Tf)
remains bound to TfR inside acidic endosomes and is recycled
to the cell surface, where apo-Tf dissociates at the slightly basic
pH of the blood (16).
TfR can form a number of complexes with HFE and Fe-Tf
(Fig. 1). TfR homodimers bind two Fe-Tf molecules to form
Fe-TfTfR complexes with 2:1 ligand/receptor stoichiometry
(17, 18). Soluble TfR homodimers also bind two HFE molecules
to form 2:1 HFETfR complexes (19, 20), although 1:1 HFETfR
complexes can be found in solution using soluble forms of HFE
and TfR (18, 20). When all three proteins are present,
HFETfRFe-Tf ternary complexes are observed in solution (18)
and in lysates from HFE-transfected HeLa cells (21, 22). Com-
petition (23), mutagenesis (20, 24), time-resolved x-ray foot-
printing (25), and electron microscopy studies (26) demonstrate
that Fe-Tf and HFE compete for overlapping binding sites on
each TfR chain; thus, HFETfRFe-Tf ternary complexes have a
1:1:1 stoichiometry, such that HFE binds to one TfR polypep-
tide chain and Fe-Tf binds to the other.
Comparison of the crystal structures of TfR alone (27) and a
2:1 HFETfR complex (19) reveals that HFE binding induces
changes at the TfR dimer interface that are distant from the
HFE binding site, suggesting that HFE binding to one polypep-
tide chain of the TfR dimer can transmit structural changes to
the other TfR chain. These changes could influence the binding
of Fe-Tf or another HFE to the other side of the TfR dimer.
Indeed, in some studies, Fe-Tf binds with a lower apparent
affinity to cell surface TfR in the presence of membrane-bound
or soluble HFE (8, 21), and an affinity reduction is also ob-
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served when Fe-Tf binds to soluble TfR in the presence of
soluble HFE (23). The apparent affinity reduction could result
from competition between Fe-Tf and HFE for binding to TfR,
from negative cooperativity due to structural changes in the
unbound TfR chain that are imparted by HFE binding to the
other chain, or from a combination of both phenomena.
Investigation of the mechanism by which HFE influences the
binding of Fe-Tf to TfR is complicated, because complexes in
addition to the HFETfRFe-Tf ternary complex form in an
equilibrium mixture of the three proteins (Fig. 1). Thus, previ-
ous quantitative binding studies have derived equilibrium dis-
sociation constants (KD values) only for binary HFETfR and
Fe-TfTfR complexes (18, 20, 24, 28). Using Fe-Tf, a soluble
serum protein, and recombinant soluble forms of HFE and TfR,
we previously measured equilibrium dissociation constants (KD
values) for the first (KD1) and second (KD2) binding events to
homodimeric TfR, demonstrating that HFE binds with lower
affinity to TfR than does Fe-Tf (18, 20, 24) (Fig. 1). In this
study, we examine how binding of HFE or Fe-Tf to one side of
the TfR dimer affects binding to the other chain in the absence
of the competing binary complexes, using a heterodimeric form
of soluble TfR (hdTfR) in which one chain can bind HFE and
not Fe-Tf and the other chain can bind Fe-Tf but not HFE.
Using analytical ultracentrifugation (AUC) and surface plas-
mon resonance (SPR) binding assays, we verified that hdTfR
binds one HFE and one Fe-Tf. We then measured the affinity of
the free TfR chain for Fe-Tf (or HFE) when HFE (or Fe-Tf) is
bound to the other chain. We found no affinity reduction for
Fe-Tf or HFE binding to hdTfR in the presence of saturating
amounts of the other ligand, suggesting that direct competi-
tion, rather than negative cooperativity, is responsible for the
apparent affinity reduction in Fe-Tf binding to cell surface and
soluble TfR in the presence of HFE.
Having determined that HFE lowers the apparent affinity
for Fe-Tf by directly competing for TfR binding sites rather
than through an allosteric mechanism, we evaluated the effects
of this competition at physiological concentrations of Fe-Tf
using HFE and TfR expressed in transfected cells. We first
demonstrate that a green fluorescent protein (GFP)-tagged
form of HFE is dependent on its association with TfR for
transport to Tf-positive endosomal compartments. We then
show that the addition of Fe-Tf to the cellular media induces a
redistribution of HFE within the cells, suggesting that fluctu-
ations in serum Fe-Tf concentration can significantly alter the
stoichiometric ratios of the possible TfR complexes and free
proteins at the cell surface. These results are discussed in
terms of the role of HFE in the control of cellular iron
homeostasis.
EXPERIMENTAL PROCEDURES
Production of Wild-type Proteins—Soluble wtTfR was produced in a
lytic baculovirus/insect cell expression system as previously described
(18). Briefly, we used a modified version of the pAcGP67A expression
vector (Pharmingen) that codes for the gp67 hydrophobic leader se-
quence followed by a His6 tag, factor Xa cleavage site, and residues
121–760 of human TfR. Soluble human HFE/2-microglobulin het-
erodimers were expressed in Chinese hamster ovary cells and purified
as previously described (18). Human Fe-Tf was prepared from apo-Tf
(Sigma) by incubation with bicarbonate and excess ferric ammonium
sulfate.
Expression of hdTfR and Homodimeric TfR Mutants—Mutations
(L619A/Y643A for the Fe-Tf-binding TfR chain and Y123S/G647A/
R651A for the HFE-binding TfR chain) were introduced into the expres-
sion vector encoding human wtTfR (wild-type TfR) using the
QuikChangeTM protocol (Stratagene). Constructs were verified by se-
quencing of the protein-coding region. His-tagged mutant TfR ho-
modimers were expressed in baculovirus-infected insect cells and puri-
fied as described above. For production of hdTfR, the L619A/Y643-TfR
construct was mutagenized further to exchange the His6 tag for the
StrepTag II affinity tag (WSHPQEK) (29), a sequence designed to bind
to streptactin, a modified form of streptavidin (30). PCR was used to
introduce restriction sites and a ribosomal binding sequence (CCTATA-
AAT) immediately upstream of the start codon and to amplify the
coding regions of the L619A/Y643A-TfR and Y123S/G647A/R651A-TfR
constructs. The mutant TfR sequences were ligated into the pFastBac-
DUAL (Invitrogen) dicistronic baculovirus expression vector. The gene
encoding Y123S/G647A/R651A-TfR was ligated 3 to the p10 promoter
site using SphI and XhoI restriction sites, and the gene encoding
L619A/Y643A-TfR was ligated downstream of the polyhedron promoter
using BssHII and NotI restriction sites. Recombinant viruses were
generated by co-transfection of a transfer vector with linearized viral
DNA (Baculogold, Pharmingen) for TfR homodimers or by use of the
Bac-to-Bac® system (Invitrogen) for hdTfR.
Purification of hdTfR—Separation of the three species of TfR pro-
duced by insect cells expressing both mutant TfR chains (HFE-binding
homodimers, Fe-Tf-binding homodimers, and hdTfR) was achieved us-
ing sequential affinity chromatography steps. Infected insect cell su-
pernatants containing the secreted TfR species were concentrated and
exchanged into 50 mM Tris, pH 7.4, 300 mM NaCl, 10% glycerol, and 15
mM imidazole. Supernatants were passed over a Ni2-NTA Superflow
agarose column (Qiagen), and the two His-tagged species (Fe-Tf-bind-
ing homodimers and hdTfR) were eluted from the column with 250 mM
imidazole. The eluted peak was loaded onto a 15-ml streptactin-Sepha-
rose column (Sigma-Genosys). After washing with a buffer containing
50 mM PIPES, pH 7.4, and 150 mM NaCl, the column was eluted by the
addition of the same buffer with 3 mM desthiobiotin to obtain hdTfR.
The column was regenerated by the addition of 1 mM 4-hydroxyazoben-
zene-2-carboxylic acid, which was removed by washing the resin accord-
ing to the manufacturer’s instructions. Due to low levels of nonspecific
binding of the different TfRs to the Ni2-NTA and streptactin resins,
the columns were washed extensively after loading (20 column vol-
umes for Ni2-NTA superflow and 5 column volumes for streptactin
superflow), which eliminated homodimer carry-through. The purity of
hdTfR was monitored throughout the purification process by reverse-
phase fast protein liquid chromatography using a Resource Phe column
(Amersham Biosciences). (NH4)2SO4 was added to protein samples to a
concentration of 850 mM prior to loading on the column, and proteins
were eluted by a gradient from 850 to 0 mM (NH4)2SO4 over 20 column
volumes. The two contaminating homodimers resolve into well sepa-
rated peaks with the hdTfR appearing as a peak between them, as
verified by Western blotting using the anti-penta-His antibody (Qiagen)
and alkaline phosphatase-conjugated streptactin (IBA) (data not
shown). After elimination of detectable contaminating TfR homodimers,
hdTfR samples were passed over a Superdex-200 column (Amersham
Biosciences) to remove aggregates and exchanged into 50 mM PIPES,
pH 7.4, 150 mM NaCl, and 0.05% NaN3.
Circular Dichroism—CD spectra and thermal denaturation profiles
were obtained using an Aviv 62A DS spectrometer with a thermoelec-
FIG. 1. Equilibrium relationships for complexes formed by
HFE, Fe-Tf, and TfR. Statistically corrected equilibrium binding con-
stants are shown for binary binding reactions (Table I). N.D., KD values
determined for hdTfR but not wtTfR.
Characterization of HFE and Fe-Tf Competition for TfR Binding 25867
63
tric cell holder and cuvette with a 1-mm path length. Measurements
were recorded using samples containing 5 M TfR protein in 20 mM
PIPES, pH 7.4, and 80 mM NaCl. Wavelength scans were collected from
200 to 250 nm in 1-nm increments. For thermal melts, the CD signal at
220 nm was recorded every 1 °C from 4 to 99 °C with an equilibration
time of 2 min and an averaging time of 1 min.
Biosensor Analyses—All biosensor experiments were carried out us-
ing a BIACORE 2000 instrument (Amersham Biosciences). Interactions
between a protein immobilized on the sensor chip (the “ligand”) and a
protein injected over the sensor surface (the “analyte”) are monitored in
real time as a change in surface plasmon resonance as measured in
resonance units (31, 32). Sensor chips were prepared using standard
primary amine coupling chemistry to attach 2000–4000 resonance
units of the anti-penta-His antibody (Qiagen) (BIACORE manual),
which was used to capture wtTfR and homodimeric TfR mutants (two
His tags) directly from insect cell supernatants as described (24). hdTfR
was covalently immobilized using primary amine chemistry (BIACORE
manual). In each experiment, one of the four flow cells of a CM5
biosensor chip (Amersham Biosciences) was mock-coupled with anti-
body but no TfR for use as a reference cell. Binding data were collected
as previously described (24).
Kinetic sensorgram data were pre-processed using Scrubber (Bio-
Logic Software Pty. Ltd.; available on the World Wide Web at www.bio-
logic.com.au), and kinetic constants were determined by simulta-
neously fitting the association and dissociation phases of all curves
using the Clamp99 program (33) to either a 1:1 model or a bivalent
ligand (2:1) model. The 1:1 model describes a simple bimolecular inter-
action and yields single association (kon) and dissociation (koff) values.
The bivalent ligand model describes the sequential binding of two
analyte molecules to a homodimeric ligand. This two-step process yields
apparent association (k1on,app, k2on,app) and dissociation (k1off,app,
k2off,app) values for each of the two reactions as follows,
A  TfR 7 A:TfR (rate constants: k1on, app and k1off, app)
REACTION 1
KD1, app  k1off, app/ k1on, app (Eq. 1)
A  A:TfR 7 A2:TfR (rate constants: k2on,app and k2off,app)
REACTION 2
KD2,app  k1off,app/k1on,app (Eq. 2)
where A represents either HFE or Fe-Tf. The apparent rate constants
can be converted to intrinsic rate constants (k1on, k2on, k1off, and k2off) by
applying statistical factors to account for the two potential binding sites
on a homodimeric TfR to which the first analyte molecule can bind and
the two sites on the fully bound TfR from which the first dissociation
event can occur. Thus, the intrinsic rate constants are related to the
apparent rate constants such that k1on  k1on,app/2 and k2off  k2off,app/2
for independent binding sites. Apparent and intrinsic rates and their
relative dissociation constants are reported in Table I to facilitate
comparison with our previous studies (20, 24).
To evaluate cooperativity in ligand binding, both hdTfR and wtTfR
were chemically coupled because of the requirement for base line sta-
bility over the period of 2 days. A concentration series of HFE or Fe-Tf
was injected to determine binding affinities in a buffer of 50 mM PIPES,
pH 7.4, 150 mM NaCl, 0.005% (v/v) surfactant P-20. The concentration
series was then repeated with the analyte diluted into a buffer to which
50 M Fe-Tf or 10 M HFE had been added. Equilibrium binding data
were collected and processed as previously described (24).
Analytical Ultracentrifugation—Sedimentation velocity experiments
were performed at 25 °C in a Beckman XL-I Ultima analytical ultra-
centrifuge using absorbance optics. Protein concentrations were deter-
mined spectrophotometrically at 280 nm using extinction coefficients of
187,199 M1 cm1 (wtTfR dimer), 190,230 M1 cm1 (hdTfR), 89,120 M1
cm1 (HFE/2-microglobulin), and 111,399 M
1 cm1 (Fe-Tf). The con-
centrations of wtTfR and hdTfR were fixed at 2.5 M for all experi-
ments. HFE and Fe-Tf were added at the indicated relative molar ratios
to TfR (see Fig. 4). Samples were brought to a final volume of 350–420
l and loaded into two-sector, charcoal-filled epon centerpieces with
quartz windows and placed in a four-hole An-60 titanium rotor. Sam-
ples were spun at 32,000, 34,000, or 36,000 rpm. Individual scans were
collected at 250 or 280 nm with a step size of 0.005 cm until samples
reached the bottom of the cell. Data were fit with the program SEDFIT
8.7 (34) using the c(s) analysis routine, which calculates the differential
distribution of sedimentation coefficients with an explicit treatment of
sample diffusion. The reported apparent sedimentation coefficients (s*)
values are not corrected to standard conditions because of difficulties
obtaining partial specific volumes of the glycosylated HFE, TfR, and
Fe-Tf proteins.
Generation of HFE-GFP-expressing TRVb and TRVb-1 Cells—PCR
was used to amplify the enhanced green fluorescent protein (EGFP)
gene in the pEGFP-1 vector (Clontech) to remove the start codon and
introduce a 5 in-frame XhoI site and 3 HindIII site. The modified gene
was subcloned into pBluescript II SK (Stratagene). PCR was used to
introduce a 5 Asp718 site and an in-frame 3 XhoI site at the 3-end of
the human HFE gene, which was then introduced into the EGFP
Bluescript vector. The resulting open reading frame encoded the entire
HFE amino acid sequence, a leucine-glutamate linker region, and
EGFP without its N-terminal methionine. The HFE-EGFP chimeric
gene was subcloned after sequencing into the mammalian cell expres-
sion vector pCB6-HindIII (gift of Ira Mellman, Yale University), which
carries a neomycin resistance gene for G418 selection (35).
TRVb and TRVb-1 cell lines were a generous gift from Dr. Timothy
McGraw (Cornell University) (36). Both cell lines were maintained in
Ham’s F-12 medium (Sigma) supplemented with 10% fetal bovine se-
rum, 2 mM glutamine, 12 mM glucose, and 400 g/ml G418 (TRVb-1 and
transfected cells only). Cells were grown to 90% confluence prior to
transfections, which were performed using the HFE-GFP expression
vector, a human 2-microglobulin expression vector (18), and the Lipo-
fectAMINE 2000 kit (Invitrogen) according to the manufacturer’s direc-
tions. Clones exhibiting green cell surface fluorescence were isolated
using limiting dilution 2 days after transfection. Cells were sorted for
GFP fluorescence using a Coulter Elite flow cytometer (Beckman
Coulter Inc.) to isolate cells with a medium level of GFP fluorescence.
Confocal Microscopy—Cells were dissociated using trypsin-free dis-
sociation buffer (Invitrogen), seeded onto glass coverslips in 6-well
plates, and grown to confluence. For redistribution experiments, the
culture medium was removed and replaced with medium containing
varying concentrations of human Fe-Tf (Sigma) or chicken iron-loaded
ovo-transferrin (Sigma), and cells were incubated at 37 °C in a 5% CO2
incubator for 1 h. The culture dishes were then placed on ice and
washed three times with ice-cold phosphate-buffered saline. Cells were
then fixed at 4 °C for 30 min in 4% paraformaldehyde in phosphate-
buffered saline, washed in cold phosphate-buffered saline, and mounted
on glass slides using Vecta Shield mounting media (Vector Laborato-
ries, Burlingame, CA). For Tf colocalization experiments, cells were
incubated for 1 h at 37 °C with 15 g/ml Alexa-546-conjugated human
Fe-Tf (Molecular Probes, Inc., Eugene, OR) in growth medium and
processed as above.
Cells were imaged on a Zeiss LSM Pascal Inverted confocal micro-
scope using a  63 oil immersion Apochromat objective (numerical
aperture 1.4). GFP was excited by the 488-nm line from an argon/
krypton laser, and Alexa-546-labeled human Fe-Tf was imaged using
the 543-nm line from a helium/neon laser. Two-color data were collected
in multitracking mode to prevent fluorophore cross-talk. Images were
collected and processed with a Zeiss LSM image examiner. Reported
images are 1-m sections collected 2–3 m above the basal side of the
cell.
RESULTS
Production of a Heterodimeric Transferrin Receptor—To con-
struct a TfR heterodimer (hdTfR) in which one chain only binds
HFE and the other chain only binds Fe-Tf, we first identified
mutations in human TfR homodimers that eliminate binding of
one TfR ligand while having a minimal effect on binding of the
other ligand. The choice of residues to substitute was compli-
cated by the fact that the HFE and Fe-Tf binding sites overlap
on the surface of TfR; thus, many residue substitutions that
reduce binding of one ligand also reduce binding of the other
(20, 24). We therefore sought to identify mutations that keep
the KD value for binding the desired ligand within the micro-
molar to nanomolar range while reducing the affinity for bind-
ing to the undesired ligand to a 10 M or higher KD. Our
choice of TfR substitutions was based on results from previous
measurements of the affinities of mutant TfRs for Fe-Tf and
HFE (24). To create a TfR chain that binds Fe-Tf but not HFE,
we combined substitutions L619A and Y643A, each of which
eliminates detectable HFE binding but has a more limited
effect on Fe-Tf binding (13- and 27.5-fold affinity reductions,
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respectively) (20, 24). To create a TfR mutant that binds HFE
but not Fe-Tf, we combined three substitutions: Y123S, G647A,
and R651A. Each of these mutations has a significant effect on
Fe-Tf binding (8.3-, 222-, and 2,800-fold affinity reductions,
respectively) (20, 24). Of these, only one substitution (G647A)
exhibits any measurable effect on HFE binding (2.6-fold affin-
ity reduction) (20, 24).
An hdTfR composed of one non-HFE binding and one non-
Fe-Tf binding chain was produced by co-expression of the two
mutant TfR chains in baculovirus-infected cells. To aid in pu-
rification, the Fe-Tf-binding TfR chain contained an N-termi-
nal StrepTagII sequence (29), and the HFE-binding TfR chain
contained a His6 tag. Expression in infected insect cells yields
three TfR dimers: HFE- but not Fe-Tf-binding homodimers,
Fe-Tf- but not HFE-binding homodimers, and hdTfR. Sequen-
tial passage of baculovirus supernatants over a Ni2-NTA col-
umn and a streptactin (30) column resulted in separation of
hdTfR from the mutant TfR homodimers and from other pro-
teins in the media. hdTfR appeared to be a stable species, since
we found no evidence of homodimers or monomers in hdTfR
samples stored for up to 2 months (data not shown). The far UV
CD spectra (Fig. 2A) and thermal denaturation (Fig. 2B) pro-
files of wtTfR and hdTfR showed no significant differences,
demonstrating that the mutations introduced into the hdTfR
do not adversely affect its folding or stability.
Binding Affinities of HFE and Fe-Tf to hdTfR and Ho-
modimeric TfR Mutants—Affinities of wtTfR and the mutant
TfRs were measured in an SPR-based assay for binding to a
soluble form of human HFE or to human Fe-Tf at pH 7.4 (18,
20, 24). Doubly His-tagged wtTfR and homodimeric TfR mu-
tants were captured on biosensor chips using a covalently
coupled anti-His tag antibody (20, 24), and the hdTfR was
chemically coupled using primary amine chemistry (see “Ex-
perimental Procedures”). Either HFE or Fe-Tf was then in-
jected over the TfR-coupled sensor chip. Binding data were fit
to a bivalent ligand model in which equilibrium dissociation
constants (KD1 and KD2) are derived for binding to the first and
the second binding sites on homodimeric wild-type and mutant
TfRs (Table I and Fig. 3) or to a 1:1 binding model in the case
of hdTfR. The Y123S/G647A/R651A mutant homodimer does
not detectably bind Fe-Tf at any tested concentration (up to 60
M) (Fig. 3B). Its binding affinity for HFE (Fig. 3A) was reduced
2.8-fold relative to wtTfR, consistent with the 2.6-fold reduction
observed for the G647A mutant in our previous studies (20, 24).
The slight affinity reduction resulted from an increased off-rate
compared with wtTfR (Table I). The L169A/Y643A mutant
homodimer exhibited no detectable binding to HFE (at concen-
trations up to 20 M) (Fig. 3C), and its affinity for Fe-Tf was
reduced 500-fold (Fig. 3D), again due to an increased off-rate
(Table I). We previously demonstrated that the loss in free
energy for binding Fe-Tf for the two single mutants that com-
pose the L619A/Y643A mutant is 1.5 kcal/mol (L619A) and 2.0
kcal/mol (Y643A), predicting a G value of 3.5 kcal/mol at
25 °C for the double mutant if the two substitutions act inde-
pendently (24). Consistent with this prediction, the observed
502-fold loss of binding affinity for the L169A/Y643A mutant
(Table I) corresponded to a G of 3.7 kcal/mol at 25 °C.
The binding data for the mutant TfR homodimers were then
compared with binding data for hdTfR. The better fit of the 1:1
binding model to binding reactions involving hdTfR (Fig. 3, G
and H) compared with wtTfR (Fig. 3, E and F, 1:1 model and
residuals) suggests that hdTfR forms 1:1 complexes with Fe-Tf
and with HFE. Analysis of the differences in derived binding
constants is complicated by the use of different binding models
for hdTfR or homodimeric TfRs: a 1:1 binding model for the
hdTfR yields a single value for the KD, whereas the bivalent
ligand model describing binding to the homodimeric TfRs
yields KD values describing the first and second binding events
(see “Experimental Procedures”). The derived KD values for the
HFE-binding and Fe-Tf-binding chains of the hdTfR are within
3-fold of statistically corrected KD1 values for their respective
homodimeric mutants (Table I), suggesting that hdTfR does not
have significantly altered binding affinities relative to the ho-
modimeric mutants from which it was derived.
Determination of Ligand-binding Stoichiometries of wtTfR
and hdTfR—To further compare the ligand-binding properties
of hdTfR and wtTfR, we used sedimentation velocity AUC.
Velocity AUC data were analyzed using the c(s) size distribu-
tion method in the program SEDFIT 8.7 (34). This method fits
the data numerically to the Lamm equation and yields a dif-
ferential distribution of s* values while explicitly correcting for
diffusion of the sedimenting species. The output is displayed as
a continuous distribution of s* values versus the c(s*) function
describing the distribution of molecular masses in solution.
We first determined the sedimentation properties of binary
HFETfR and Fe-TfTfR complexes. Each of the individual pro-
teins migrates as a single sharp peak when spun alone (Fig. 4,
dashed black lines labeled HFE, Fe-Tf, wtTfR, or hdTfR). Fig.
FIG. 2. Circular dichroism spectra and thermal denaturation profiles of wtTfR (pink triangles) and hdTfR (blue diamonds). A,
far-UV CD spectra of wtTfR and hdTfR. The measured CD signal is given as []r, the molar ellipticity per residue. Data points represent the average
and standard deviation of three (wtTfR) or five (hdTfR) replicate scans. B, comparison of thermal denaturation profiles for wtTfR and hdTfR. The
CD signal at 220 nm was monitored as a function of increasing temperature and plotted as fraction unfolded after normalization. The transition
midpoints derived from a plot of d[]r)/dT versus T are 64.8 °C for wtTfR and 65.0 °C for hdTfR.
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4A shows the results of mixing HFE and wtTfR in molar ratios
of 1:1, 2:1, 4:1, and 6:1, confirming previous findings of both 1:1
and 2:1 HFE/TfR complexes in solution (18, 20), with 2:1 being
the terminal stoichiometry as indicated by the presence of
excess HFE at the higher mixing ratios. By contrast, mixing
excess HFE in the presence of hdTfR resulted in a peak corre-
sponding to a 1:1 HFETfR complex, confirming that hdTfR
does not readily form 2:1 HFETfR complexes (Fig. 4D). Anal-
ogous experiments were performed to investigate binary inter-
actions of Fe-Tf with wtTfR and hdTfR. Fig. 4B shows the
results of mixing Fe-Tf and wtTfR at various ratios, confirming
previous reports of a 2:1 terminal Fe-Tf/TfR stoichiometry (17,
18). Here we note evidence for formation of a 1:1 Fe-TfTfR
complex at the 1:1 mixing ratio, which, although predicted to be
present in an equilibrium mixture of Fe-Tf and TfR (Fig. 1), has
not been previously reported. Mixing Fe-Tf with hdTfR re-
sulted in two connected peaks in the c(s*) distribution (Fig. 4E).
The smaller peak represents free hdTfR, and the larger peak is
due to the 1:1 Fe-TfhdTfR complex. The slightly different po-
sition for the 1:1 Fe-TfhdTfR peak compared with the position
for the 1:1 Fe-TfwtTfR peak results from the faster kinetics of
complex association and dissociation for hdTfR compared
with wtTfR (Table I). We see no evidence of a 2:1 Fe-TfhdTfR
complex (Fig. 4E).
We next used sedimentation velocity AUC to characterize
the complexes formed when hdTfR and wtTfR are mixed with
both HFE and Fe-Tf. At a mixing ratio of 1:1:1 HFE/wtTfR/Fe-
Tf, a broad peak centered at 11.8 S was observed (Fig. 4C). The
TABLE I
HFE and Fe-Tf binding to TfR constructs at 25 °C
Kinetic and equilibrium constants derived from fitting of the surface plasmon resonance data shown in Fig. 3. Numbers in parentheses are
corrected for statistical factors (see ‘‘Experimental Procedures’’). NB, no binding detected at concentrations of injected analyte up to 80 M Fe-Tf
or 20 M HFE.
Ligand (immobilized protein)
Analyte
(injected
protein)
kon1 koff1 kon2 koff2 KD1 KD2
KD1, KD2
(relative
to wild
type)
Ms1 s1 Ms1 s1 nM nM
wtTfR HFE 3.7  106 (1.8  106) 0.09 2.6  106 0.37 (0.20) 24 (48) 154 (77)
wtTfR Fe-Tf 1.7  106 (8.3  105) 1.0  103 1.6  105 5.8  103 (3.2  103) 0.6 (1.3) 40.6 (20.3) 2.8, 2.5
Y123S/G647A/R651A-TfR HFE 3.6  105 (1.8  106) 0.25 2.2106 0.82 (0.41) 67 (134) 384 (192)
Y123S/G647A/R651A-TfR Fe-Tf NB NB 27,000
L619A/Y643A-TfR HFE NB NB 800
L619A/Y643A-TfR Fe-Tf 5.2  105 (2.4  105) 0.15 1.5  105 0.46 (0.23) 314 (627) 2,940 (1,470) 502, 73
hdTfR HFE 6.8  105 0.27 390 8.1
hdTfR Fe-Tf 1.9  105 0.23 1,210 930
FIG. 3. SPR analysis of HFE and
Fe-Tf binding to TfR proteins. Exper-
imentally observed response (black lines)
of HFE or Fe-Tf binding to the indicated
TfR molecules is shown with superim-
posed best fit binding curves (colored
lines) derived from a bivalent ligand bind-
ing model (wtTfR and homodimeric mu-
tant TfRs except where noted) or a 1:1
binding model (hdTfR). Residual plots
(difference between the observed and cal-
culated binding data) are shown in E–H
below the response data. The wtTfR bind-
ing data shows fits and residuals for both
1:1 (green) and bivalent ligand (red) bind-
ing models. The highest concentrations in
the injection series for each sensorgram
are 5 M (A), 60 M (B), 20 M (C), 6 M
(D), 2 M (E), 111 nM (F), 1.6 M (G), and
10 M (H). Subsequent injections are re-
lated by 3-fold dilutions.
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location of the center of the peak midway between the peaks for
the 2:1 HFEwtTfR and 2:1 Fe-TfwtTfR complexes and the fact
that the peak spans the positions of the binary complexes are
consistent with identification of this peak as a mixture of the
1:1:1 HFETfRFe-Tf ternary complex with binary 2:1 Fe-TfTfR
and 2:1 HFETfR complexes (Fig. 4C, red curve). Mixing of the
three proteins at higher ligand ratios (2:1:2 and 3:1:3 HFE/TfR/
Fe-Tf) resulted in a peak closer to the one observed for 2:1
Fe-Tf/TfR, demonstrating that Fe-Tf effectively competes HFE
away from TfR in solution, due to the intrinsically higher TfR
binding affinity of Fe-Tf compared with soluble HFE. Mixing of
HFE and Fe-Tf with the hdTfR also resulted in a peak between
the 2:1 HFEwtTfR and 2:1 Fe-TfwtTfR complexes (Fig. 4F).
The distribution was more narrow for the ternary complex
involving hdTfR, consistent with the expectation that binary
complexes with a 2:1 ligand/hdTfR stoichiometry do not form.
Comparison of HFE and Fe-Tf Binding to hdTfR and wtTfR
Rules Out Cooperativity in Ligand Binding—Having demon-
strated that the engineered hdTfR binds to one HFE and one
Fe-Tf to form a ternary complex, we could use the hdTfR to
evaluate the potential for heterotropic cooperativity in ligand
binding in the absence of the competition observed when using
wtTfR. Cooperativity in binding was assessed using an SPR-
based binding assay to compare the binding behavior for either
HFE or Fe-Tf to hdTfR in the presence and absence of excess
Fe-Tf or HFE. If cooperativity is a feature of TfR interactions
with HFE or Fe-Tf, then incubation of TfR with saturating
amounts of one ligand will perturb the equilibrium binding
curve of the second ligand. For these experiments, wtTfR and
hdTfR were immobilized on adjacent flow cells of the same
sensor chip using primary amine coupling chemistry. We then
evaluated the binding of HFE to each TfR in the presence and
absence of a saturating concentration of Fe-Tf (50 M). Binding
data were collected using an equilibrium-based approach in
which binding reactions reached or closely approached equilib-
rium. Data for HFE binding to hdTfR in the presence and
absence of Fe-Tf (Fig. 5B) showed no significant differences,
indicating that binding of Fe-Tf to one chain of TfR does not
alter the binding properties of the other chain for HFE. Simi-
larly, the binding of Fe-Tf for hdTfR was not altered by the
presence of a saturating amount of HFE (10 M) (Fig. 5D). By
contrast, when the same binding experiments were performed
with wtTfR, we observed competition between HFE and Fe-Tf
for binding to TfR. When HFE was injected in the presence of
FIG. 4. Stoichiometries of HFE and Fe-Tf binding to wtTfR and hdTfR from sedimentation velocity ultracentrifugation. The c(s*)
distribution was determined for each protein alone or in the mixing ratio indicated to the right of each panel. Reference curves for individual
proteins or specific complexes are shown as dotted black lines. Peak heights were normalized to the height of the species with the largest s* value
in the distribution.
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excess (50 M) or near physiological (5 M) (37) quantities of
Fe-Tf (Fig. 5A), only a small amount of HFE binding was
observed at the highest concentrations tested (Fig. 5A). This
binding was observed as a decrease in SPR signal, because the
binding of HFE requires the displacement of Fe-Tf, which is 1.8
times heavier than HFE, from its binding site on TfR (20, 24,
25). When Fe-Tf was injected in the presence of saturating
amounts of HFE (10 M), there was a reduction in Fe-Tf bind-
ing (Fig. 5C), consistent with previous reports that HFE re-
duces the observed binding affinity of Fe-Tf to TfR (8, 21, 23).
Consistent with the lower TfR binding affinity of HFE as com-
pared with Fe-Tf, HFE begins to compete with Fe-Tf for bind-
ing wtTfR only when it is present at a 4-fold or higher concen-
tration than Fe-Tf, whereas Fe-Tf begins to compete with HFE
for binding wtTfR when it is present at one-tenth the concen-
tration of HFE. Taken together, these experiments confirm
that HFE and Fe-Tf compete for TfR binding sites and rule out
the effects of negative cooperativity in the HFE/hdTfR/Fe-Tf
ternary interaction.
Cell Surface HFE Competes Effectively with Fe-Tf for Bind-
ing to Cell Surface TfR—The demonstration that negative co-
operativity is not involved in heterotropic interactions between
TfR, HFE, and Fe-Tf indicates that direct competition between
HFE and Fe-Tf for binding to cell surface TfR is solely respon-
sible for the observation that HFE lowers the affinity of TfR for
Fe-Tf (5, 21, 23). Our SPR and AUC experiments demonstrate
that soluble HFE competes poorly against Fe-Tf for TfR bind-
ing because of its lower affinity for TfR compared with Fe-Tf
(Figs. 4C and 5A). Under physiological conditions, however,
HFE and TfR are tethered to the same membrane (19), thereby
increasing their effective local concentrations and permitting
potential interactions between the HFE and TfR cytoplasmic
tails (22). Either or both of these effects could allow HFE to
compete more effectively against Fe-Tf for binding to TfR.
To evaluate how the addition of Fe-Tf affects complex forma-
tion between full-length HFE and TfR proteins tethered to a
common membrane, we first showed that binding to TfR is
required for a GFP-tagged form of HFE to traffic to Tf-positive
endosomal compartments, and then asked if the addition of
Fe-Tf affects endosomal localization of HFE-GFP. For these
experiments, we expressed an HFE-GFP chimeric protein, in
which GFP was fused to the C terminus of full-length HFE, in
two forms of Chinese hamster ovary cells: TRVb cells, which
lack expression of endogenous hamster TfR, and TRVb-1 cells,
which lack endogenous TfR but stably express human TfR (36).
Confocal imaging of HFE-GFP-expressing TRVb-1 (HFE/
TfR) cells reveals primarily intracellular fluorescence (Fig.
6A, middle panel), which co-localizes with endocytosed Alexa-
546-labeled human Fe-Tf (Fig. 6A, right panel), demonstrating
that the HFE traffics to Tf-positive endosomes in cells express-
ing TfR. By contrast, most of the GFP fluorescence in HFE-
GFP-expressing TRVb cells (HFE/TfR) was primarily local-
ized at the cell surface (Fig. 6A, left panel), and these cells show
no significant intracellular fluorescence in Alexa-546 Fe-Tf up-
take experiments (data not shown). These data demonstrate
that binding to cell surface TfR is required for HFE localization
in Tf-positive endosomes, consistent with the lack of an obvious
endocytic signal in the HFE cytoplasmic tail (3, 8, 21). Thus,
endosomal localization of HFE-GFP can be used to evaluate
competition between Fe-Tf and HFE for binding to cell surface
TfR.
Since HFE binding to TfR is required for HFE translocation
to Tf-positive endosomes, we investigated whether endosomal
localization of HFE could be prevented by the presence of high
concentrations of extracellular Fe-Tf. To address this question,
we incubated TRVb-1-HFE-GFP (HFE/TfR) cells in growth
medium supplemented with Fe-Tf at concentrations ranging
from 0 nM to 50 M. At relatively low concentrations of extra-
cellular Fe-Tf (500 nM), HFE-GFP fluorescence began to redis-
tribute from intracellular locations to the cell surface (Fig. 6B).
Upon the addition of micromolar concentrations of Fe-Tf corre-
sponding to serum Fe-Tf levels (37), we saw a substantial
reduction of endosomal GFP fluorescence with a concomitant
increase in cell surface fluorescence (Fig. 6B). At Fe-Tf concen-
trations exceeding 5 M, little or no HFE-GFP fluorescence
localized to endosomes, indicating that Fe-Tf has competed
effectively with HFE to occupy virtually all binding sites on cell
surface TfR molecules (Fig. 6B). The addition of the same
concentrations of iron-loaded ovotransferrin, a transferrin or-
tholog that does not bind human TfR (38), did not result in
detectable redistribution of HFE-GFP from endosomal com-
partments to the cell surface (Fig. 6C), indicating that the HFE
FIG. 5. SPR assay of competition between HFE and Fe-Tf for binding to wtTfR versus hdTfR. Plots are of the normalized equilibrium
biosensor response value versus the log of the indicated protein concentration. HFE binding in the absence (blue diamonds) or presence of Fe-Tf
(50 M Fe-Tf (red square) and 5 M Fe-T (cyan triangle)) to wtTfR (A) or to hdTfR (B). Fe-Tf binding is shown in the absence (green circle) or presence
of 10 M HFE (magenta square) to wtTfR (C) or to hdTfR (D). Data points are related by a 1.6-fold dilution series.
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redistribution effect is due to direct competition between HFE
and human Fe-Tf for TfR binding sites.
DISCUSSION
TfR is a homodimeric receptor that binds two ligands at
neutral or basic pH: Fe-Tf and HFE. TfR can form binary
complexes with either HFE or Fe-Tf and can bind both ligands
simultaneously to form a 1:1:1 HFETfRFe-Tf ternary complex
(18–20). Characterizing the ternary complex is of interest,
because both soluble and membrane-bound HFE reduce the
apparent affinity of soluble and membrane-bound TfR for Fe-Tf
(8, 21, 23, 39). Since mixtures of binary and ternary complexes
form when all three proteins are present (Fig. 1), it has not
been possible to determine if HFE reduces the affinity of TfR
for Fe-Tf via direct competition for overlapping binding sites on
TfR and/or if structural changes induced by HFE binding to one
chain of the TfR dimer (19) lowers the binding affinity for
ligand on the other TfR chain. Although several studies have
demonstrated that HFE and Fe-Tf compete for binding to a
common site on TfR (20, 24, 25), the potential role for negative
cooperativity in the binding of Fe-Tf to 1:1 HFETfR complexes
has not been addressed because of complications arising from
the competing side reactions that lead to 2:1 HFETfR and
Fe-TfTfR complexes when both HFE and Fe-Tf are incubated
with homodimeric wtTfR. To directly evaluate the effects of
heterotropic ligand binding to TfR, we constructed a hdTfR in
which one chain binds HFE but not Fe-Tf and the other chain
binds Fe-Tf but not HFE, such that only ternary complexes can
form when hdTfR is incubated with Fe-Tf and HFE.
FIG. 6. Confocal images of HFE-
GFP distribution in TRVb (TfR) and
TRVb-1 (TfR) cells. A, cells expressing
HFE-GFP (green fluorescence) in the ab-
sence (left) or presence (middle) of co-ex-
pressed human TfR. Co-localization of
HFE-GFP fluorescence with Alexa-546-
labeled human Fe-Tf in TfR cells is
shown on the right. B, cells expressing
HFE-GFP and human TfR incubated with
the indicated concentrations of unlabeled
human Fe-Tf in the culture media. C, cells
expressing HFE-GFP and TfR incubated
with the indicated concentrations of
chicken Fe-Tf (Fe-oTf) in the culture
media.
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Although many substitutions in the TfR ligand-binding site
affect binding to both ligands (20, 24), we were able to produce
an hdTfR in which the HFE-binding chain retains a 390 nM
affinity for HFE, but no detectable affinity for Fe-Tf, and the
Fe-Tf-binding chain retains a 1.2 M affinity for Fe-Tf but does
not bind detectably to HFE (Fig. 3, A–D, Table I). Sedimenta-
tion velocity AUC and biosensor binding assays demonstrate
that the hdTfR binds only one HFE and only one Fe-Tf and that
it forms a 1:1:1 HFETfRFe-Tf ternary complex when all three
proteins are mixed together. Having confirmed that hdTfR does
not participate in side reactions leading to binary complexes
(Fig. 1), we used it to evaluate whether binding of ligand to one
chain of TfR affects the binding affinity of the other ligand for
TfR. Biosensor binding assays conducted in the presence and
absence of a saturating concentration of Fe-Tf reveal no signif-
icant differences in the binding affinity of HFE for hdTfR.
Similarly, Fe-Tf binding to hdTfR is not altered by prebinding
HFE to one chain of hdTfR. By contrast, when wtTfR is incu-
bated with a saturating amount of HFE, we observe a reduction
in the apparent binding affinity for Fe-Tf, as previously re-
ported (23). The experiments using hdTfR demonstrate that
there is no cooperativity, either negative or positive, in hetero-
tropic ligand binding by hdTfR, suggesting that the apparent
lowering of the Fe-Tf affinity of cell surface and soluble wtTfR
by HFE (8, 23, 39, 40) results entirely from competition be-
tween HFE and Fe-Tf for overlapping binding sites on the TfR
surface. Extending these results to wtTfR requires the assump-
tion that the mutations used to create the hdTfR do not them-
selves disrupt cooperativity. Because we cannot evaluate coop-
erativity using wtTfR, we cannot directly address this issue.
However, it is unlikely that the mutations themselves disrupt
cooperativity, because the substituted residues are on the ex-
terior of the protein in locations that are distant from the TfR
dimer interface, across which structural changes would need to
be propagated for cooperativity in ligand binding to occur.
Having shown that direct competition rather than allostery
affects heterotropic ligand binding by TfR in solution, we next
evaluated the effects of competition as a function of ligand
concentration. Using wtTfR in a biosensor-based binding assay,
we find that HFE shows only minimal binding to wtTfR when
Fe-Tf is present at concentrations of 5 M and above, demon-
strating that it can compete with Fe-Tf, but only when it is
several times more concentrated. Consistent with this result,
sedimentation velocity AUC experiments show that 2:1 Fe-
TfTfR complexes are the dominant species when HFE, Fe-Tf,
and wtTfR are mixed such that the HFE and Fe-Tf are at
higher concentrations than wtTfR. Therefore, soluble HFE is a
poor competitor for binding to soluble TfR when Fe-Tf is pres-
ent at high concentrations, including the micromolar concen-
trations corresponding to physiological levels of Fe-Tf in blood
(37).
If TfR binding is required for HFE to act as a regulator of
cellular iron homeostasis, then it must compete effectively
against physiological levels of Fe-Tf when TfR and HFE are
both present at the surface of a cell. Since HFE and TfR are
tethered to the same cellular membrane (19), the effective
concentrations of both proteins may be much higher than in the
biochemical assays involving soluble proteins used here. We
therefore developed a cell-based assay to evaluate the effects of
the addition of soluble Fe-Tf on the interaction between mem-
brane-bound HFE and membrane-bound TfR. As an indication
of HFETfR complex formation, we monitored the localization
of an HFE-GFP chimeric protein in transfected cells, assuming
that HFE-GFP fluorescence in endosomes represents HFE-
GFP that trafficked there as a result of binding to cell surface
TfR. This assumption was verified by showing that HFE traf-
ficks to Tf-positive endosomes in TfR-positive but not TfR-
negative cells; thus, TfR binding is required for HFE to enter
endosomes. By incubating the TfR-positive cells with Fe-Tf, we
then demonstrated a loss of endosomal HFE-GFP fluorescence
at relatively low concentrations of exogenous Fe-Tf (500 nM),
with a substantial redistribution of GFP fluorescence to the cell
surface at near physiological concentrations of exogenous Fe-Tf
(micromolar) (37). Thus, external levels of Fe-Tf can influence
both the localization and binding state of HFE in cells. The
relatively high concentrations of Fe-Tf required to affect HFE
localization and binding to TfR suggest a reevaluation of pre-
vious studies using transfected cells in which subphysiological
concentrations of Fe-Tf were used as the iron source (7, 21, 22,
39–44). Our data suggest that redistribution of HFE at micro-
molar concentrations of Fe-Tf in blood has functional conse-
quences that may not be observed in studies using submicro-
molar levels of Fe-Tf.
Indeed, competition between HFE and Fe-Tf for binding to
TfR has been hypothesized to be critical for controlling iron
metabolism (45, 46). In one model involving HFE/Fe-Tf compe-
tition, the concentration of Fe-Tf controls whether HFE binds
to TfR, thereby inhibiting uptake of Fe-Tf, or if HFE binds to
another cell surface protein (e.g. ferroportin, an iron-export
protein (47–49)), thereby inhibiting export of intracellular iron.
Although our results show that soluble HFE competes poorly
with Fe-Tf for binding to soluble TfR, membrane-bound HFE
can compete effectively with physiological concentrations of
exogenous Fe-Tf for binding to cell surface TfR. Thus, the
amount of cell surface HFE bound to cell surface TfR can be
controlled by the concentration of exogenous Fe-Tf, alone or in
concert with changes in TfR expression levels, allowing regu-
lation of the binding configuration of HFE at the cell surface.
There are three possible binding configurations of HFE at the
cell surface (bound to TfR, bound to another protein(s), or free),
each of which could be involved in regulation of iron homeosta-
sis. For example, HFE bound to TfR can prevent uptake of iron
in the form of Fe-Tf. If Fe-Tf binding to TfR competes away
HFE, allowing it to bind to an iron transport protein such as
ferroportin or DMT1 (an iron import protein (50)), then fluctu-
ations in the level of free versus bound HFE could regulate
either the rate of cellular iron export (ferroportin) or import
(DMT1). Additionally, if cells can sense the amount of cell
surface or endosomally localized HFE, then fluctuations in
those levels could affect downstream signaling.
Elucidating the details of the interactions between HFE,
TfR, and Fe-Tf will be critical for understanding the mecha-
nisms by which mammals regulate iron levels. We have clari-
fied the interactions between these proteins, demonstrating
that several TfR/ligand stoichiometries are possible, that HFE/
TfR binding is required for HFE transport to endosomes, and
that there is strong allostery-free competition between HFE and
Fe-Tf for TfR binding at the cell surface. These results provide
experimental support for models of iron regulation in which
competition between HFE and Fe-Tf for binding to TfR plays a
central role in maintaining cellular iron homeostasis (45).
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Chapter 4:
A Hydrophobic Patch on Transferrin
Receptor Regulates the Iron-Release
Properties of Receptor-Bound Transferrin
This chapter is being submitted for publication.  We test our hypothesis that the
transferrin receptor residues required for specifically binding apo-Tf are important in
transferrin receptor’s role in stimulating iron release from iron-loaded transferrin.  I
produced the W641A/F760A-TfR mutant described, purified it, and performed the
binding analysis.  Peter Halbrooks and Anne B. Mason produced the FeC-Tf mutant and
performed the iron-release experiments.
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Abstract
The transferrin receptor (TfR), a dimeric membrane glycoprotein, is responsible for iron
uptake in most mammalian cells.  At the basic pH of blood (pH 7.4), TfR binds iron-
loaded transferrin (Fe-Tf) in serum, and transports it to acidic recycling endosomes where
iron is released from Fe-Tf in a TfR-facilitated process.  Iron-free transferrin (apo-Tf)
remains bound to TfR and is recycled to the cell surface, where apo-Tf rapidly dissociates
from TfR upon exposure to the basic pH of blood.  We previously demonstrated that
substitution of either Trp 641 or Phe 760 in the TfR helical domain reduces TfR’s
binding to apo-Tf but not to Fe-Tf.  Studies with a double mutant of TfR, W641A/F760A,
substantiate the earlier finding by demonstrating a 300-fold weaker affinity for apo-Tf
relative to wild-type TfR.  To evaluate the effects of the mutations on TfR-facilitated iron
release from Fe-Tf, we measured release rates at acidic pH from a monoferric form of Tf
(FeC-Tf) alone and when bound to wild-type TfR or W641A/F760A. We find that iron
release from FeC-Tf is 200-fold slower when it is bound to the mutant TfR than when
bound to wild-type TfR. Whereas binding of FeC-Tf to the wild-type TfR accelerates iron
release rate by 100-fold compared to free FeC-Tf, binding to the mutant TfR slows the
iron release rate by two-fold as compared free FeC-Tf.  These findings demonstrate that
the conserved hydrophobic patch on TfR that includes W641 and F760 is required for the
receptor-mediated stimulation of iron release from the C-lobe of Tf at low pH.
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Introduction
Iron is a fundamental nutrient required for sustaining numerous cellular processes in all
cell types. The primary pathway for iron uptake by most mammalian cells involves the
transferrin receptor (TfR), a dimeric transmembrane glycoprotein that traffics between
the cell surface and acidic intracellular compartments (1).  At the basic pH of the cell
surface (pH 7.4), TfR binds iron-loaded transferrin (Fe-Tf) (2), an iron transport protein
present at micromolar concentrations in the blood (3).  Fe-Tf binds to the TfR at pH 7.4
with an equilibrium dissociation constant  (KD) of ~1 nM (4).  Fe-Tf/TfR complexes enter
acidic endosomes through receptor-mediated endocytosis where iron is released from Fe-
Tf at acidic pH in a TfR-assisted process (5-10).  The resulting iron-free transferrin (apo-
Tf) remains bound to TfR at acidic pH (KD ~5 nM) during recycling of apo-Tf/TfR
complexes back to the cell surface, but dissociates from TfR upon exposure to the
slightly basic pH of blood (11).
Crystallographic studies have revealed the structures of TfR and several forms of Tf and
Tf-related molecules (12). The structure of the soluble ectodomain of TfR has been
reported alone (13) and in complex with HFE (14), the protein mutated in patients with
the iron-overload disorder hereditary hemochromatosis (15).  Each monomer of the TfR
ectodomain is comprised of three structural domains: a protease-like domain resembling
amino- and carboxypeptidases (residues 121-188 and 384-606), an apical domain
(residues 189-383), and a helical domain involved in homodimerization (residues 607-
760).  Membrane-bound TfR also includes a glycosylated stalk region (residues 90-120),
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a transmembrane region (residues 62-89), and an N-terminal cytoplasmic domain
(residues 1-61) that contains a tyrosine-based endosomal sorting sequence (YTRF) (1).
Transferrin contains two ~40 kDa lobes (the N- and C-lobes), related by sequence and
structural homology (Fig. 1A).  Each lobe consists of two domains (N-I and N-II in the
N-lobe; C-I and C-II in the C-lobe).  A single Fe3+ atom is held deep within a cleft
formed at the interface between the two domains of each lobe. Each iron atom is
octahedrally coordinated by four sidechains from Tf (two tyrosine residues, one histidine,
and one aspartate) and by a synergistic anion, which is bicarbonate in vivo (16).  Iron
release results in large conformational changes in each lobe and in the interface between
lobes (17,18). There is a 54-63º rotation between the domains that comprise each lobe
and a repacking of the interface between each lobe, burying previously exposed residues
and exposing previously buried residues (19,20) (Fig. 1B).  It is presumed that
conformational changes resulting from iron loss occur while Tf is bound to TfR inside
acidic vesicles, as the two proteins remain complexed throughout endocytosis and
recycling (11). Iron release studies have shown that iron dissociates slowly from Fe-Tf at
pH 7.4 in the absence of a chelator (half-life >days).  The rate is accelerated at the acidic
pH of endosomes (half-life >3 hours at pH 5.5), but is still slow compared with the rate
observed for iron transfer from Fe2-Tf/TfR complexes to the cellular interior (2-3
minutes) (21).  The discovery that binding to TfR accelerates the release of iron from Fe-
Tf at acidic pH by 100- to 300-fold (9,10) suggests that iron is released inside acidic
endosomes during a single round of endocytosis and recycling, but the mechanism by
which TfR facilitates iron release from Fe-Tf is not known.
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Understanding the mechanism by which TfR facilitates iron release from Fe-Tf requires
structural information about how TfR binds to both Fe-Tf and to apo-Tf. Despite the lack
of a crystal structure for a Tf/TfR complex, competition (22), mutagenesis (23,24), and
time-resolved X-ray footprinting (25) studies have mapped the binding site on TfR for Tf,
revealing that the Tf C-lobe binds to the central portion of the TfR helical domain and the
Tf N-lobe contacts the bottom of the TfR protease-like domain.  Consistent with the
mutagenesis and mapping results, a recent ~7.5 Å resolution structure of an Fe-Tf/TfR
complex derived by cryoelectron microscopy shows the C-lobe contacting the TfR helical
domain and the N-lobe making contacts with the TfR protease-like domain (26).  Apo-Tf
is believed to bind to TfR in a similar manner, based on the fact that most substitutions
that strongly reduce Fe-Tf binding to TfR at basic pH exhibit a similar reduction of apo-
Tf binding at pH 6.3 (24).  However, at least some differences in the specific contacts of
apo-Tf versus Fe-Tf to TfR are suggested by two substitutions in TfR (W641A and
F760A) (Fig. 1C or 1D), which reduce binding to apo-Tf without significantly affecting
binding to Fe-Tf (24). From these mutagenesis results, we suggested that specific
contacts at low pH between Tf and the W641/F760 region of TfR stabilize an open
conformation of the Tf C-lobe, thereby allowing protons and chelators to more easily
access the Fe3+ binding site and accelerate iron release from TfR-bound Fe-Tf.
To further evaluate involvement of the apo-Tf-specific region of TfR in affecting iron
release from Fe-Tf, we produced a double mutant of TfR that binds Fe-Tf at basic pH
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with wild-type affinity, but shows greatly reduced affinity for apo-Tf at acidic pH. This
TfR mutant was made by combining the W641A and F760A substitutions and expressed
as a recombinant soluble protein for binding and iron release studies in solution.
Quantitative binding studies in solution demonstrate that the W641A/F760A mutant
retains a wild-type affinity for Fe-Tf at pH 7.4, but binds apo-Tf with an ~300-fold
reduced affinity at pH 6.3.  Using a fluorescence-based iron release assay we demonstrate
that the rate of iron release from the C-lobe of Tf bound to the mutant TfR is 200-fold
slower than the rate for Fe-Tf bound to wild-type TfR and two-fold slower than iron
release from uncomplexed Fe-Tf.  These results suggest a mechanism by which TfR
facilitates iron release from Fe-Tf and are relevant to an understanding of the
conformational changes in both Fe-Tf and TfR that are necessary for iron release on
biological time scales.
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Results
Production and Tf-binding properties of wild-type and mutant TfRs
To construct a TfR that binds Fe-Tf but not apo-Tf, we combined two amino acid
substitutions previously identified to lower the binding affinity of TfR for apo-Tf at pH
6.3 but not Fe-Tf at pH 7.4:  W641A (~56-fold reduction) and F760A (~16-fold
reduction) (24).  6x-His tagged soluble wild-type TfR (wtTfR) and W641A/F760A-TfR
(hereafter referred to as W641A/F760A) were expressed and purified as previously
described (27).  To evaluate the binding characteristics of W641A/F760A, we derived
equilibrium dissociation constants (KDs) for binding to human Fe-Tf at pH 7.4 and to
apo-Tf at pH 6.3 using a surface plasmon resonance (SPR) binding assay.  His-tagged
wtTfR and mutant TfR were captured directly from baculovirus-infected insect cell
supernatants on the surface of a biosensor chip using a covalently coupled anti-His tag
antibody as previously described (24,28). Experiments involving apo-Tf were done in the
presence of 50 µM desferrioxamine, a potent iron chelator (reviewed in 29).
The SPR experiments demonstrate that W641A/F760A exhibits the expected properties,
binding to Fe-Tf at pH 7.4 with no reduction in affinity compared to wtTfR, but binding
to apo-Tf at pH 6.3 with a significantly reduced affinity (Fig. 2, Table 1). The 4.7 µM KD
for apo-Tf binding to W641A/F760A represents an ~270-fold reduction in affinity
compared to wtTfR, which corresponds to a ΔΔG value of 3.3 kcal/mol at 25 ºC.  In our
previous mutagenesis study, we demonstrated that the loss in free energy for binding apo-
Tf for the two single mutants that comprise the W641A/F760A mutant is 2.4 kcal/mol
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(W641A) and 1.6 kcal/mol (F760A), predicting a ΔΔG value of 4.0 kcal/mol if the two
substitutions act independently. The difference between the predicted and observed ΔΔG
values suggests that the two substitutions do not act completely independently, perhaps
because the substituted residues are in van der Waals contact (Fig. 1C, 1D, or Fig. 5) (3.3
Å as measured using the structure of free TfR (13), PDB code 1CX8).
Comparison of TfR-facilitated iron release from Fe-Tf bound to wtTfR versus
W641A/F760A
We next sought to determine the effects of a reduced binding affinity for apo-Tf at pH 6.3
on the ability of W641A/F760A to facilitate iron release from Fe-Tf.  For these
experiments, we used a spectrofluorometric assay that yields a rate of iron release as
reported by an increase in protein fluorescence due mainly to the release of quenching of
tryptophan residues that are exposed as a result of iron loss (there are five Trp residues in
the C-lobe of Tf).  The kinetics of iron release from diferric-Tf are complicated by
different rates of iron release from the N- and C-lobes (30,31) and from the influence of
the iron status of the N-lobe on the release rate from the C-lobe (10).  Since only the Fe-
Tf C-lobe makes significant interactions with the TfR helical domain (24-26), which
contains the hydrophobic patch formed by W641 and F760 (13), we conducted iron
release assays using a mutant form of Tf capable of binding an iron atom in the C-lobe,
but not in the N-lobe (32), referred to here as Fec-Tf and in other studies as N-His-
Y95F/Y188F hTf-NG. Fec-Tf contains an N-terminal His-tag, substitutions in the C-lobe
that eliminate N-linked glycosylation sites (N413A and N611D), and substitution of two
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of the four ligands to the iron in the N-lobe (Y95F and Y188F) to prevent iron binding.
Previous studies demonstrated that the His-tag and the absence of glycosylation do not
affect Tf binding to TfR (33,34).
We first verified that Fec-Tf forms complexes with wtTfR and W641A/F760A. Each
form of TfR was mixed with a molar excess of Fec-Tf and passed over a gel filtration
column at pH 8.5 to purify the Fec-Tf/TfR complex from free Fec-Tf (Fig. 3A).  SDS-
PAGE analysis of the column fractions verified that the slower migrating peak
corresponds to a Fec-Tf:TfR complex in the case of both wtTfR and W641A/F760A (Fig.
3B).
Measurement of iron removal for Fec-Tf alone at pH 5.6 yielded a release rate of 2.6 ±
0.2 × 10-3 s-1.  Binding of wtTfR to Fec-Tf increases the rate by ~100 to a rate of 270 ± 46
× 10-3 s-1.  By contrast, binding of W641A/760A to Fec-Tf decreased the iron release rate
to 1.3 ± 0.03 × 10-3 s-1, a factor of two slower than free Fec-Tf and 200-fold slower than
Fec-Tf complexed with wtTfR (Fig. 4 & Table I).  The assay conditions used here differ
from a previous study using a similar methodology to monitor iron release from the C-
lobe of transferrin in the presence and absence of TfR (10).  Therefore, the comparison of
rates may only be made when the experiment was performed under identical assay
conditions (34,35).  We note that the use of a higher concentration of protein used here
eliminates problems with photobleaching described in the earlier work (10).
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Discussion
An important aspect of iron homeostasis is the proper transport, delivery, and uptake of
iron into cells, since misdirection of toxic iron atoms can result in large-scale oxidative
damage (36).  In vertebrates, this process is controlled by the interplay of Tf with its cell-
surface receptor, TfR.  Tf binds iron with a very high affinity (KD = 10
-22 M) and exhibits
slow release kinetics at pH 7.4 (37).  However, when bound to TfR and exposed to acidic
pH, iron release is greatly accelerated (9,10,38,39).  Within the cell Fe-Tf releases its
bound iron to a chelator within 2-3 minutes after TfR-mediated endocytosis (21).  The
requirement for TfR binding, a low pH environment, possibly reducing agents, and a
chelator ensures that iron is not prematurely released from Fe-Tf in the bloodstream or
when Fe-Tf is bound to TfR at the cell surface.  Instead, these requirements ensure that
only when Fe-Tf enters the appropriate endosomal compartment is the iron safely
released.
In a previous site-directed mutagenesis study of TfR (24) we noted differences in the
binding footprints for Fe-Tf and apo-Tf on the TfR surface.  While apo-Tf and Fe-Tf
require the same binding determinants in the central region of the TfR helical domain,
apo-Tf requires two additional residues in the TfR helical domain:  W641 and F760.  The
sidechains of these two residues are in van der Waals contact with each other and form a
hydrophobic patch on the outside edge of the TfR helical domain (Fig. 5).  We
hypothesize that these residues play a role in TfR-stimulated iron release at low pH by
binding to and stabilizing the iron-free form of Tf.  We therefore combined the two
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substitutions to make a W641A/F760A-TfR and investigated its binding and iron-release
stimulating properties.
Using an SPR-based binding assay we demonstrated that W641A/F760A binds Fe-Tf at
pH 7.4 with the same affinity as wtTfR.  However, its binding to apo-Tf at pH 6.3 is
reduced ~300-fold relative to wtTfR.  Using a fluorescence-based iron release assay we
showed that the W641A/F760A mutant does not stimulate iron release from Fe-Tf at low
pH under conditions at which wtTfR accelerates iron release from Fe-Tf by 100-fold
relative to unbound Fe-Tf.  Instead, the W641A/F760A mutant slows iron release by two-
fold relative to free Fe-Tf. W641 and F760 are conserved (24) in all known sequences of
TfR and also in sequences of transferrin receptor 2 (TfR2), a recently identified receptor
for Fe-Tf (40,41). The conservation of these residues across all known TfR and TfR2
sequences suggests a conserved role for these residues in facilitating iron release from
TfR-bound Fe-Tf at acidic pH.
These results, taken together with previous structural and mutagenesis data regarding Tf
binding to TfR (23-26), allow speculation on the mechanism of TfR-induced iron release
from Fe-Tf at acidic pH. From structural and mutagenesis data we know that Fe-Tf binds
to TfR at basic pH with the C-lobe contacting a central region of the TfR domain and the
N-lobe contacting residues in the TfR protease-like domain in the vicinity of Tyr 123
(24,26). This binding interaction must stabilize Fe-Tf in a closed conformation as iron
release from TfR-bound Fe-Tf is slower than iron release from free Fe-Tf (9,10,38,39).
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At basic pH, Fe-Tf does not make functionally important contacts with the hydrophobic
patch on TfR that includes W641 and F760 (24). Upon acidification, the Tf molecule
makes new contacts on TfR to the hydrophobic patch defined by W641 and F760, and no
longer makes significant contacts to the Y123 region of the TfR protease-like domain
(24). Our current results demonstrate that the new contacts with TfR residues W641 and
F760 are critical for accelerating iron release from Fe-Tf at acidic pH. We therefore
suggest that at acidic pH, the sampling rate of the open and closed conformations of Fe-
Tf when bound to TfR is slower than that of free Fe-Tf under the same conditions due to
constraints imposed by receptor binding.  This is consistent with our observation that free
Fec-Tf spontaneously releases iron more rapidly than Fec-Tf bound to the
W641A/F760A-TfR.  However, we propose that even though the rate of conformational
sampling is slowed, that receptor-bound Fe-Tf still samples open conformations and that
contacts between Fe-Tf and the W641/F760 hydrophobic patch trap Fe-Tf in an open
form. If these contacts are prevented by mutating W641 and F760, as in the
W641A/F760A-TfR mutant, then we suggest that the Fe-Tf will rapidly revert to its more
closed conformation inhibiting iron release even at the acidic pH.  This is consistent with
studies showing that conditions favoring the open state of Tf result in accelerated iron
release, while conditions that favor the closed conformation inhibit iron release (42).
Our model for TfR-facilitated iron release from Fe-Tf is supported by an examination of
the 7.5 Å EM structure of an Fe-Tf/TfR complex (26) (PDB code: 1SUV). The EM
structure suggests that TfR residues Trp641 and Phe760 are in close proximity to the C-I
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domain of the Tf C-lobe, but are unlikely to make direct contacts, consistent with the Fe-
Tf binding data in this and previous studies (24,26).  Inspeecttion of the EM model
suggests that small structural changes could bring the patch into contact with the Tf.
Interestingly, a straight line connecting the sidechains of Trp641 and Phe760 to the Fe3+
atom in the C-lobe bisects the C-I/C-II domain interface (Fig. 5A), which must open to
expose iron for release. The resolution of the EM model does not allow us to speculate on
what specific interactions would be made between TfR and Fe-Tf at this interface, but the
placement of the Trp641 Phe760 hydrophobic patch in this proximity and orientation to
the C-lobe’s cleft and ferric binding site, coupled with its clear activity in binding apo-Tf
and stimulating iron release, indicates a functional significance of the interactions in this
region.  Therefore, we hypothesize that the two residues act on Fe-Tf by stabilizing, and
possibly even initiating, an opening in the intralobe cleft that enhances the exposure of
the iron atom to protons and chelators for iron removal.
A corollary of this model is that cleft opening is only one step in the iron release process and is
not sufficient to release iron as collapse back to the closed state is still possible.  However this
would require that the iron remain bound to the protein in the open conformation, even though
domain opening requires that some of the iron ligands dissociate.  From the EM structure of the
Fe-Tf/TfR complex it has been noted that the C-I domain is in contact with the TfR helical
domain while the C-II domain makes no receptor contacts.  Therefore, C-II is free to swing away
from the receptor to achieve the open conformation associated with apo-Tf.  However, if domain
opening is not sufficient for iron release, then the ferric iron must stay associated with one of the
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two domains.  There is evidence that iron can remain bound to transferrin with only a partial
complement of protein ligands.  A crystal structure of camel lactoferrin (43) shows both the N-
and C-lobes in the open conformation exhibited by other apo-protein structures, except that both
lobes contain a bound iron.  Both irons are coordinated by bicarbonate and the two tyrosine
ligands, whereas the aspartate and histidine ligands normally associated with the iron
coordination are distant from the site.  Similarly, structures of a fragment of duck ovotransferrin
corresponding to the N-II lobe  show an iron coordinated by bicarbonate, the two tyrosine
ligands, and either an aspartate donated by an adventitiously bound peptide  (44) or added
nitrilotriacitic acid (NTA) (45).  While the iron is octahedrally coordinated, these structures
demonstrate that the N-II domain is capable of binding iron without ligand contributions from
the N-I lobe.  A recent study showed that binding to TfR at acidic pH has the effect of raising the
reduction potential of the coordinated Fe3+ on Fe-Tf by nearly 200 mV (46), suggesting that the
potential for biological reduction to Fe+2, which has a lower affinity for Tf by a factor of 1014
(Harris, 1986), is enhanced by TfR binding and precedes iron loss.  This elevation of the
reduction potential does not occur at basic pH.  To evaluate the reduction potential of the bound
iron atom, chelators were not used to prevent dissociation of iron from the Tf/TfR complex.  It is
possible that the reduction potential measured corresponds to the tetrahedral intermediate that we
propose forms before cellular reducing agents and chelators abstract the iron from the Tf/TfR
complex.
The mechanism for transferrin-mediated iron donation to cells is very complex and exhibits pH
dependence, anion and chelator requirements, conformational changes to transferrin, and binding
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to TfR.  Our model is that at acidic pH, stabilization of the open-form of Tf by interactions with
W641 and F760 results in the presentation of an exposed tetrahedrally coordinated iron center
from which cellular chelators can remove it from the protein.  However, this model relies on
observations for lactoferrin and ovotransferrin which, while very similar to human Tf in
sequence and structure, may have subtle differences in their modes of iron release.  Continued
biochemical and structural analysis of this system will be required to develop a comprehensive
model of receptor-enhanced iron release.
87
Materials and Methods
Expression of Soluble TfRs
Soluble wtTfR was produced in a lytic baculovirus/insect cell expression system as
previously described (27).  Briefly, we used a modified version of the pAcGP67A
expression vector (Pharmingen) that codes for the gp67 hydrophobic leader sequence
followed by a 6x-His tag, factor Xa cleavage site, and residues 121-760 of human TfR.
To make the W641A/F760A mutant, the W641A mutation was introduced into the
F760A-TfR expression vector (24) using the Quickchange protocol (Stratagene).  The
construct was verified by sequencing of the protein-coding region. His-tagged wtTfR and
W641A/F760A were expressed in baculovirus-infected insect cells and purified by a
combination of Ni-NTA and size exclusion chromatography as previously described (27).
Human Fe-Tf was prepared from apo-Tf (Sigma) by incubation with bicarbonate and 3-
fold excess of ferric ammonium sulfate.
Biosensor Analyses
All biosensor experiments were carried out using a BIACORE 2000 instrument
(Pharmacia, LKB Biotechnology).  Interactions between a protein immobilized on the
sensor chip (the “ligand”) and a protein injected over the sensor surface (the “analyte”)
are monitored in real time as a change in surface plasmon resonance as measured in
resonance units (RU) (47,48).  Sensor chips were prepared using standard primary amine
coupling chemistry to attach 2000-4000 RU of the anti-pentaHis antibody (Qiagen)
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(BIACORE manual), which was used to capture wtTfR and TfR mutants directly from
insect cell supernatants as described (24).  For each experiment one of the four flow-cells
of a CM5 sensor chip (Pharmacia) was coupled with antibody but no TfR to act as a
reference cell.  Binding data were collected, processed, and the kinetics fit to a bivalent
ligand model to derive KDs as previously described (24).
Expression of N-HisY95F/Y188F hTf-NG (Fec-Tf)
Production and purification of the recombinant Tf containing iron only in the C-lobe has
recently been described in detail (49). Both spectral data and urea gel analysis confirm
the inability of the N-lobe to bind iron. This authentic monoferric preparation allows
assessment of iron release from the C-lobe with no possibility of adventitious iron uptake
by the N-lobe due to the strategic mutations of the two liganding tyrosines.
Preparation of FeC-Tf /TfR complexes
A molar excess of Fec-Tf  in 100 mM NH4HCO3  pH 8.5 was  incubated with wtTfR or the
W641A/F760A-TfR for 30 min at room temperature followed by size-exclusion
chromatography to separate the Fec-Tf/TfR complexes from free Fec-Tf. The column was
equilibrated and run in 100 mM NH4HCO3 at a flow rate of 2 mL/Min using a BioCad
Sprint chromatography system.
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Measurements of iron release kinetics
The rate of iron release from the recombinant Fec-Tf in the presence and absence of the
wt and W641A/F760A-TfR was measured by an adaptation of the spectrofluorometric
assay previously described (10,50). A QuantaMaster Spectrofluorometer  (Photon
Technology International, South Brunswick NJ) equipped with a 75 Watt Xenon arc lamp
as an excitation source and excitation/emission monochrometers was used to measure
steady-state fluorescence.  Fluorescence emission spectra were measured by exciting the
sample at 280 nm and collecting the emitted fluorescence at 330 nm.  Experiments were
carried out at ambient temperature with an entry slit of 0.25 nm and an exit slit of 1.0 nm.
Data were recorded in 1 second intervals immediately following the addition of 4.8 µL of
Fec-Tf alone or 9.6 µL of the TfR to a magnetically stirred cuvette containing 1.8 mL of
0.1 M Mes, pH 5.6.  The assay conditions were 500 nM Fec-Tf in 300mM KCl and 4 mM
EDTA.
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Table 1.  wtTfR and W641A/F760A binding properties and effects on iron release from Fe-Tf
Protein Fe-Tf
pH 7.4
KD1 (nM)
Fe-Tf
pH 7.4
KD2 (nM)
apo-Tf
pH 6.3
KD1 (nM)
apo-Tf
pH 6.3
KD2
 (nM)
Iron Release
Kobs(s-1x 103)
wtTfR 0.90 59 18 39
W641A/F760A 1.5 53 4,700 56,000
Tf-FeC 2.6 ± 0.2
(n=4)
wtTfR/Tf-FeC 270 ± 46
(n=4)
W641A/F760A/Tf-FeC 1.3 ± 0.03
(n=3)
Table I: The KDs for binding of Fe-Tf at pH 7.4 and apo-Tf at pH 6.3 were derived from fits to
the sensorgrams shown in figure 2.  Rates for iron release from Tf-FeC alone or complexed
with wtTfR or W641A/F760A are derived from the fits to release curves in figure 4.
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Figure 1.  Ribbon diagrams of Fe-Tf, apo-Tf, and TfR. (A)  Structure of di-ferric
ovotransferrin (51) colored by domain as shown.  Residues coordinating the iron atoms
(red spheres) are shown as sticks and colored at atom type (yellow, carbon; blue,
nitrogen; red, oxygen).  (B) Structure of apo-ovotransferrin (20) colored as in (A)
illustrating the large structural change associated with iron release.
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Figure 1 continued: (C)  Structure of the TfR dimer with one monomer colored brown
and the other magenta.  Residues specific for binding apo-Tf (W641 and F760) are
highlighted in green.  Residues contributing significantly to Fe-Tf binding are shown
with carbons yellow, nitrogens blue, and oxygens red.  (D)  Closeup of the TfR helical
domain.  Residues are colored as in (C).
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Figure 2.  SPR analysis of Fe-Tf and apo-Tf binding to wtTfR and W641A/F760A at pH
7.4 and pH 6.3.  Experimentally observed responses are shown as black lines with the
best-fit binding curves (red lines) derived from a bivalent ligand model (see Methods and
Materials) superimposed. The highest concentration in the injection series for each
sensorgram is A, 73 nM; B, 73 nM; C, 625 nM; D, 10 µM. Subsequent injections are
related by 3-fold dilutions.
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Figure 3.  Preparation and purity of TfR proteins, Tf-Fec, and their complexes.  (A) Size
exclusion chromatogram of wtTfR (magenta), W641A/F760A (cyan), and Tf-Fec (green).
(B) Chromatogram of the Tf-Fec/wtTfR (blue) and the Tf-Fec/W641A/F760A (green)
complexes showing a peak for the complex and a peak for excess Tf-Fec. (C) 10% SDS-
PAGE gel showing purified wtTfR, W641A/F760A-TfR, Tf-Fec and peaks one and two
from the sizing column traces showing the presence of Tf-Fec/TfR complex in the first
peak and only Tf-Fec in the second.
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Figure 4.  Kinetics of iron release from Tf-FeC alone and in complex with TfR proteins.
Release was monitored as a change in relative fluorescence intensity versus time.  Loss of
iron results in an increase in fluorescence signal that was fit to a first order rate equation
to derive the rate constants shown in Table I.
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Figure 5.  Structure-based hypothesis for the mechanism of TfR accelerated iron release.
A)  The structure of the Tf/TfR complex based on the 7.5 Å EM model (24).  Protein
domains are colored as shown.  W641 and F760 are shown in green and the residues
coordinating the iron (red sphere) are shown in yellow.  A line connecting the F760 and
the iron atom is shown in white dashes and bisects the C-I/C-II domain boundary.  B)
Structures as in (A) except that transferrin has been replaced with the structure of camel
lactoferrin bound to iron, but in the open conformation (39).  Model was made by
superimposing the C-I domain of the lactoferrin structure with the C-I domain of the
human Tf in the EM model (RMSD 0.77 Å for 470 Cα atoms).  The iron is coordinated
by two tyrosines and a bicarbonate ion.
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Chapter 5:
Crystallographic Studies of the H41D
Mutant of the Hereditary Hemochromatosis
Protein Alone and in Complex with
Transferrin Receptor
This chapter is being prepared for publication and describes the crystallographic structure
determination of a mutant form of HFE linked to increased body iron.  I performed all the
crystal growth, data collection, building, and refinement, with the exception the
unliganded H41D-HFE crystal which was grown, and a dataset collected, by Dr. Melanie
Bennett.
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Crystallographic studies of the H41D mutant of the hereditary
hemochromatosis protein HFE alone and in complex with
transferrin receptor
Anthony M. Giannetti, Melanie J. Bennett, and Pamela J. Björkman
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Abstract.
The iron overload disorder hereditary hemochromatosis (HH) is caused by mutations to
the gene coding for the hemochromatosis protein HFE.  The most common disease-linked
mutation, C260Y, prevents proper folding and cell surface expression of HFE.  A second
mutation, H41D, correlates with higher body iron levels by exacerbating the iron
overload in individuals who are heterozygous for C260Y.  H41D-HFE folds, transports to
the cell surface, and exhibits wild-type affinity for the only currently documented HFE
binding partner, transferrin receptor (TfR), therefore the mechanism by which the
substitution affects iron levels is unclear.  To assess the potential structural changes
caused by the mutation, we determined crystal structures of H41D-HFE alone and
complexed with TfR, and compared these structures to their wild-type HFE counterparts.
The unliganded H41D-HFE exhibits almost no structural differences from wild-type
HFE.  However, comparison of the two forms of the protein complexed with TfR reveals
structural rearrangement of two loops in the HFE structure.  The potential significance of
these structural changes as they relate to primary iron overload are discussed.
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Introduction.
The identification of mutations to HFE as the causative agent of type I hemochromatosis,
also known as hereditary hemochromatosis, implicated HFE as a modulator of
mammalian iron homeostasis.  Positional cloning of the HFE gene revealed that most
hemochromatosis patients carry the mutation C260Y (Feder et al., 1996).  This
substitution acts as a loss-of-function mutation by eliminating a conserved disulphide
bridge in the α3 domain of the protein preventing proper folding, association with the β2-
microglobulin light chain, and transported the cell surface (Feder et al., 1996; Feder et
al., 1997; Waheed et al., 1997a).  Another mutation, H41D, which is found in some
hemochromatosis patients who are heterozygous for C260Y, appears to be linked to
increased risk for developing iron overload (Feder et al., 1996; Risch, 1997).  A recent
study using transgenic mice demonstrated that mice carrying an H41D-HFE allele exhibit
a greater body iron load compared to mice that have at least one wild-type copy of the
gene (Tomatsu et al., 2003).  A study utilizing macrophages demonstrated that while
wild-type HFE (wt-HFE) decreases iron export from cells, H41D-HFE does not
(Drakesmith et al., 2002).  These results suggest that the H41D substitution impairs
HFE’s activity in modulating iron homeostasis.
HFE is structurally similar to class I MHC molecules (Lebrón et al., 1998), which present
antigenic peptides to T lymphocytes (Garcia et al., 1999).  The heavy chain is composed
of three domains (α1, α2, α3) and is noncovalently associated with the light chain β2-
microglobulin (β2m) (figure 1).  His-41 is located on a loop (loop II) connecting ß-
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strands 3 and 4 on the outside edge of the α1- α 2 platform, where it forms a salt bridge
with Asp-73 (Fig. 1; 4A) (Lebrón et al., 1998). It was originally proposed that
substitution of the histidine for a negatively charged residue would disrupt the salt bridge
with Asp-73 and juxtapose two negative charges, perhaps leading to a change in loop
structure (Lebrón et al., 1998).  The loop is potentially mobile as judged from map
quality and the crystallographic temperature factors (B-factor) in the unliganded HFE
structure.  The average B-factor for atoms in loop II is 94.3 Å2 compared to 64.5 Å2 for
the entire HFE molecule.
HFE binds to the transferrin receptor (TfR) (Parkkila et al., 1997; Feder et al., 1998), a
homodimeric type II membrane glycoprotein found on the surface of most mammalian
cell types (Leibman & Aisen, 1977).  TfR binds transferrin, a circulating iron transport
protein, and transports it to acidic recycling endosomes by receptor-mediated endocytosis
(Dautry-Varsat et al., 1983).  Iron is removed from transferrin in the endosome
(Rothenberger et al., 1987; Bali et al., 1991; J.F. Collawn et al., 1991; Sipe & Murphy,
1991; J. F. Collawn et al., 1993; Zak & Aisen, 2003) and transported to the cytosol where
it is used for the metabolic requirements of the cell, or stored in the iron storage protein
ferritin (Radisky & Kaplan, 1998).  While the mechanism for HFE modulation of iron
homeostasis is not known, binding to TfR is most likely an important part of that
mechanism.
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The X-ray crystal structure an HFE/TfR complex reveals two HFE molecules bound to
TfR, one on each side of the obligate dimer (Bennett et al., 2000).  The interaction is
mediated mostly through the long α1 helix on HFE with some contacts from the α2 helix
and the platform domain with the helical domain on TfR (Fig. 3A).  Biochemical and
biophysical studies using soluble forms of HFE have not demonstrated an effect of the
H41D mutation on the stability or binding affinity of HFE to TfR (Feder et al., 1998;
Lebrón et al., 1999), but potential structural differences between H41D-HFE and wt-HFE
that could affect HFE’s activity in TfR-independent functions have not been addressed.
In order to determine the structural consequences of the H41D mutation, we determined
the X-ray structures of H41D-HFE alone and complexed with TfR.  We find that aside
from a slight reorientation of Asp-41 relative to His-41, that there are no structural
differences between unliganded H41D-HFE and wt-HFE.
However, comparison of H41D-HFE crystallized while bound to TfR reveals a
rearrangement of the loop relative to that of the wt-HFE/TfR structure.  By comparing the
structures of unliganded HFE, wt-HFE bound to TfR, and H41D-HFE bound to TfR, we
find loop II to be a mobile structure and that this mobility may have longer-range effects
on other regions of the HFE structure.  The potential consequences of this structural
variability are discussed in terms of HFE’s role in maintaining iron balance.
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Results.
Structure of H41D-HFE
Crystals of H41D-HFE were grown as described for wt-HFE (Lebrón et al., 1998) in
spacegroup P212121 with two molecules per asymmetric unit.  The structure was solved
by molecular replacement to 2.9 Å resolution using the 2.6 Å structure of wt-HFE
(Lebrón et al., 1998).  Data collection and refinement results are presented in Table I.
Before data processing and rigid-body refinement, the histidine residue at position 41 was
converted to an asparate in both molecules of the asymmetric unit. A σA-weighted 2Fo-Fc
annealed omit map in the vicinity of Asp-41 after rigid-body refinement shows negative
density around the aspartate sidechain with a small peak of positive density nearby (Fig.
2A).  This positive peak can be occupied by the aspartate sidechain by a rotation about
the Asp-41 χ1 torsion angle.  Rebuilding and refinement produced the model and
annealed omit density (entire loop omitted) in figure 2B.  The position of the Asp-41
sidechain is not clearly defined as loop II is not well ordered in either this structure or the
structure of wild-type HFE, as judged either from the quality of the electron density and
comparison of the average B-factors for the loop (94.3 Å2) compared to the entire HFE
heavy chain (64.5 Å2) (based on the wt-HFE structure).  The map in figure 2B shows
residual density for the Asp-41 sidechain in its original position suggesting alternate
conformations for the sidechain, but the only moderate resolution of the structure (2.9Å)
and the low quality of the electron density in the vicinity of residue 41 did not warrant
building alternate sidechain conformations followed by occupancy refinement.  Figure
2C shows the superposition of the refined H41D-HFE and wt-HFE structures,
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demonstrating that that the H41D mutation does not cause an overall structural
rearrangement of the H41-containing loop.
Structure of the H41D-HFE/TfR complex
H41D-HFE/TfR complex crystals formed in space group C2 space group and were
isomorphous with wt-HFE/TfR crystals (Bennett et al., 2000), but did not diffract beyond
3.5 Å, as compared with the wt-HFE/TfR crystals, from which the crystal structure was
determined to 2.8 Å resolution.  Coordinates for the wt-HFE/TfR binary structure (PDB
code: 1DE4) were used for molecular replacement.  Refinement statistics are given in
Table 2 and the final model in the vicinity of loop II and σA-weighted annealed omit
electron density in shown in Figure 2E.  Figure 2D shows an initial FO,mut-FC,wild-type,φC
difference map with the carbon-α coordinates from the wt-HFE/TfR structure.  Positive
(blue) and negative (red) 2σ difference density shows that loop II occupies an alternate
position in the H41D-HFE/TfR structure.  The loop, and all nearby areas, were rebuilt
and refined.
Comparison of the backbones of loop II region in the wt-HFE/TfR and H41D-HFE/TfR
structures reveals a change in the path of the main chain, with the largest difference being
5.7 Å between the α-carbons of Glu 42 in each structure (Fig. 2F).  Figure 3 compares a
half-complex of HFE/TfR (one HFE/β2m heterodimer bound to one chain of the TfR
dimer) from the wt-HFE/TfR (Bennett et al., 2000) and H41D-HFE/TfR structures.  Loop
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II is near the interface between HFE and TfR but does not directly contact the receptor.
The shift in the overall loop position observed in the H41D-HFE/TfR structure flips Asp-
41 out of the interior of the protein, relative to His-41 in the wild-type complex, and
directs it towards solvent.  Interestingly, loop II is not well ordered in the structure of wt-
HFE alone or complexed with TfR, but is better ordered in the H41D-HFE/TfR structure
(data not shown).
We also note a small amount of change to the loop connecting the first and second ß-
strands of the HFE platform (loop I).  The position of loop I is constrained because HFE
residue Leu-22 makes direct contacts to TfR Leu-619 contributing 140 Å2 of buried
surface area (7% of the total buried surface area in the interface (Bennett et al., 2000).
This interaction is preserved in the H41D-HFE/TfR structure.  The largest change for
loop I is the movement of Asp-17 from a buried position, where it forms a hydrogen bond
to His-41, to a completely solvent-exposed position in the H41D-HFE/TfR structure
(compare Fig. 4B and C).  The exposed surface area for this residue increases from 65.3
Å2 to 143.1 Å2.  The functional consequences of this transition are not known at this time.
Even in this new position Asp-19 is too far from TfR (closest TfR atom is 12 Å away) for
the change to be relevant to TfR binding.
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Discussion.
HFE has a demonstrated role in maintaining iron homeostasis, yet the mechanism for
HFE function in regulating iron homeostasis in unknown.  Early cellular and biochemical
studies did not demonstrate significant differences between wt-HFE and H41D-HFE in
terms of either TfR binding or effects on transfected cells (Waheed et al., 1997b; Lebrón
et al., 1999; Roy et al., 2000; Feeney & Worwood, 2001).  However, a recent study
utilizing transgenic ‘knock-in’ mice shows heightened hepatic iron load in H41D-HFE
mice compared to wt-HFE mice (Tomatsu et al., 2003).  Additionally, H41D-HFE does
not inhibit iron release from macrophages to the same degree as wt-HFE (Drakesmith et
al., 2002).  Therefore, characterization of the structure of H41D-HFE may help explain
how H41D affects HFE’s function.  HFE has been proposed to interact with other
proteins in the membrane (Townsend & Drakesmith, 2002; Frazer & Anderson, 2003),
such as ferroportin, a membrane protein that exports iron from cells (Abboud & Haile,
2000; Donovan et al., 2000; McKie et al., 2000).  The proposals suggest that the
chemical and/or structural changes induced by the H41D substitution may alter HFE’s
proposed interactions with these other proteins.
To characterize any potential structural changes caused by the H41D mutation in HFE,
we determined the crystal structures of H41D-HFE alone and in complex with TfR to 2.9
Å and 3.5 Å resolution, respectively.  Comparison of the unliganded H41D-HFE
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structure with unliganded wt-HFE reveals no significant differences, suggesting that the
substitution does not lead to major changes in the structure of the protein.  However,
when H41D-HFE is bound to TfR, we see a rearrangement to the local structure of the
loop containing the H41D mutation (loop II) and slight changes to a nearby loop (loop I
connecting ß-strands 1 and 2).  Loop II is not well ordered in the structures of wt-HFE
alone or the wt-HFE/TfR complex, but is better ordered in the H41D-HFE/TfR structure.
It has been hypothesized that HFE functions to regulate iron homeostasis through
interactions with other, as yet unidentified, binding partners in addition to TfR
(Townsend & Drakesmith, 2002; Frazer & Anderson, 2003).  Our crystallographic
investigations have revealed that the region around His-41 is flexible and that
substitutions could lead to changes in flexibility.  Figure 4A shows that His-41 forms a
salt bridge with Asp-73 in the structure of wt-HFE alone.  In contrast, the structure of wt-
HFE bound to TfR exhibits a local rearrangement of loop II that positions His-41 to
interact with Asp-19 and Glu-26 (Fig. 4B).  Substitution of His-41 to aspartate would
create repulsive interactions in this region and indeed, in the structure of H41D-HFE
bound to TfR we observe that Asp-19 has moved to a position closer to that observed in
the structure of unliganded wt-HFE (Fig. 4C), although motion is constrained in the case
of loop I because of the important interactions of Leu-22 with TfR.  The H41D-HFE/TfR
structure also shows that Asp-41 is pointing away from HFE and into solution.  The Asp-
41 sidechain is in a position to form hydrogen bonds or salt bridge interactions with Arg-
45 on the other side of the loop (Fig. 4C).  Additionally, the structural changes in this
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region have also moved the sidechain of Asp-40 into a position to interact with R45.  It
may be these interactions that lead to the decreased flexibility of the loop in this structure
relative to that observed in the wt-HFE/TfR complex.
While these data and observations do not directly explain why H41D leads to an increase
in body iron load, they demonstrate that the structures of loop I and loop II in HFE can be
affected by this mutation.  These changes could affect the interaction of HFE with a
ligand other than TfR. If HFE can bind this hypothesized ligand by itself, then His-41
might be directly involved in the interaction since substitution of this residue does not
lead to large perturbations of the local structure.  However, if binding of HFE to TfR is
required for binding to this new ligand (such that the HFE/TfR complex forms a receptor
for the other protein), then the loop rearrangements observed in the H41D-HFE/TfR
structure could reduce or prevent binding.  Alternatively, His-41 may not be directly
involved in the interaction at all, but may act to stabilize other regions of the structure
through longer-range interactions, as in the case of the 10 Å translation of Asp-19 in the
H41D-HFE/TfR structure relative to the wt-HFE/TfR structure.  New experiments and
structures will be necessary to determine if the structural changes induced by H41D
observed here play a significant role in the mechanism of H41D-induced iron overload.
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Materials and Methods.
Data collection and structure solution
An H41D-HFE crystal was grown as previously described (Lebrón et al., 1998).  A
dataset for a crystal of unliganded H41D-HFE was collected at the Stanford Synchrotron
Radiation Laboratory (SSRL) at beamline 7-1 to a resolution of 2.9 Å.  The dataset was
processed and scaled with the HKL package (Otwinowski, 1993).
Transferrin receptor and H41D-HFE were kindly provided by J.A. Lebrón and were
mixed in a ratio of one HFE to one TfR monomer and concentrated to 50 µM 2:1
HFE/TfR complex.  Crystals of the H41D-HFE/TfR binary complex were grown in
hanging-drops in conditions similar to the wt-HFE/TfR complex (Bennett et al., 2000),
but with higher concentrations of PEG 8000 ( 8.4% PEG 8000, 200 mM tris pH 8.0, and
10 mM trimethylamine HCl).  Crystals were cryoprotected by stepwise transfer into
higher concentration glycerol and PEG concentrations to a final solution of 20% glycerol
and 12% PEG 8000 and flash frozen in liquid nitrogen. A dataset complete to 3.5 Å was
collected on a Raxis-IV mounted on a Rigaku RU-200 generator. and a 3.7 Å dataset was
collected at beamline 7-1 at the Stanford Synchrotron Radiation Laboratory.  A combined
dataset was used for building but only the higher resolution dataset was used for
refinement.
The H41D-HFE and H41D-HFE/TfR complex structures were solved by molecular
replacement using the structures of wild-type HFE (Lebrón et al., 1998)(PDB code:
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1A6Z) or the wild-type HFE/TfR binary complex (Bennett et al., 2000)(PDB code:
1DE4) followed by rigid-body refinement freeing individual protein domains (α1, α2, α3
and β2m for HFE, and the protease-like domain, apical domain, and helical domain for
TfR).  Models were inspected and rebuilt in O (Jones & Kjeldgaard, 1997) using σA-
weighted 2Fo-Fc annealed omit or composite omit density maps.  Refinement was
performed with CNS (Brünger et al., 1998) using simulated annealing torsional
refinement with grouped B factors, bulk-solvent corrections, and tight NCS restraints
(300 kcal/mol Å2) for all residues not involved in crystal contacts.  The calcium ions,
carbohydrate residues, and tris molecules observed in the wt-HFE/TfR model were
eliminated from the H41D-HFE/TfR model due to the lower resolution of the data for the
mutant complex (3.5 Å versus 2.8 Å for wt-HFE/TfR).  Figures were prepared with
Molscript (Kraulis, 1991), Bobscript (Esnouf, 1997), Raster3D (Merritt & Bacon, 1997),
Swiss-PDB viewer (Kaplan & Littlejohn, 2001), and PyMol (DeLano, 2002).  All surface
area calculations were performed with VADAR (Willard et al., 2003).
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Figure 1.  Ribbon diagram of the structure of wt-HFE.  The positions of residues mutated
in HH are highlighted.
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Figure 2.  Initial and refined models for loop II in the structures of H41D-HFE and
H41D-HFE/TfR.  A) Initial model for H41D-HFE in difference density.  Red corresponds
to FO-FC,φC density contoured at –2σ.  Magenta density is annealed omit 2FO-FC,φC
contoured at 1σ.  There is a large negative peak near the Asp41 side chain.  B)  Refined
structure of H41D-HFE in annealed omit-type density.  C)  Superposition of wt-HFE and
H41D-HFE loop II showing the sidehchains of His-41 and Asp-41.  D)  Initial orientation
of loop II in wt-HFE/TfR structure superimposed on FO-FC,φC difference density for the
H41D-HFE/TfR dataset.  Density is contoured +2σ (blue) and –2σ (red).  E)  Rebuilt and
refined model for loop II in annealed omit density.  F)  Superposition of loop II in wt-
HFE/TfR and H41D-HFE/TfR.  The largest difference is the atomic shift for the α-
carbon of Glu-42 as indicated.
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Figure 3.  Comparison of wt-HFE/TfR and H41D-HFE/TfR structures.  A half complex
(one HFE bound to one polypeptide chain of the TfR dimer) is shown for each.  The
helical domain of TfR (magenta) interacts with the helical regions of HFE.  HFE is
shown in green, β2m in blue.  β1 and β2 are colored red and loop II is shown in yellow.
His-41 and Asp-41 are shown in stick representation.
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Figrue 4.  Comparison of HFE structures in the vicinity of loops I and II.  Secondary
structural elements and relevant amino acids are labeled.  A)  The structure of unliganded
wt-HFE (PDB code 1A6Z) (Lebrón et al., 1998) is shown in green and the salt bridge
between His-41 and Asp-73 is highlighted.  B)  The structure of wt-HFE bound to TfR
(PDB  code 1DE4) (Bennett et al., 2000).  Hydrogen bonds between His-41 and Asp-19
and Glu-26 are indicated.  (C)  Structure of H41D-HFE bound to TfR.  Loop II has
shifted closer to the position observed in (A) with Asp-19 reoriented towards the solvent.
Asp-41 is in a different position than His-41 in the other two structures and appears
poised to from an H-bond or salt bridge to Arg-45.  The structure of this loop also
positions Asp-40 for a potential interaction with Arg-45.  Exact distance measurements
are not provided given the low resolution of the structures.  As measured from these
models no interaction is longer than 3.4 Å.
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Appendix I:
Mutational Analysis of the Transferrin
Receptor Reveals Overlapping HFE and
Transferrin Binding Sites
This appendix details the characterization of some of the first TfR mutants that were
characterized further in Chapter II.  I contributed some of the mutants, to the
development of surface plasmon resonance methods and data analysis procedures that
improved the data, and produced the structure figures in the manuscript.
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0022-2836/01/020385–13 $35.00/0The transferrin receptor (TfR) binds two proteins critical for iron metab-
olism: transferrin (Tf) and HFE, the protein mutated in hereditary hemo-
chromatosis. Previous results demonstrated that Tf and HFE compete for
binding to TfR, suggesting that Tf and HFE bind to the same or an over-
lapping site on TfR. TfR is a homodimer that binds one Tf per polypep-
tide chain (2:2, TfR/Tf stoichiometry), whereas both 2:1 and 2:2 TfR/HFE
stoichiometries have been observed. In order to more fully characterize
the interaction between HFE and TfR, we determined the binding stoichi-
ometry using equilibrium gel-filtration and analytical ultracentrifugation.
Both techniques indicate that a 2:2 TfR/HFE complex can form at submi-
cromolar concentrations in solution, consistent with the hypothesis that
HFE competes for Tf binding to TfR by blocking the Tf binding site
rather than by exerting an allosteric effect. To determine whether the Tf
and HFE binding sites on TfR overlap, residues at the HFE binding site
on TfR were identified from the 2.8 A˚ resolution HFE-TfR co-crystal
structure, then mutated and tested for their effects on HFE and Tf bind-
ing. The binding affinities of soluble TfR mutants for HFE and Tf were
determined using a surface plasmon resonance assay. Substitutions of
five TfR residues at the HFE binding site (L619A, R629A, Y643A, G647A
and F650Q) resulted in significant reductions in Tf binding affinity. The
findings that both HFE and Tf form 2:2 complexes with TfR and that
mutations at the HFE binding site affect Tf binding support a model in
which HFE and Tf compete for overlapping binding sites on TfR.
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Mammals possess complex mechanisms to regu-
late the absorption of iron on both the cellular and
organism level. The transferrin receptor (TfR) plays
a central role in cellular iron uptake: iron-loaded
serum transferrin (Tf) binds to cell surface TfR,
which is followed by endocytosis of the TfR/Tf
complex (reviewed by Richardson & Ponka1). In
the acidic endosome environment, iron is released
from Tf, transported across the endosomal mem-
brane, and enters a chelatable intracellular pool
from which it is utilized for the metabolic needs of
the cell or incorporated into the storage protein fer-
ritin. Iron-free Tf (apo-Tf) remains bound to TfR at
the low pH of the acidic vesicle (4pH 6.5) and the# 2001 Academic Press
Figure 1. Stoichiometries of the TfR/Tf and TfR/HFE
complexes observed in solution or in crystals.
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135TfR/apo-Tf complex is then recycled to the cell
surface, where apo-Tf dissociates at the higher pH
of blood (pH 7.4). Cellular uptake of iron by TfR
and intracellular iron levels are regulated at the
translational level by iron-responsive elements in
the untranslated regions of mRNA for TfR and
ferritin.1,2
An additional component of the iron regulatory
machinery was recognized from the positional
cloning of the gene responsible for hereditary
hemochromatosis (HH),3 a disease characterized
by excessive intestinal iron absorption leading to
progressive organ failure.4 The gene mutated in
HH encodes a class I major histocompatibility com-
plex (MHC)-related protein called HFE. Like class I
MHC molecules, HFE is composed of a heavy
chain with three extracellular domains (a1, a2, and
a3), a single transmembrane-spanning region, a
short cytoplasmic domain, and the non-covalently
associated light chain, b2-microglobulin (b2m).
Class I MHC proteins bind peptides in a groove
within the a1-a2 superdomain and present them to
T-cells as part of the adaptive immune response
against pathogens.5 HFE contains a narrowed ver-
sion of the class I peptide binding groove and does
not bind peptides or play any known role in the
immune system.6 Instead, HFE associates with
TfR7,8 in a pH-dependent interaction, such that a
nanomolar binding affinity is observed at pH 7.5
with no detectable binding at pH 6 and below.6 In
cell lines and in tissues such as the intestine and
placenta, TfR associates with HFE.7,8 In transfected
cell lines, HFE association with TfR negatively
regulates Tf-mediated iron uptake.9 – 11
Crystal structures of HFE,6 TfR,12 and the HFE/
TfR complex13 reveal the molecular basis for the
interaction between TfR and HFE. However, little
is known about the binding site on TfR for Tf. Two
mutational analyses report localization of the Tf
binding site to a region identified from the TfR
crystal structure12 as the helical domain. In the
first, Tf binding studies using human/chicken chi-
meric TfRs suggested that species-specific Tf bind-
ing ability is conferred by a region corresponding
to the helical domain.14 In the second, site-directed
mutagenesis of an RGD (Arg-Gly-Asp) sequence
(residues 646-648) within the TfR helical domain
resulted in reduced affinities for Tf binding. HFE
binds to the helical domain of TfR and contacts
portions of the RGD sequence at residues 646-
648,13 suggesting that the HFE and Tf binding sites
on TfR at least partially overlap. Indeed, HFE bind-
ing to TfR results in a reduced affinity for Tf, both
in transfected cells7,9 and in a solid-phase assay
involving soluble proteins.15 In principle, the
reduction in Tf binding affinity could occur due to
direct competition between Tf and HFE for TfR
binding caused by overlapping binding sites, or
through an allosteric effect.
Understanding the nature of the competitive
binding is complicated by the apparent differences
between the stoichiometries of TfR/Tf and TfR/
HFE complexes observed in solution. In gel-fil-tration experiments conducted under non-equili-
brium conditions, two molecules of Tf bind per
TfR homodimer (2:2, TfR/Tf stoichiometry),
whereas only one molecule of HFE binds per TfR
homodimer (2:1, TfR/HFE stoichiometry)6
(Figures 1 and 2(a)). In the TfR/HFE co-crystals,
however, a 2:2 TfR/HFE stoichiometry was
observed.13 If only 2:1 TfR/HFE complexes form in
solution or on cells, Tf affinity reduction would
require an allosteric mechanism, since formation of
a Tf/TfR/HFE ternary complex, as observed in
solution,6 demonstrates that binding of one HFE
molecule does not block both Tf binding sites. If
2:2 TfR/HFE complexes can form in solution, then
a pure competition model could explain the
observed reduction in Tf affinity. To develop a
more detailed microscopic model of the HFE-TfR-
Tf system, we have further investigated the TfR/
HFE stoichiometry in solution using equilibrium
gel-filtration and analytical ultracentrifugation, and
verified the overlapping binding site hypothesis by
demonstrating that TfR mutations that affect HFE
binding also affect Tf binding. We find that several
mutations at the crystallographically determined
binding site for HFE eliminate HFE binding and
reduce Tf affinity. These data confirm that HFE
and Tf bind to overlapping sites on TfR and
further localize the Tf binding site on TfR.
Results
Stoichiometry of the TfR/HFE complex by
equilibrium gel-filtration
To determine the stoichiometry of the TfR/HFE
interaction in solution under equilibrium con-
ditions, we performed a series of equilibrium gel-
filtration experiments. Conventional gel-filtration
experiments are often used to assess the stoichi-
ometry of protein complexes. However, transient
dissociation of weak complexes during chromatog-
raphy can lead to altered stoichiometries.16 To
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136avoid this problem, gel-filtration experiments can
be done under equilibrium conditions by including
one of the binding partners in the running buffer,17
as described for previous studies of the interaction
between FcRn and its IgG or Fc ligands.16,18,19
For our experiments, the gel-filtration column
was equilibrated and run using a buffer containing
a fixed concentration of HFE (the equilibration buf-
fer). Different ratios of HFE plus TfR were then
injected onto the column in equilibration buffer.
Although transient dissociation of TfR/HFE com-
plexes occurs as in a conventional gel-filtration
experiment, HFE molecules that dissociate from
the complex can be replaced by HFE in the equili-
bration buffer. For each concentration of HFE in
the equilibration buffer, there is a ratio of injected
proteins such that no peak or trough appears at
the elution volume of free HFE (Figure 2(b)-(e)). By
determining this ratio at several concentrations of
HFE in the equilibration buffer, one can perform a
Scatchard analysis yielding both a stoichiometry
and a solution phase affinity.20 The Scatchard anal-
ysis in Figure 2(f) shows an x intercept of 2.1, thus
the stoichiometry of the TfR/HFE complex is 2:2
(two molecules of HFE bind to each TfR homodi-
mer), in contrast to the 2:1 stoichiometry obtained
from non-equilibrium gel-filtration experiments
(Figure 2(a)).6
Stoichiometry of the TfR/HFE complex by
analytical ultracentrifugation
As an independent verification of the solution
phase 2:2 TfR/HFE stoichiometry, we examined
the sedimentation behavior of TfR/HFE complexes
using analytical ultracentrifugation. In a sedimen-
tation equilibrium experiment, the processes of
sedimentation and diffusion are allowed to come
to equilibrium, at which point a stable concen-
tration gradient is formed. Under these conditions,
the observed concentration gradient can be
described by either a single-exponential curve (for
a single sedimenting species) or a sum of exponen-
tials (for a mixture of species). From these fitted
curves, the molecular mass of sedimenting species
can be determined.21
Soluble forms of HFE and TfR alone each sedi-
mented as a single species, with experimentally
derived molecular masses of 48.3 kDa and
150 kDa, respectively, corresponding to an HFE/
b2m heterodimer and a homodimeric TfR (Table 1).Table 1. Apparent molecular mass (M) of HFE, TfR, and TfR
gation (sedimentation equilibrium)
Sample Concentration (mM) sw (at 900
HFE 0.4, 6 0.497 (0.474
TfR 0.4, 2, 6 1.45 (1.40
2:1 TfR/HFE 0.4 1.93 (1.87
2:2 TfR/HFE 0.4 2.16 (2.08
a Calculated from the amino acid sequences of the expressed ectodFitting the data from centrifugation of TfR/HFE
mixtures to a single exponential yields sw, the
weight-average buoyant molecular mass, which
includes information from all species present in
solution. The value of sw for a TfR/HFE sample
loaded at a 2:1 stoichiometry in which the concen-
tration of each TfR polypeptide chain was 0.4 mM
was within 1 % of the calculated sum of sHFE and
sTfR, indicating formation of a 2:1 complex
(sw  1.934, sw,calc  1.948) (Figure 3). The sw
value for a TfR/HFE sample loaded at a 2:2 stoi-
chiometry (TfR concentration of 0.4 mM) was
between the values calculated for the 2:1 and 2:2
complexes, suggesting formation of a mixture of
2:1 and 2:2 complexes (sw  2.157, sw,calc for the
2:1 complex  1.948, sw,calc for the 2:2 com-
plex  2.444). The data for the sample loaded with
2:2 stoichiometry at 0.4 mM TfR can be described
as an equilibrium between free TfR, free HFE, 2:1
complex, and 2:2 complex. When the data are ana-
lyzed with these assumptions, the 2:1 and 2:2 com-
plexes make up 21 % and 75 %, respectively, of the
species in solution at the highest concentrations
tested. That the 2:2 complex predominates at
0.4 mM TfR implies that the equilibrium dis-
sociation constant (KD) for binding the second HFE
is submicromolar.
Derivation of stepwise binding affinities for
HFE binding to TfR
In a previous surface plasmon resonance-based
study,6 we observed that the apparent affinity of
the TfR/HFE interaction depended on the orien-
tation of the binding experiment, such that TfR
bound to immobilized HFE with an 1 nM equili-
brium dissociation constant (KD), whereas HFE
bound to immobilized TfR with a 100-600 nM KD.
This difference can now be interpreted in light of
the 2:2 TfR/HFE stoichiometry in solution demon-
strated by equilibrium gel-filtration and ultracentri-
fugation (Figures 2 and 3). The higher apparent
affinity when TfR is bound to immobilized HFE is
due to an avidity effect, in which a TfR molecule in
solution can be bound to two HFE proteins on the
chip. In the original derivation of the affinity of
TfR for immobilized HFE,6 we used a 1:1 binding
model, which does not extract stepwise binding
affinities between TfR and HFE. In order to deter-
mine the sequential binding affinities between HFE
and TfR, we analyzed surface plasmon resonance-/HFE mixtures as determined by analytical ultracentrifu-
0 rpm) Apparent M (kDa) Calculated Ma (kDa)
-0.519) 48.3 (46.0-50.4) 44.0
-1.50) 150 (144-155) 148
-2.00) 196 (190-203) 192
-2.23) 216 (209-224) 236
omains, excluding carbohydrate contributions.
Figure 2 (legend opposite)
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Figure 3. Sedimentation equilibrium data for 2:1 (left) and 2:2 (right) mixtures of wild-type TfR and HFE, both con-
taining 0.40 mM TfR. The inset displays the same data on an expanded y-axis. All six curves in each panel were glob-
ally fitted, with the residuals for the fit shown below each panel. The 2:1 TfR/HFE sample sedimented as a single
species with a molecular mass corresponding to a 2:1 TfR/HFE complex. The 2:2 TfR/HFE sample sedimented as a
mixture of 2:1 and 2:2 species, with the 2:2 species predominating.
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138based binding data for the interaction between TfR
and immobilized HFE using a bivalent analyte
model. In this model, KD values are derived for
sequential interactions between HFE and TfR,
yielding KD1  46 nM and KD2  210 nM (Figure 4).
Analysis of the same data using a 1:1 binding
model yields a KD of 1 nM, consistent with pre-
vious results6 (see Materials and Methods). These
results, together with the equilibrium gel-filtration
and ultracentrifugation data, give a consistent pic-
ture showing that both the first and second HFE
binding affinities are submicromolar.
Structure-based design of TfR mutants at the
HFE binding site
To test whether the binding sites on TfR for HFE
and Tf overlap, we made a series of mutants at the
HFE binding site on TfR. Residues at the HFE
binding site were identified from the 2.8 A˚ resol-
ution TfR-HFE co-crystal structure13 (Protein DataFigure 2. Gel-filtration analyses of TfR/HFE complexes. (
and 2:2 TfR/HFE mixtures (1.0 mM TfR plus 0.5 or 1.0 mM
under these conditions. (b)-(e) Equilibrium gel-filtration of T
250, 500, 750, or 1000 nM HFE were injected onto a co
(c) 125 nM, (d) 250 nM or (e) 500 nM HFE. The peak that el
peak or trough is at the elution volume of free HFE (1.6
HFE concentration that, when co-injected with 500 nM TfR
tration of HFE in the equilibration buffer (i.e. no HFE peak/
the legend account for the baseline unbound HFE in the eq
equilibration buffers containing 62.5, 125, 250, and 500 nM H
cept of 2.1.Bank code 1DE4). This structure shows that two
helices in the helical domain of TfR (highlighted in
green in Figure 5) interact with the HFE a1 and a2
domain helices, forming an extensive interface. The
interface includes both apolar and polar inter-
actions and buries 1000 A˚2 of solvent-accessible
surface area per subunit. Previous work showed
that HFE residues Val78 and Trp81 are critical for
TfR binding,22 hence we chose to mutate TfR resi-
dues (Leu619, Val622, Arg623, and Tyr643) that
contact these HFE residues. Substitution of TfR
residue Gly647, which is within 6.5 A˚ of HFE but
does not form a direct contact, was previously
shown to reduce the affinity for Tf,23 so we gener-
ated the G647A mutant to determine its effect on
HFE binding. Additional TfR residues that were
altered include TfR Arg629, which forms salt-
bridges with HFE Glu85 and Glu146, TfR Gln640,
which contacts HFE His150 and Arg153, TfR
Trp641, which forms a hydrophobic contact with
HFE Ile152, TfR Ser644, which contacts HFEa) Non-equilibrium gel-filtration chromatography of 2:1
HFE) demonstrating formation of only the 2:1 complex
fR/HFE mixtures. Samples containing 500 nM TfR plus
lumn equilibrated in a buffer containing (b) 62.5 nM,
utes first corresponds to a TfR-HFE complex. The second
ml). From this series of injections, one can calculate the
, yields a free HFE concentration equal to the concen-
trough). The injected TfR/HFE stoichiometries given in
uilibration buffer. (f) Scatchard plot including data from
FE. The best fit line yields a KD of 47 nM and an x-inter-
Figure 4. Plots of equilibrium binding responses ver-
sus the log of the concentration of injected TfR derived
from biosensor experiments in which binding responses
closely approached or reached equilibrium. TfR was
injected over HFE, which was immobilized at low, med-
ium, and high coupling densities to vary the avidity
effect on apparent TfR affinity. All three binding curves
were globally fit to a bivalent analyte model, yielding
affinities that are similar to those obtained in the oppo-
site orientation (HFE injected over TFR).
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139His150, and Phe650, which contacts HFE Gly71
and His74 (Table 2). All residues chosen for muta-
genesis were changed to alanine, with the excep-
tion of Phe650. This residue was changed toTable 2. Comparison of the Tf and HFE binding affinities of
HFE
Mutant KD1 (nM) KD2 (nM)
KD1, KD2
Relative to wt KD1 (nM
wt TfR 89  14 650  150 0.92  0
L619A N.B. >500 21
V622A 140 1000 1.6, 1.5 0.38
R623A 380 2100 4.3, 3.2 0.15
R629A 2500 8700 28, 13 6.0
Q640A 1200 6800 13, 10 1.3
W641A 220 1400 2.5, 2.1 0.42
Y643A N.B. >500 35
S644A 350 1600 4.0, 2.5 4.0
G647A 300 2500 3.4, 3.8 140
F650Q 6200 9900 70, 15 8.2
TfR mutant affinities for HFE and Tf were determined by bivale
wild-type TfR are averages derived from five independent measure
deviation. TfR mutant affinities relative to wild-type derived from
derived values reported here. Mutants with relative TF affinity chang
N.B., no binding detected. Number of hydrogen bonds (in parent
protein-protein interactions server.44 Accessible surface area (%), pe
vdW, interactions with HFE involving only van der Waals interactioglutamine, the side-chain found at this position in
chicken TfR, which does not bind human Tf.14
The soluble ectodomains of TfR mutants were
expressed in baculovirus-infected insect cells with
polyhistidine tags at their N termini, as described
for production of soluble wild-type TfR.6 Correct
folding of mutants that had altered HFE or Tf affi-
nities was verified by gel-filtration elution profiles
(ensuring they formed homodimers migrating
similarly to wild-type TfR) and by comparing their
far-UV circular dichroism spectrum to that of wild-
type TfR. All TfR mutants that showed reduced
affinities for Tf, HFE, or both showed gel-filtration
profiles and circular dichroism spectra similar to
those of the wild-type TfR (data not shown).
Measurements of affinities of wild-type TfR
and TfR mutants for HFE and Tf
For analyses of the affinities of TfR mutants for
HFE and Tf, we also used a surface plasmon reson-
ance-based assay. For these measurements, TfR
proteins were coupled to the chip so that the affi-
nities for HFE and Tf could be derived using the
same flowcell. Purified His-tagged TfR mutants
were immobilized on the sensor chip using an anti-
His-tag antibody, and various concentrations of Tf
or HFE were injected at pH 7.5. Use of the anti-
His-tag antibody allowed oriented coupling of TfR
to the biosensor chip, providing a uniform ligand
population. All mutant affinities were determined
using wild-type TfR coupled to one flowcell as an
internal control. Analysis of Tf binding to wild-
type TfR (Figure 6(a)) yields two KD values (calcu-
lated from kinetic constants), KD1  0.92(0.17) nM
and KD2  37(17) nM, when the data were fit to a
model assuming sequential binding of two mol-
ecules of Tf to each TfR homodimer (see Materials
and Methods). These results are similar to resultsTfR mutants
Tf
From TfR-HFE crystal
structure
) KD2 (nM)
KD1, KD2
Relative to wt
Accessible
with HFE (%)
Type of
interaction
.17 37  17
510 23, 14 10 vdW
13 0.41, 0.36 2 vdW
19 0.16, 0.52 7 vdW
160 6.5, 4.1 10 H bonds (4)
42 1.4, 1.1 10 H bond (1)
72 0.46, 1.9 5 vdW
870 38, 23 4 vdW
130 4.3, 3.6 4 vdW
950 150, 25
240 8.9, 6.5 7 vdW
nt ligand analysis of biosensor kinetic data. The KD values for
ments and the number after the  sign represents the standard
independent equilibrium measurements parallel the kinetic-
es greater than fivefold are shown underlined and in bold.
heses) and accessible surface area (%) were calculated using the
rcentage of total interface area contributed by each TfR residue;
ns; H bond, interactions with HFE that include hydrogen bonds.
Figure 5. TfR structure. (a) Ribbon diagram of the structure of TfR derived from the 2.8 A˚ HFE/TfR complex
structure.13 The HFE binding site on the helical domain closest to the viewer is highlighted in green. The HFE bind-
ing site on the other helical domain is omitted for clarity. (b) Close-up of the HFE binding site on TfR. The a-carbon
trace of one polypeptide chain of the TfR dimer is shown with the side-chains of mutated TfR residues shown in ball
and stick representation. Color-coding of the TfR side-chains summarizes the effects of the substitutions as indicated.
The Figures were made with MOLSCRIPT42 and rendered with Raster3D.43
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140obtained from previous biosensor and cell-based
measurements of the affinity between TfR and
Tf.1,6 Using the same model for HFE binding to
wild-type TfR we calculate KD1  89(14) nM and
KD2  650(150) nM (Figure 6(b)), consistent with
values obtained when wild-type TfR interacts with
immobilized HFE (Figure 4).
The affinities of ten TfR mutants were measured:
L619A, V622A, R623A, R629A, Q640A, W641A,
Y643A, S644A, G647A, and F650Q. Residues with
significant effects on the affinity between TfR and
HFE (Table 2) are highlighted on the TfR structure
in Figure 5. Two mutants, L619A and Y643A, had
no detectable HFE binding and exhibited over a
tenfold decrease in their affinity for Tf. Three other
mutants had a greater than tenfold effect on HFE
binding: R629A, Q640A, and F650Q. Of these, two
(R629A and F650Q) also had a greater than five-
fold effect on Tf affinity. The G647A TfR mutant
had a large effect on Tf affinity and three- to four-
fold effect on HFE binding.
Discussion
Competition studies suggested that HFE and Tf
bind to the same or an overlapping site on TfR.15
Binding to overlapping sites on TfR implies the
stoichiometry of the TfR-Tf and TfR-HFE inter-
actions are the same. Both in solution and on thecell surface, TfR homodimers bind two molecules
of Tf (2:2 TfR/Tf stoichiometry),6,24 whereas a 2:1
TfR/HFE stoichiometry was observed by non-equi-
librium gel-filtration using soluble forms of TfR
and HFE.6 Since the TfR/HFE co-crystal structure
revealed two molecules of HFE bound per TfR
homodimer,13 it was apparent that 2:2 TfR/HFE
complexes could form under some conditions. If
only 2:1 TfR/HFE complexes can form in solution,
however, this would suggest that HFE binds to
TfR in a quite different manner from that of Tf,
whereby one HFE molecule would prevent binding
of Tf or another molecule of HFE through an allo-
steric effect exerted across the TfR homodimer. In
order to ascertain whether TfR can form 2:2 com-
plexes with HFE in solution, we used equilibrium
gel-filtration and analytical ultracentrifugation to
determine the binding stoichiometry. Both tech-
niques indicate that 2:2 TfR/HFE complexes can
form at submicromolar concentrations. This
implies that the previously reported 2:1 stoichi-
ometry observed by gel-filtration chromatography
(see also Figure 2(a)) resulted from the non-equili-
brium nature of the experiment and not from a
drastically reduced TfR affinity for binding a
second HFE molecule. Indeed, using a sequential
binding model to analyze equilibrium binding
data, we derived submicromolar KD values for the
first and second binding affinities for the HFE
interaction with TfR (Figure 4).
Figure 6. Biosensor analyses of Tf and HFE binding to immobilized wild-type and mutant TfR . (a) Sensorgrams
(colored curves) of injected Tf binding to wild-type TfR (left panel) or the L619A TfR mutant (right panel) immobi-
lized using a covalently attached anti-His-tag antibody. Best fit binding curves (assuming a bivalent ligand model)
are shown as thin black lines. (b) HFE binding to immobilized wild-type (left panel) or L619A TfR mutant (right
panel).
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141To determine if HFE and Tf compete for TfR
binding because they bind at overlapping sites, we
characterized the binding properties of a series of
soluble TfR proteins with substitutions at the HFE
binding site, under the hypothesis that some of the
HFE-interacting residues in TfR are likely to con-
tribute to the Tf binding site. A previous study
suggested that the RGD sequence in TfR (residues
646-648, a region of TfR that contacts HFE in the
co-crystal structure13) interacts with Tf, by analogy
with fibronectin RGD interactions with integrins.23
Although a direct structural analogy is unlikely,
because RGD sequences that interact with integrins
are located on extended loops,25 whereas the TfRRGD sequence is located within a helix,12,13 site-
directed mutagenesis of the RGD sequence reduced
Tf binding to TfR.23 Consistent with these results,
we find that two of our TfR mutants, L619A and
Y643A, each altering a residue at the HFE binding
site, show no detectable HFE binding and a 20-
fold reduced affinity for Tf. Of three other mutants
having a greater than tenfold effect on HFE bind-
ing, two (R629A and F650Q) also had a greater
than fivefold effect on Tf affinity. The observation
that five mutations at the HFE binding site signifi-
cantly affect Tf affinity (>fivefold reduction)
strongly supports a model in which HFE and Tf
compete for overlapping binding sites on TfR.
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142The residues that we have mutated may be
classified using the scheme of Wells and col-
leagues26 that distinguishes structural and func-
tional epitopes of a protein-protein interaction.
Structural epitope residues are defined as all resi-
dues at the contact site between two proteins,
whereas functional epitope residues are those hav-
ing a major effect on the binding affinity (defined
as G > 2 kcal/mol for substitution of a single
amino acid, which corresponds to an affinity
reduction of at least 30-fold). From the crystal
structure of the TfR-HFE complex,13 we have
already identified the structural epitope for HFE
binding on TfR. The results of this mutagenesis
study now identify Leu619, Tyr643, and Phe650 as
functional epitope residues for HFE binding. That
only a few structural epitope residues are critical
for HFE binding is as expected: in mutagenesis stu-
dies involving human growth hormone and its
receptor, it was found that only 25 % of residues
within the structural epitope on the hormone are
responsible for the majority of the binding energy
between the hormone and receptor.26 For localiz-
ation of the Tf binding site, we can provisionally
assign structural epitope residues as those that
reduce the affinity by 5 to 30-fold when substituted
and functional epitope residues as those with a
greater than 30-fold effect on the affinity. Thus TfR
residues Gly647 and Tyr643 are part of the func-
tional epitope for Tf binding, and TfR Leu619,
Arg629, and Phe650 are likely to be at the structur-
al epitope for Tf binding. Because the structures of
HFE6 and Tf27,28 are very different, the two pro-
teins must therefore bind differently to TfR even
though their binding sites overlap. Thus we would
not expect the same TfR residues to serve as func-
tional epitope residues for both proteins.
Although Tf and HFE binding appear to be
mutually exclusive at their shared binding site on
TfR,15 the homodimeric nature of TfR permits for-
mation of a 1:2:1 Tf/TfR/HFE ternary complex.
The observation of ternary complexes in solution
using purified proteins,6 where the stoichiometry
was established as 1:2:1,15 and in HFE-transfected
cell lysates9 raises the possibility that Tf/TfR/HFE
ternary complexes may play a role in HFE func-
tion. Although we have demonstrated that TfR can
readily bind two HFE molecules in solution, the
stoichiometry of a TfR/HFE complex on a cell
membrane, and how that is influenced by serum
Tf, remain to be determined.
What happens when circulating Tf and mem-
brane-bound HFE compete for binding to cell sur-
face TfR? Both Tf and HFE possess advantages for
binding TfR that could prevent exclusive formation
of either 2:2 TfR/Tf or 2:2 TfR/HFE complexes. In
the case of Tf, its presence in micromolar concen-
trations in serum29 and its intrinsically higher affi-
nity for TfR compared with HFE make it an
effective competitor. In the case of HFE, tethering
to a common membrane with TfR facilitates bind-
ing of TfR to HFE compared with binding to Tf.
The ongoing competition between Tf and HFE forbinding TfR and the presence of 2:1 TfR/HFE cell
surface complexes may result in formation of Tf/
TfR/HFE ternary complexes. Two observations are
consistent with ternary complexes being involved
in Tf uptake: (i) expression of HFE in transfected
cells does not prevent TfR-mediated endocytosis of
Tf under conditions in which HFE is associated
with TfR at the cell surface, even when HFE is
over-expressed and Tf is present at sub-physiologi-
cal concentrations;9,11 (ii) HFE is transported to
acidic endosomes by TfR in the presence and
absence of added Tf.30 The finding that the HFE
and Tf sites on TfR overlap further supports a tern-
ary complex stoichiometry of 1:2:1. Thus HFE-
bound TfR should transport only half as much Tf
into cells as non HFE-bound TfR, which may
explain why ferritin levels are lowered in cells
expressing HFE.9,11,30,31
Recently, a second receptor for Tf, TfR2, was
identified32 and found to share 45 % sequence iden-
tity with TfR in its extracellular domain. A surface
plasmon resonance-based assay and immunopreci-
pitation experiments demonstrated that soluble
HFE does not bind to soluble TfR2.33 About half of
the TfR residues that form contacts with HFE are
replaced by different amino acids in TfR2,13
suggesting a structural basis for the lack of HFE
binding by TfR2. While some critical binding resi-
dues are identical (e.g. TfR Leu619 and Tyr643 cor-
respond to TfR2 Leu651 and Tyr675), some
substitutions in TfR2 compared to TfR can now be
identified that contribute to the inability of TfR2 to
bind HFE: TfR residues Arg629 (corresponding to
TfR2 residue Ser661) and Phe650 (corresponding to
TfR2 residue Ile682) strongly affect HFE binding,
and TfR Arg623 (corresponding to TfR2 Gly655)
has a moderate effect (Table 2). Together, these
differences in TfR2 compared to TfR are expected
to strongly destabilize its interaction with HFE.
While soluble TfR2 did not bind to HFE in surface
plasmon resonance-based experiments, it bound to
Tf with tenfold weaker affinity than observed for
Tf binding to TfR. Of the five TfR residues
observed to reduce Tf binding affinity by greater
than fivefold when mutated, three are conserved in
TfR2: TfR residues Leu619 (TfR2 Leu651), Tyr643
(Tyr675) and Gly647 (TfR2 Gly679).
A key question that remains to be answered is
whether HFE has any action besides competing
with Tf for binding to TfR and thereby directly
reducing Tf-mediated iron uptake. A recent study
provides evidence that HFE inhibits apical iron
uptake by DMT1,34 though it remains unclear
whether HFE interacts directly with DMT1. Alter-
natively, HFE that is brought into endosomes
while bound to TfR could be the HFE fraction that
transmits a signal. We recently tested this second
possibility by producing a form of HFE that does
not bind to TfR but localizes to endosomes due to
addition of a constitutive internalization
sequence.30 This form of HFE did not lead to the
reduced ferritin levels observed when wild-type
HFE was used in the same assay, thus endosomal
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143localization of HFE alone is not sufficient for alter-
ing iron homeostasis. The stoichiometry of the
TfR/HFE complex may critically influence the
uptake of iron into cells. Further studies measuring
the ratio of HFE to TfR in tissues expressing HFE
will be important to determine if HFE regulates
iron homeostasis by direct competition with Tf for
TfR binding.
Materials and Methods
Protein reagents
Soluble forms of human HFE (residues 1-275 of the
mature protein plus b2m) and wild-type human TfR
(residues 121-760) were prepared as described.6 Human
Tf (Sigma) was further purified by gel-filtration chroma-
tography. Protein concentrations were determined spec-
trophotometrically using extinction coefficients at
280 nm of 83,360 Mÿ1 cmÿ1 (Tf), 96570 Mÿ1 cmÿ1 (HFE),
and 93790 Mÿ1 cmÿ1 (TfR monomer). Extinction coeffi-
cients were calculated as described.6 All TfR concen-
trations are reported in terms of a single polypeptide
chain of the TfR homodimer.
Equilibrium gel-filtration
The equilibrium column chromatography method of
Hummel & Dreyer17 including Scatchard analysis20 was
used to analyze the association of HFE with TfR. Chro-
matography was performed at room temperature at a
flow-rate of 0.1 ml/minute using a SMART micropurifi-
cation system (Pharmacia), and the absorbance of the
eluant was monitored at 280 nm. A Superdex 200 PC
3.2/30 gel-filtration column was equilibrated with and
run in 20 mM Tris (pH 7.4), 150 mM NaCl containing
62.5, 125, 250, or 500 nM HFE (equilibration buffer):
20 ml samples including 500 nM TfR and various concen-
trations of HFE (250, 500, 750, or 1000 nM) were incu-
bated for 20 minutes at room temperature prior to
injection. Relative trough and peak areas were deter-
mined by integrating the HFE elution region using the
SMART system software. By plotting the area of the
trough or peak versus the injected HFE concentration,
one can derive the concentration of injected HFE that
would give a flat baseline with no peak or trough at the
position where free HFE elutes. At this injected HFE con-
centration, the concentration of free HFE is equal to that
in the equilibration buffer. The concentration of bound
HFE can be determined by subtracting the equilibrium
buffer concentration from the injected concentration.
Thus each series of injections at a single equilibration
buffer concentration gives one datum point (HFE bound,
HFE bound/HFE free) for a Scatchard analysis.
Determination of stoichiometry by
analytical ultracentrifugation
We analyzed the molecular mass of soluble TfR, sol-
uble HFE, and TfR/HFE complexes by sedimentation
equilibrium experiments in a Beckman XL-I Ultima ana-
lytical ultracentrifuge. Samples of HFE alone (0.4 and
6 mM), TfR alone (0.4, 2, and 6 mM), and mixtures of TfR
and HFE at 2:1 and 2:2 TfR/HFE stoichiometries (0.4
and 6 mM TfR) were spun at speeds of 9000, 12,000,
16,000, and 20,000 rpm at 20 C. The buffer consisted of
20 mM Tris (pH 7.4) and 150 mM NaCl. Sample volumesof 110 ml were loaded into six-hole, charcoal-filled Epon
centerpieces, with 115 ml of matching buffer as reference.
Scans were collected at 280, 250, and 230 nm. Samples
were judged to be at equilibrium when successive scans
collected two hours apart superimposed, typically after
14-16 hours. Data files were trimmed using the program
XLAEDIT (D. Yphantis) and analyzed using the program
WinNONLIN.35 Trimmed data sets were globally fitted,
using the non-linear least-squares fitting program Win-
NONLIN, to equation (1):
Ar  elnA0 esw
r2ÿr2
0
2
 
 d 1
where A(r) is the observed absorbance as a function of
radial position, A0 is the absorbance at reference position
r0, sw is the weight-average reduced buoyant molecular
mass, r is the radial position (in cm), and d is the baseline
offset. For HFE, data collected at 12,000, 16,000, and
20,000 rpm were globally analyzed, whereas for TfR
alone and TfR/HFE mixtures, data collected at 9000,
12,000, and 16,000 rpm were analyzed. Data from TfR
alone and the 2:1 and 2:2 TfR/HFE mixtures showed
decreasing trends in the weight-average buoyant mol-
ecular mass (sw) with increasing loading concentration,
indicating non-ideal behavior due to glycosylation (data
not shown). An estimate of the corrected sw was deter-
mined by plotting the apparent sw at each loading con-
centration and extrapolating to infinite dilution. These
extrapolated values agreed closely with the values of sw
determined from a global fit in which the non-ideality
parameter B was included. For TfR, the corrected value
of sw determined from the global non-ideal fit is
reported in Table 1. For the 2:1 and 2:2 mixtures, the cor-
rected values for sw from a global non-ideal fit of both
the 0.4 and 3 mM data were within 3 % of the values
determined for the 0.4 mM data that is reported in
Table 1. Molecular mass was calculated from values of
sw according to the relation:
sw M1ÿ
nro2
RT
2
where n is the partial specific volume of the macromol-
ecule, r is the buffer density, o2 is the square of the
rotor’s angular velocity (rpm/30)2, R is the gas constant
(in g/mol K), and T is the absolute temperature. The par-
tial specific volume for each protein was calculated from
amino acid sequence information using the program
Sednterp36 and corrected for the estimated level of glyco-
sylation by using a n of 0.63 for the saccharide moiety
as described.37 The experimentally determined sw values
for HFE and TfR were consistent with 9 % and 1 % of the
total mass being due to glycosylation, respectively; the
resulting n values were 0.719 for HFE and 0.735 for TfR.
Expression and purification of TfR mutants
Soluble human TfR mutants were expressed in a lytic
baculovirus/insect cell expression system using the
approach described previously for expression of soluble
wild-type TfR.6 A construct encoding residues 121-760 of
TfR follows a gene segment encoding the leader peptide
from the baculovirus protein GP67, a His6-tag, and a fac-
tor Xa cleavage site in a modified form of the pAcGP67A
expression vector (Pharmingen). Mutagenesis of TfR was
performed using the Quikchange protocol (Stratagene),
and all mutants were verified by DNA sequencing.
Recombinant virus was generated by co-transfection of
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144the transfer vector with linearized viral DNA (Baculo-
gold, Pharmingen). TfR mutants were purified from
supernatants of baculovirus-infected High 5 cells using
Ni-NTA chromatography (Ni-NTA superflow; Qiagen)
followed by gel-filtration chromatography using a Super-
dex-200 FPLC column (Pharmacia).
Verification of correct folding of TfR mutants
The mutations of TfR were at residues that are
solvent-exposed in the TfR crystal structure,12 and thus
would not be expected to influence folding. Correct fold-
ing of the mutants was confirmed by verifying homodi-
mer formation by gel-filtration elution profile and by
comparing the far-UV CD spectrum of wild-type TfR
with the spectra of all mutants having significantly
altered HFE or Tf affinities. All mutants migrated on the
gel-filtration column in the same position as wild-type
TfR (data not shown). CD spectra were obtained by col-
lecting wavelength scans (190-250 nm) at room tempera-
ture on an Aviv 62A spectropolarimeter from 1-3 mM
protein samples in 25 mM sodium phosphate (pH 7.5)
using a 0.1 mm path-length cell. All CD spectra were
characteristic of folded proteins with significant a-helical
structure. No significant difference was observed
between wild-type and mutant spectra (data not shown).
Biosensor-based affinity measurements
A BIACORE 2000 biosensor system (Pharmacia, LKB
Biotechnology) was used to assay the interaction of TfR
proteins with HFE and human Tf. The BIACORE system
includes a biosensor chip with a dextran-coated gold sur-
face to which one protein (referred to as the ligand) is
immobilized. Binding of an injected protein (the analyte)
to the immobilized protein results in changes in surface
plasmon resonance that are directly proportional to the
amount of bound protein and read out in real time as
resonance units (RU).38,39
In our previous analysis of TfR binding to immobi-
lized HFE,6 a 1:1 binding model was used. Since this
model does not take into account the avidity effect of a
bivalent analyte, it yields higher apparent affinities than
measured when the bivalent protein is coupled to the
biosensor chip. In the present experiments, we analyzed
equilibrium-based binding data using a bivalent analyte
model, which fits binding data to sequential reactions
deriving microscopic KD values for the binding reactions
that produce singly and doubly-liganded TfR molecules:
HFE Tfrka1
kd1
HFE=TfR KD1  kd1
ka1
HFEHFE=TfRka2
Ka2
HFE=TfR=HFE KD2  kd2
ka2
The intrinsic binding constants for the first and second
HFE binding to TfR (KD,first and KD,second) are related to
the calculated stepwise dissociation constants (KD1 and
KD2).
40 In the case of independent binding sites:
KD;first  2KD1
KD;second  KD2=2
Hence, if the binding of a TfR ligand was independent of
whether a ligand was bound on the other face of the TfR
homodimer, we would expect that KD2  4 KD1 (sinceour definitions of KD1 and KD2 do not include statistical
factors).
To obtain data exhibiting both weak and strong avid-
ity effects, we immobilized HFE using standard primary
amine chemistry (as described in the BIACORE manual)
at three different densities (180, 640, and 2000 RU). Vary-
ing concentrations of wild-type TfR were injected in
50 mM Pipes (pH 7.5), 150 mM NaCl, 0.005 % (v/v) sur-
factant P20. Binding reactions were allowed to closely
approach or to reach equilibrium by using long injec-
tions (48 minutes) with slow flow rates (5 ml/minute),
and chips were regenerated after binding reactions by
injection of a pH 6.0 buffer. Equilibrium binding
responses (Req) to varying concentrations of injected TfR
were derived for the three coupling densities, and data
were globally fit to obtain KD1 and KD2 using the bivalent
analyte model as described19 (Figure 4). The fit values,
KD1  46 nM and KD2  210 nM, are consistent with
those derived from HFE binding to immobilized TfR
(Table 2). Analyzing the medium and high coupling den-
sity data with a 1:1 binding model yields high apparent
affinities (KD < 1 nM) similar to those reported earlier.
6
For comparisons of binding by wild-type TfR and TfR
mutants, purified TfR proteins were immobilized using
an oriented coupling procedure in which an anti-His-tag
antibody (anti-pentahis; Qiagen) was covalently attached
to the chip surface followed by injection of the His-
tagged protein. The anti-His-tag antibody was coupled
at 2000-3000 RU to all four flow-cells on a CM5 biosen-
sor chip (Pharmacia) using standard primary amine
coupling chemistry (BIACORE manual). His-tagged TfR
was then injected in 50 mM Pipes (pH 7.5), 150 mM
NaCl, 0.005 % surfactant P20 and allowed to bind to
individual flow-cells at levels between 200 and 400 RU.
Although a small portion of the bound TfR dissociates
within a few minutes of this binding step, the majority
(>85 %) remains bound during the course of the exper-
iment. A flow-cell containing only immobilized antibody
served as a blank. HFE or Tf was injected over the TfR-
coupled flow-cells at 25C in 50 mM Pipes (pH 7.5),
150 mM NaCl, 0.005 % surfactant P20. Chips were regen-
erated after analyte binding by injection of 0.5 M MgCl2,
50 mM Pipes (pH 7.5), 150 mM NaCl, 0.005 % surfactant
P20, which did not result in dissociation of TfR from the
anti-His-tag antibody. Equilibrium dissociation constants
(KD) were calculated from association and dissociation
rate constants, which were derived from binding exper-
iments with four minute association and four minute dis-
sociation phases using a flow-rate of 50 ml/minute.
Kinetic constants were calculated from sensorgram data
using simultaneous fitting of the association and dis-
sociation phases with global fitting to all curves in the
working set using CLAMP 99.41 The data were fit to a
bivalent ligand model, i.e. two sequential binding steps
for either Tf or HFE binding to TfR.
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Appendix II:
Heterotypic Interactions Between
Transferrin Receptor and Transferrin
Receptor 2
This paper describes work I did in collaboration with Caroline Enns’ group at the Oregon
Health Sciences Institute.  They found that TfR and TfR2 heterodimerize in cells.  I used
sequence alignments, computational contact analysis, and manual graphical inspection of
the dimer interface of the known TfR crystal structures.  I was able to determine that
there would be few, if any differences in a TfR1/TfR2 heterodimer that would prevent the
chains from associating.
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